<SEC-DOCUMENT>0001698530-18-000021.txt : 20180515
<SEC-HEADER>0001698530-18-000021.hdr.sgml : 20180515
<ACCEPTANCE-DATETIME>20180515170445
ACCESSION NUMBER:		0001698530-18-000021
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180515
DATE AS OF CHANGE:		20180515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55764
		FILM NUMBER:		18837606

	BUSINESS ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exicure10q33118.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD0BF676EBABE52B198EFA1AEF38C5DDF"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended March 31, 2018</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">or</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 000-55764</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">_____________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">81-5333008</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(IRS Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8045 Lamon Avenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 410</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Skokie, IL 60077</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code (847) 673-1700</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:3%;"></td><td style="width:55%;"></td><td style="width:21%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of April 30, 2018, there were 39,454,821 shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s22A913064D645C239E35747D0F9F1844"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#sD6E7498C199B5D14872504B10066E0EC"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD6E7498C199B5D14872504B10066E0EC">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s5D133804564059A491DA1AE59F61A19C"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF733A208D9865EEF8F11CA5A91A81458">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE060E7696E9B59B4A4274EDDF7D85A34"><font style="font-family:Times New Roman;font-size:10pt;">Item 1. Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF733A208D9865EEF8F11CA5A91A81458">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF733A208D9865EEF8F11CA5A91A81458"><font style="font-family:Times New Roman;font-size:10pt;">Unaudited Condensed Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF733A208D9865EEF8F11CA5A91A81458">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF39DE074AF51589DA09EE2C42A7E0090"><font style="font-family:Times New Roman;font-size:10pt;">Unaudited Condensed Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF39DE074AF51589DA09EE2C42A7E0090">6</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s8A3533318FA75AD991CB62674F058289"><font style="font-family:Times New Roman;font-size:10pt;">Unaudited Condensed Consolidated Changes in Stockholders&#8217; Equity</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s8A3533318FA75AD991CB62674F058289">7</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCB69C3081937561792F149658A2F5BE0"><font style="font-family:Times New Roman;font-size:10pt;">Unaudited Condensed Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCB69C3081937561792F149658A2F5BE0">8</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s1BFB8F19BA485B868E511F31755285AB"><font style="font-family:Times New Roman;font-size:10pt;">Notes to Unaudited Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE379F8FACFCF5435A5DCEBAFBEE8C53D">9</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBDB9D6A64AC8549C9A6D51D21BC0CB52"><font style="font-family:Times New Roman;font-size:10pt;">Item 2. Management's Discussion and Analysis and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBDB9D6A64AC8549C9A6D51D21BC0CB52">23</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s213B96CD2A81533894D39E7337ED3F63"><font style="font-family:Times New Roman;font-size:10pt;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s213B96CD2A81533894D39E7337ED3F63">33</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s97E51EC7E22652158C3791BEBE7744C7"><font style="font-family:Times New Roman;font-size:10pt;">Item 4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s97E51EC7E22652158C3791BEBE7744C7">33</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s7613DD62978555E8AEC018304441B665"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s512CA2DAA9CA58EBA11D26873A81E943">35</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s512CA2DAA9CA58EBA11D26873A81E943"><font style="font-family:Times New Roman;font-size:10pt;">Item 1. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s512CA2DAA9CA58EBA11D26873A81E943">35</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sB7688808B3FE51B0A60E302430411435"><font style="font-family:Times New Roman;font-size:10pt;">Item 1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sB7688808B3FE51B0A60E302430411435">35</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s325AD1559EB95ACD84031E94E3A6CF57"><font style="font-family:Times New Roman;font-size:10pt;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s325AD1559EB95ACD84031E94E3A6CF57">72</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD587154A20295929A0A619991FE2F340"><font style="font-family:Times New Roman;font-size:10pt;">Item 3. Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD587154A20295929A0A619991FE2F340">73</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s4628008496A85BA1B834B077A738D450"><font style="font-family:Times New Roman;font-size:10pt;">Item 4. Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s4628008496A85BA1B834B077A738D450">73</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAEA079C5FB045A439533AB8168552A81"><font style="font-family:Times New Roman;font-size:10pt;">Item 5. Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAEA079C5FB045A439533AB8168552A81">73</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s230230A0E4C75A6F88B7605392AB2F2F"><font style="font-family:Times New Roman;font-size:10pt;">Item 6. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s230230A0E4C75A6F88B7605392AB2F2F">73</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s0F73A67C62D05262A4B1B60D9014FE5E"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0F73A67C62D05262A4B1B60D9014FE5E">74</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sD6E7498C199B5D14872504B10066E0EC"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Quarterly Report on Form&#160;10-Q&#160;contains express or implied &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as mended (the &#8220;Exchange Act&#8221;) that are based on our management&#8217;s belief and assumptions and on information currently available to our management. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and Investigational New Drug application (&#8220;IND&#8221;), Investigational Medicinal Product Dossier, Clinical Trial Application (&#8220;CTA&#8221;), New Drug Application (&#8220;NDA&#8221;), or other regulatory submissions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our dependence on current and future collaborators for developing, obtaining regulatory approval for and commercializing therapeutic candidates in the collaboration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our or a current or future collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the rate and degree of market acceptance of any approved therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercialization of any approved therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain collaborations and retain commercial rights for our therapeutic candidates in the collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our estimates of our expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to the use of proceeds from our private placement offering, and our needs for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to obtain additional funds for our operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our reliance on third parties to conduct our preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to attract and retain qualified key management and technical personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our financial performance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In Part I., Item 4. Controls and Procedures, the statements regarding internal controls</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the impact of government regulation and developments relating to our competitors or our industry; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other risks and uncertainties, including those listed in Part II, Item 1A&#8212;&#8220;Risk Factors.&#8221;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in Part II, Item 1A&#8212;&#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, references to &#8220;Exicure,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or similar terms refer to Exicure, Inc. and our wholly-owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s5D133804564059A491DA1AE59F61A19C"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sE060E7696E9B59B4A4274EDDF7D85A34"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sF733A208D9865EEF8F11CA5A91A81458"></a></div><div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONDENSED CONSOLIDATED BALANCE SHEETS </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March&#160;31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&#160;31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unbilled revenue receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">23,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:100px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">24,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,103</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 39,454,821 issued and outstanding, March 31, 2018; 39,300,823 shares issued and outstanding, December 31, 2017 </font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">54,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(38,090</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(33,615</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">24,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sF39DE074AF51589DA09EE2C42A7E0090"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended,<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,357,289</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">169,794</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s8A3533318FA75AD991CB62674F058289"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except shares)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.60493827160494%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:66%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Additional Paid-in- Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(33,615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">19,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Adoption of new accounting standard - ASC 606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(32,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">21,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8,532</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Issuance of common stock, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">145,466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(5,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(5,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,454,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">54,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(38,090</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">16,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sCB69C3081937561792F149658A2F5BE0"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Adjustments to reconcile net loss to cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Amortization of long-term debt issuance costs and fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value of warrant liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unbilled revenue receivable and accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(449</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,581</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capital expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(245</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(245</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Proceeds from exercise of common stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net increase decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,199</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents - beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12,424</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-cash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Issuance of common stock for professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred offering costs (accounts payable and accrued expenses)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-cash investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capital expenditures (accounts payable and accrued expenses)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s1BFB8F19BA485B868E511F31755285AB"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sE379F8FACFCF5435A5DCEBAFBEE8C53D"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">1. Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure, Inc. (&#8220;Parent&#8221;) is a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">clinical-stage</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;design of the Company&#8217;s SNAs gives rise to chemical and biological properties that </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Throughout this Quarterly Report on Form 10-Q, the terms &#8220;the Company&#8221; and &#8220;Exicure&#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">References to the &#8220;Merger&#8221; refer to the September 26, 2017 transaction whereby Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation, or Max-1, merged with and into Exicure Operating Company (f/k/a Exicure, Inc.), a privately-held Delaware Corporation referred to herein as Exicure OpCo, with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 (which then changed its name to Exicure, Inc.).  References to the &#8220;Private Placement&#8221; refers to the transactions following the Merger that occurred in several closings on September 26, 2017, October 27, 2017 and November 2, 2017 in which we sold to accredited investors approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$31,513</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;worth of shares of common stock (before deducting placement agent fees and expenses which are approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">), or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a privately-held Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these notes to unaudited condensed consolidated financial statements as the corporate conversion.   In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18,837</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was reclassified to Additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and December 31, 2017, and for the three months ended March 31, 2018 and 2017, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Going Concern</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the Company has generated an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,927</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Unaudited Interim Financial Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying interim consolidated balance sheet as of March 31, 2018, the interim consolidated statements of operations for the three months ended March 31, 2018 and 2017, the interim consolidated statement of changes in stockholders&#8217; equity for the three months ended March 31, 2018, and the interim consolidated statements of cash flows for the three months ended March 31, 2018 and 2017, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and the results of its cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in these notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, or any other interim periods, or any future year or period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revision of Prior Period Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We have revised the accompanying comparative financial statements to correct the immaterial errors. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The correction of the errors increased prepaid expense and other current assets by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$933</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, decreased accrued expenses by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$96</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and decreased accumulated deficit by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at December 31, 2017. </font></div><div><a name="sC5E151ADE940508EB2ED0622425635C8"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2. Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form&#160;10-K, except as required by recently adopted accounting pronouncements, as discussed below.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(ASC 605).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the contract with the customer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determine the transaction price.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Allocate the transaction price to performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recognize revenue when or as the Company satisfies a performance obligation.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Licenses of intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone payments:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the Company&#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Company adopted ASC 606 on a modified retrospective basis.  See above &#8220;Revenue Recognition&#8221; for a discussion of the Company&#8217;s updated policies related to revenue recognition effective January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Impact of adoption of ASC 606</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of the date of adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2018; (ii) there were no impacts to the balances of the accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;each in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&#8217;s statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div><a name="sD72103DFC8FE5FAEBC3A95B90D9E4B4B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">3. Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma, L.P. (&#8220;Purdue&#8221;) and referred to herein as the &#8220;Purdue Collaboration.&#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Company is eligible to receive up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$776,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Note 13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for recent developments related to the Purdue Collaboration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the adoption of ASC 606, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, the Company recorded the unamortized deferred revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as an adjustment to the beginning balance of retained deficit at January 1, 2018.  See Note 2, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information related to the adoption of ASC 606.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company identified multiple performance obligations as part of the Purdue Collaboration agreement, including the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, discussed above, and the research and development services.  The Company determined that the performance obligations should not be combined, the license should be recognized at the time the license is granted and the research and development services at the time the service is performed.  The Purdue Collaboration agreement includes contingent promises related to specified research, development and regulatory milestones and sale-based milestones.  Each contingent promise related to contingent and milestone payment is evaluated to determine whether it represents a material right.  The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which it is determined that the revenue is not subject to a significant reversal.  To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration agreement as revenue.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the three months ended March 31, 2018, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which consisted entirely of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the three months ended March 31, 2017, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,432</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$363</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="s02E402F6D5175976BD6717749C3912DD"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">4. Supplemental Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(918</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$86</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$38</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;ended March 31, 2018 and 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s96CDFC50666A529BACAB11ADB9361602"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">5. Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 15, 2018, the Company and Hercules Technology Growth Capital Limited (&#8220;Hercules&#8221;) amended its loan agreement so that amortization payments due for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">thirteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, shall begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">eighteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(18) consecutive months.  Any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At March 31, 2018 and December 31, 2017, the carrying value of the current and non-current portion of long-term debt is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,879</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,855</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At March 31, 2018, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:86%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Principal balance outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,879</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Noncurrent portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,103</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$136</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$153</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the three months ended March 31, 2018 and 2017, respectively.</font></div><div><a name="s83A839F082675670857FD8CE05DE2726"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">6. Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018 and December 31, 2017, the Company had authorized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">200,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of March 31, 2018, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,454,821</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.  As of December 31, 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,300,823</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The holders of shares of the Company&#8217;s common stock are entitled to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&#160;non-assessable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018 and December 31, 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of preferred stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div><a name="sCA1567B081D35472A06F402EC34B58E7"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">7. Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,498,264</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at March 31, 2018 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,997</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.8 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:59%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.9 to 6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.72%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">82.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2018 and 2017 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. At March 31, 2018, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is the per share price paid by outside investors in the Private Placement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.13</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.92</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,672,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">674,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercisable - March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,597,078</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vested and Expected to Vest -</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,916,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the three months ended March 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$202</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div><a name="s654DF3D9F3B05CF5AF9BC77E14B89E3F"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">8. Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company incurred a pretax loss in each of the three months ended March 31, 2018 and 2017, which consists entirely of loss in the U.S. and resulted in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;provision for income tax expense during the periods then ended. The effective tax rate is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in each of the three months ended March 31, 2018 and 2017 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div><div><a name="sD5AA4D1082A151B0BA1AC52AE34F25DF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">9. Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2018 and 2017.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three months ended March 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,357,289</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">169,794</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,683,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">413,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s8D7534D66635512C99EE0335A93698B3"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">10. Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s common stock warrant liability is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:79%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;change in the estimate of expected volatility at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;change in the estimate of fair value of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">common stock at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$94</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s16751C2F6E06568A90B588D858C820D9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">11. Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$52</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of March 31, 2018 and December 31, 2017, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Future minimum lease payments as of March 31, 2018 are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, we obtained exclusive license as to NU&#8217;s rights in certain SNA technology we jointly own with NU (the &#8220;February 2016 license agreement&#8221;). Our license to NU&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of March 31, 2018, the Company has paid to NU an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,419</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in consideration of each of the obligations described above. </font></div><div><a name="sB2664A6C5CF65BCF98C202EAD33D98DC"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">12. Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC, our former parent and largest stockholder.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at March 31, 2018 and December 31, 2017, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in each of the three months ended March 31, 2018 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.</font></div><div><a name="s6CE5EACEEC7A5C4F9D846B41B7ED97D8"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">13. Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that, other than the recent developments related to the Purdue Collaboration disclosed above, there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="sBDB9D6A64AC8549C9A6D51D21BC0CB52"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated interim financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q. Management&#8217;s Discussion is designed to provide an understanding of our operations and financial performance and should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading &#8220;Forward-Looking Statements&#8221; elsewhere in this Quarterly Report on Form 10-Q. You should review the disclosure under the heading &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</font></div><div><a name="sB3A0CE64C3B15C9F929CAFFD5BFDEA38"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operating Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in a Phase 1 clinical trial of our therapeutic candidate, AST-005, and in preclinical studies of our two other therapeutic candidates, XCUR17 and AST-008, both of which are currently in Phase 1 clinical trials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have three clinical programs: AST-008, XCUR17, and AST-005.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">AST-008</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-008 is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications. AST-008 has exhibited anti-tumor activity as both a monotherapy and in combination with certain checkpoint inhibitors across a range of preclinical models of solid and hematological cancers. In the third quarter of 2017, we received an authorization from the MHRA, the competent health authority of the United Kingdom, to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. We expect this trial to be completed in the third quarter of 2018. Our current plan anticipates preparing and commencing a Phase 1b/2 clinical trial for AST-008 late this year. We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">XCUR17</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17 is an SNA targeted to IL-17RA for the treatment of mild to moderate psoriasis. We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. Our CTA was approved in February 2018 and we began dosing patients in our Phase 1 clinical trial in April 2018. We expect this clinical trial to be completed in the third quarter of 2018.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">AST-005</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting tumor necrosis factor, or TNF, for the treatment of mild to moderate psoriasis that is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of tumor necrosis factor messenger RNA, or TNF mRNA.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of Exicure&#8217;s collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial evaluated the safety, tolerability, and plaque thickness following topical application of different strengths of AST-005 formulated as a </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">topical gel. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied. Seventy-five areas of skin were treated with AST-005 gel across twenty-five patients. One mild and one moderate adverse event in a single patient was reported in a placebo treated area. No serious adverse events were observed in any patient. As designed, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to&#160;AST-005,&#160;an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets.&#160; Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue has notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and all of our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in revenue since inception through March 31, 2018 has been earned through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. In addition to our revenue, from inception through March 31, 2018, we have funded our operations through private placements of preferred stock with gross proceeds totaling $42.8&#160;million, sales of common stock in the Private Placement with gross proceeds totaling $31.5 million, and debt financing totaling $6.0&#160;million. As of March 31, 2018, our cash and cash equivalents were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception, we have incurred significant operating losses. Our net loss was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018, our accumulated deficit was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to incur significant and increasing losses in the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">conduct further preclinical studies and clinical trials of AST-008 and XCUR17;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase research and development for the discovery and development of additional therapeutic candidates;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">advance other therapeutic candidates into preclinical and clinical development;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase our research and development to enhance our technology;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">procure clinical trial materials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operate as a public company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have not generated any commercial product revenue nor do we expect to generate substantial revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates. Successful therapeutic development and regulatory approval are subject to significant </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">uncertainty and we expect will take at least five years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="s10E02A6835D85F568FDEF282A00337C0"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Registration Statement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed and caused to become effective a registration statement with the SEC on February 6, 2018 registering the resale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,714,143</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock issued in 2017 in connection with the Private Placement. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have been informed by our sponsoring market maker that FINRA has cleared our Form 211.  We are now addressing final administrative items in order to begin trading on the OTCQB tier of the OTC.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Appointment of Chief Operating Officer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 20, 2018, we announced that Matthias G. Schroff, Ph.D, was appointed to serve as Chief Operating Officer (&#8220;COO&#8221;) of the Company, effective April 16, 2018.  Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TLR9 biology and broad clinical program management. For more information on the appointment of Dr. Schroff, please see the Current Report on Form 8-K filed with the SEC on April 20, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of Exicure&#8217;s collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial evaluated the safety, tolerability, and plaque thickness following topical application of different strengths of AST-005 formulated as a topical gel. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied. Seventy-five areas of skin were treated with AST-005 gel across twenty-five patients. One mild and one moderate adverse event in a single patient was reported in a placebo treated area. No serious adverse events were observed in any patient. As designed, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue has notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We view our operations and manage our business as one segment, which is the discovery, research and development of treatments based on our SNA technology.</font></div><div><a name="s32C125B5739E566E9D682DC5E349B4DF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our critical accounting policies require the most significant judgments and estimates in the preparation of our consolidated financial statements. There have been no significant changes to our critical accounting policies from those which were discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, with the exception of our policy relating to revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As discussed in Note 2 of the accompanying unaudited condensed consolidated financial statements, we adopted Accounting Standards Update No.&#160;2014-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(&#8220;ASU 2014-09&#8221;) effective January 1, 2018.  Refer to Note 2 of the accompanying unaudited condensed consolidated financial statements for a description of policy related to revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently adopted accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 2 of the accompanying unaudited condensed consolidated financial statements for a description of recently adopted accounting pronouncements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent accounting pronouncements not yet adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 2 of the accompanying unaudited condensed consolidated financial statements for a description of recent accounting pronouncements not yet adopted.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="sF8049324C6BE5092B6A0AA6041725C06"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Comparison of the Three Months Ended March 31, 2018 and 2017</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the results of our operations for the three months ended March 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,802</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Revenue in both the three months March 31, 2018 and 2017 related to the Purdue Collaboration.  In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million in December 2016.  Prior to the adoption of ASC 606, the upfront payment of $10.0&#160;million was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, we recorded the unamortized deferred revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as an adjustment to the beginning balance of accumulated deficit at January 1, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$36 thousand</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the three months ended March 31, 2018 related to research and development activities that is reimbursable by Purdue and is presented on a gross basis in the accompanying consolidated statement of operations.  We recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of collaboration revenue in the three months ended March 31, 2017, which consisted of three months of amortization of deferred revenue mentioned above and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying consolidated statement of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reimbursement of certain research and development expenses, in connection with the Purdue Collaboration or any future collaboration and licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recent Developments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;above for more information on the Purdue Collaboration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three&#160;Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Clinical development programs expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Platform and discovery-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">915</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Employee-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Facilities, depreciation, and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March&#160;31, 2017, a decrease of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The decrease in research and development expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily due to a net decrease in costs related to our clinical development programs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, partially offset by higher employee-related expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and higher platform and discovery-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The net decrease in clinical development programs expense was mostly due to lower costs associated with AST-005 (for which the Phase 1b clinical trial, subject of the Purdue Collaboration, ended during the first quarter of 2018) and lower costs for preparation for the Phase 1 clinical trial of XCUR17, partially offset by increased costs for Phase 1 clinical trial activities of AST-008.  Included in clinical development expense for the three months ended March 31, 2018 and 2017 was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$36 thousand</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of expense that is reimbursed by Purdue (included in revenue) related to the Phase 1b trial of AST-005.  Higher employee-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was mostly the result of salary increases and a change in mix of scientific staff as well as higher non-cash stock-based compensation expense.  The increase in platform and discovery-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is mostly due to higher costs to maintain our intellectual property portfolio, partially offset by lower costs related to contract research organizations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our research and development expenses to increase in 2018 as we continue spending on our clinical development programs, further develop our SNA technology platform and broaden our pipeline of SNA-based candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">General and administrative expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">General and administrative expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2017, an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">43%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This increase is due to higher legal costs of $0.2 million associated with the preparation of Form S-1 to register the shares of common stock in connection with the Merger and the Private Placement as well as other activities to obtain regulatory approval for </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the trading of our common stock on the over-the-counter market and higher compensation and related expenses of $0.2 million associated with salary increases.  Also contributing to the increase in general and administrative expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were higher costs of $0.2 million associated with being a public company, including higher expense for director and officer insurance and investor and public relations.    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company. These increases will likely include legal, accounting and filing fees, directors&#8217; and officers&#8217; liability insurance premiums and fees associated with investor relations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Interest expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other income (loss), net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our common stock warrant liabilities, and gains and losses on foreign currency transactions.</font></div><div><a name="s98BDEF1CD012523BB788E68822EBF56A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To date we have primarily funded our operations through private placements of equity securities, the Purdue Collaboration, a debt financing, and grants from governmental agencies. Since inception and through March 31, 2018, we have received approximately $95.3 million in aggregate gross proceeds from these transactions, including $42.8 million in aggregate gross proceeds from private placement offerings of preferred stock, $31.5 million in gross proceeds from sales of common stock in the Private Placement with gross proceeds totaling $31.5 million, an upfront payment of $10.0&#160;million in connection with the Purdue Collaboration, $6.0 million in debt financing, and an aggregate of $5.0 million from grants awarded by governmental agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception, we have not generated any product revenue and have incurred recurring net losses.  Our Company is not profitable, and we cannot provide any assurance that we will ever be profitable. As of March 31, 2018, we have an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on our current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to us. If we are unable to obtain such additional financing, we will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;See &#8220;&#8212;Funding Requirements&#8221; below for additional information on our future capital needs.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a summary of our cash flows for the three months ended March 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three&#160;Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(245</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net increase decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,199</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash used in operating activities was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2018 and 2017, respectively. The decrease in cash used in operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily due to the absence of the first quarter 2017 payment of $1.5&#160;million in connection with the Northwestern University license agreements and lower cash used for working capital.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash used in investing activities was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the three months ended March 31, 2018 and 2017, respectively. Cash used in investing activities for the 2017 period was primarily due to the purchase of scientific equipment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Hercules Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February&#160;17, 2016, we entered into a loan and security agreement with Hercules. The loan agreement provided for funding in an aggregate principal amount of up to $10.0&#160;million in two separate tranches. The first tranche was funded on February&#160;17, 2016 in the amount of $6.0&#160;million. A second tranche of $4.0&#160;million was available provided that we met certain milestones on or before December&#160;31, 2016. We did not meet these milestones and, therefore, we did not draw the second tranche, the availability of which expired on December&#160;31, 2016. The principal balance of the term loan under the Hercules loan facility bears interest at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in The Wall Street Journal) minus 3.50%. We were required to make interest-only payments through June 2017. Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019. Pursuant to an amendment dated January 15, 2018, amortization payments due for the thirteen (13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, shall begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to eighteen (18) consecutive months. Any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date. On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement. In addition, if we prepaid the term loan on or prior to February&#160;1, 2017, we would be required to pay a prepayment charge equal to 3% of the amount being prepaid, if we prepaid the term loan after February&#160;1, 2017 but on or prior to February&#160;1, 2018, we would be required to pay a prepayment charge equal to 2% of the amount being prepaid, and if we prepay the term loan after February&#160;1, 2018, we must pay a prepayment charge of 1% of the amount being prepaid. As of the date of this report, we have not prepaid the Hercules term loan.  The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The term loan under the Hercules loan facility is secured by substantially all of our assets, other than intellectual property, which is the subject of a negative pledge. Under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without Hercules&#8217; prior consent.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing. Hercules has not yet exercised this right to participate which expires on the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect that our primary uses of capital will continue to be third-party clinical research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on our current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;However, we may require additional capital for the further development of our existing therapeutic candidates and may also need to raise additional funds sooner to pursue other development activities related to additional therapeutic candidates. We believe that we will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements to fund our current operating plans, which we believe will allow us to execute on the strategy and pipeline development as described in this Quarterly Report on Form 10-Q. To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We cannot assure you that such additional financing, if available, can be obtained on terms acceptable to us. If we are unable to obtain such additional financing, we would need to reevaluate our future operating plans.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements are difficult to forecast and will depend on many factors, including:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number and characteristics of therapeutic candidates that we pursue;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the progress, costs and results of our preclinical studies and clinical trials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the outcome, timing and cost of regulatory approvals;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays that may be caused by changing regulatory requirements;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost and timing of hiring new employees to support our continued growth;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in this Quarterly Report on Form 10-Q for additional risks associated with our substantial capital requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Until such time, if ever, we generate product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="sB7D34AB472C25C8485992697B5B8C5A5"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no material changes outside the ordinary course of business during the period covered by this Quarterly Report on Form 10-Q from the contractual obligations and commitments discussed in our Annual Report on Form 10-K for the year ended December 31, 2017</font></div><div><a name="sC24115ECD17353BEA0ACAABBF3DD0637"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></div><div><a name="s5786233E3032526B9AFB8308C03D1530"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">JOBS Act</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted by the federal government. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="s213B96CD2A81533894D39E7337ED3F63"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Some of the securities that we invest in may have market risk related to changes in interest rates. As of March 31, 2018 and December&#160;31, 2017, we had cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, consisting of interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100&#160;basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, money market funds, government and non-government debt securities and corporate obligations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to interest rate risk in connection with our borrowings under the $6.0 million term loan with Hercules.  The principal balance of the term loan under the Hercules loan facility bears interest at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in The Wall Street Journal) minus 3.50% which bears interest at a variable per annum rate calculated for any day as the greater of either (i) the prime rate plus 6.80%, and (ii) 10.55%. We currently do not engage in any interest rate hedging activity and we have no intention to do so in the foreseeable future. Based on the current interest rate of the term loan with Hercules and the scheduled payments thereunder, we believe a 100 basis point increase in interest rates would not have a material impact on our financial condition or results of operations.</font></div><div><a name="s97E51EC7E22652158C3791BEBE7744C7"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item&#160;4. Controls and Procedures.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As we are an emerging growth company and a newly public company, we have not prepared a formal management&#8217;s report on internal control over financial reporting, as would otherwise be required by Section 404 of the Sarbanes-Oxley Act of 2002, nor have we engaged an independent registered public accounting firm to perform an audit of our internal control over financial reporting as of any balance sheet date in our condensed consolidated interim financial statements. Our compliance with Section 404 of the Sarbanes-Oxley Act will first be subject to management&#8217;s assessment regarding internal control over financial reporting in connection with the filing of our Annual Report on Form 10-K for the fiscal year ending December 31, 2018, and we will not be required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting until the filing of our first Annual Report on Form 10-K after we lose emerging growth company status, which may not be until the 2022 Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2018. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the evaluation of our disclosure controls and procedures as of March 31, 2018, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that all information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and forms, due to a material weakness in internal control over financial reporting.  The material weakness related to a deficiency in the Company&#8217;s information and communication controls, which led to ineffectively designed controls over management&#8217;s review of certain research and development contracts to ensure expenses were recognized as incurred by third-party contract research organizations.  Specifically these ineffectively designed controls, which arose in a prior period and were identified in the quarter ended March 31, 2018, resulted in an immaterial error, which was corrected in this Quarterly Report on Form 10-Q in previously issued financial statements as disclosed in Note 1 to the unaudited condensed consolidated interim financial statements for the period ended March 31, 2018. </font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Remediation Plan for Material Weakness in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are working towards remediating the deficiencies that led to the material weakness by enhancing the information used for periodic assessment of contract progress and increasing the frequency of communication in the process for accounting for certain research and development contracts with contract research organization</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">s</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to ensure expenses are recognized as incurred.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We are working to remediate the material weakness as quickly and efficiently as possible and expect that the material weakness will be remediated by the end of fiscal 2018.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other than the remediation efforts related to the material weakness discussed above, no changes occurred in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during the fiscal quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><a name="s7613DD62978555E8AEC018304441B665"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8211; OTHER INFORMATION</font></div><div><a name="s512CA2DAA9CA58EBA11D26873A81E943"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item&#160;1. Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sB7688808B3FE51B0A60E302430411435"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary SNA technology. We have a limited operating history. Since our inception in June 2011, we have devoted our resources to the development of SNA technology. We have had significant operating losses since our inception. As of March 31, 2018, we have generated an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. For the three months ended March 31, 2018 and 2017, our net loss was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We plan to develop a pipeline of therapeutic candidates using our proprietary SNAs as therapeutic agents. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNAs and the identification and optimization of SNAs is relatively new. Further, the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">scientific evidence to support the feasibility of developing therapeutic treatments based on SNAs is both preliminary and limited. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may discover that the SNAs do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNAs. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNAs may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock will decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) has limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize therapeutics using SNAs, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board (&#8220;IRB&#8221;), approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. In our completed Phase 1 trial, AST-005 did not show an antipsoriatic effect. Although we believe this result was due to the short length of this clinical trial, there is no guarantee that AST-005 will show an antipsoriatic effect in future </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">clinical trials of longer duration. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays in submitting INDs or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency (&#8220;EMA&#8221;) or European Union national competent authorities, regarding the scope or design of our clinical trials; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays in enrolling research subjects in clinical trials; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">high drop-out rates of research subjects; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">greater than anticipated clinical trial costs; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">poor effectiveness of our therapeutic candidates during clinical trials; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">failure of our third party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular, especially in light of the novelty of our therapeutic candidates; or </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">varying interpretations of data by the FDA and similar foreign regulatory agencies; or</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">refusal of the FDA to accept data from clinical trials conducted outside the United States, or acceptance of these data subject to certain conditions by the FDA.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time and at any stage during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of any subsequent clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to&#160;lack of efficacy or adverse safety profiles despite promising results in earlier clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. &#160;If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenues from any of these therapeutic candidates will be delayed.&#160; In addition, any delays in completing clinical trials will increase our costs, slow down our therapeutic candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.&#160; Any of these occurrences could materially and adversely affect our business, financial condition, results of operations or prospects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale. As of March 31, 2018 and December&#160;31, 2017, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and cash equivalents, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on our current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to establish and maintain successful licenses, collaborations and alliances; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to satisfy the requirements of clinical trial protocols, including patient enrollment; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain regulatory approvals; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain additional capital to support and expand our operations; and </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to market our products to achieve acceptance and use by the medical community in general. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to realize revenue from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants, and proceeds from our loan agreement with Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">variations in the level of expense related to our therapeutic candidates or future development programs; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additions and departures of key personnel; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory developments affecting our therapeutic candidates or those of our competitors; and </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in general market and economic conditions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent on Purdue for the successful development of therapeutic candidates in our collaboration arrangement with Purdue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue. As part of the agreement, Purdue has the option to obtain from us the full worldwide development and commercial </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rights to AST-005, an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. In April 2018, Purdue notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development with Exicure of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5 million upon successful completion of certain research, regulatory and commercial sales milestones. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The success of our collaboration programs with Purdue depends largely upon the efforts of Purdue. Purdue has sole discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, it applies to the development and, if approval is obtained, commercialization and marketing of the therapeutic candidates covered by the collaboration. Purdue may not be effective in obtaining approvals for the therapeutic candidates developed under the collaboration arrangement or marketing or arranging for necessary supply, manufacturing or distribution relationships for any approved products. Purdue may change its strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Purdue has a variety of marketed products, and its own corporate objectives may not be consistent with our best interests. If Purdue fails to develop, obtain regulatory approval for or ultimately commercialize any therapeutic candidate under our collaboration or if Purdue terminates our collaboration, our business, financial condition, results of operations and prospects could be materially and adversely affected. In addition, any dispute or litigation proceedings we may have with Purdue in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We rely on third party clinical investigators, contract research organizations (&#8220;CROs&#8221;), clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable Good Laboratory Practices (&#8220;GLPs&#8221;) and clinical trials to be conducted in accordance with applicable FDA regulations and Good Clinical Practices (&#8220;GCPs&#8221;), including requirements for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Because we rely on third party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We rely on third party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a single source supplier on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as current Good Manufacturing Practices (&#8220;cGMPs&#8221;). In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to rely on third party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">loss of the cooperation of a future collaborator; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">requirements to cease distribution or to recall batches of our therapeutic candidates; and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may not successfully engage in strategic transactions, including any collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expense, and present significant distractions to our management. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or in-licensing of therapeutic candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved therapeutic candidate do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired therapeutics, therapeutic candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and may have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our therapeutic candidates and have a negative impact on the competitiveness of any therapeutic candidate that reaches market. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded pharmaceutical, biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Dynavax Technologies Corp., Idera </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pharmaceuticals, Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our lead therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie Inc.&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab and pembrolizumab. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third party payors to accept and use, or to provide favorable reimbursement for, any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of our receipt of any marketing and commercialization approvals; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the terms of any approvals and the countries in which approvals are obtained; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the safety and efficacy of our therapeutic candidates; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">relative convenience and ease of administration of our therapeutic candidates; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the willingness of patients to accept any new methods of administration; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of our physician education programs; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the availability of adequate government and third party payor reimbursement; </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the pricing of our products, particularly as compared to alternative treatments; and </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication. During such period, marketing applications for similar medicinal products will not be accepted, unless certain exceptions apply. In the EU, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, David S. Snyder, our Chief Financial Officer, Ekambar Kandimalla, Ph.D., our Chief Scientific Officer, and Matthias G. Schroff, our Chief Operating Officer.  The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have limited experience in therapeutic development and limited experience with clinical trials of therapeutic candidates. As our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment, registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, for nationally authorized medicinal products, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Price controls imposed in foreign markets may adversely affect our future profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control at the national level, and in some cases also at the regional level. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of our therapeutics or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including debarment or disqualification of those employees from participation in FDA-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operations. For instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive, and financial penalties may also apply. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Skokie, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Skokie facilities comply with the relevant guidelines of Skokie, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our information technology systems could face serious disruptions that could adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current operations are located in our facilities situated in Skokie, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018 and as of December&#160;31, 2017, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and cash equivalents, respectively. We historically have invested excess cash in certificates of deposit or money market mutual funds that invest in U.S. government or U.S. government agency securities, floating rate and variable rate demand notes of U.S. and foreign corporations, and commercial paper. These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S. sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues. We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounting methods and policies for biotechnology companies, including policies governing revenue recognition, research and development and related expenses, and accounting for stock-based compensation, are subject to review, interpretation and guidance from our auditors and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise change or revise our historical financial statements, including those contained in this report. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have identified a&#160;material weakness&#160;in our internal control over financial reporting, and if we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock may be adversely effected, and we may become subject to litigation and regulatory investigation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have identified one&#160;material weakness&#160;in our internal control over financial reporting related to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a deficiency in our information and communication controls, which led to ineffectively designed controls over management&#8217;s review of certain research and development contracts to ensure expenses were recognized as incurred by third-party contract research organizations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. A&#160;material weakness&#160;is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the registrant&#8217;s annual or interim condensed consolidated financial statements will not be prevented or detected in a timely basis. This deficiency resulted in the overstatement of accumulated deficit by $1.0 million, the understatement of prepaid expense and other current assets by $0.9 million, and the overstatement of accrued expenses by $0.1 million as of December 31, 2017. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As further described above and in Part I, Item 4 &#8220;Controls and Procedures,&#8221; of this Form 10-Q, management is implementing a remediation plan to implement controls in the near term </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">by enhancing the information used for </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">periodic assessment of contract progress and increasing the frequency of communication in the process for accounting for certain research and development contracts with contract research organizations to ensure expenses are recognized as incurred.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, if we identify new material weaknesses in the future in our internal controls over financial reporting, we may not detect errors in a timely manner and our condensed consolidated financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. We may also fail to report our financial results on a timely and accurate basis, which could result in sanctions, lawsuits, or other adverse consequences that would materially harm our business. In addition, we could become subject to investigations by the stock exchange on which our securities are eventually listed, the SEC, or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and our financial condition, or divert financial and management resources from our core business. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and expect to incur continued losses in the future. We must obtain additional funds to finance our operations and to remain a going concern. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern. As a result, we included an explanatory paragraph in our consolidated financial statements for the period ended March&#160;31, 2018 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional funding. We believe that our existing working capital will be sufficient to fund our current operating plans through at least the end of March 2019. We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available financial resources much faster than we currently expect and need to raise additional funds sooner than we anticipate. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The perception&#160;of our ability&#160;to continue&#160;as a&#160;going concern&#160;may&#160;make&#160;it&#160;more&#160;difficult&#160;for&#160;us to obtain&#160;financing for&#160;the&#160;continuation&#160;of our operations&#160;and could&#160;result&#160;in the&#160;loss&#160;of confidence&#160;by investors,&#160;suppliers&#160;and employees. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business may be affected by litigation and government investigations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, defense of litigation claims can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of March 31, 2018, our patent portfolio consists of over 55 issued patents and allowed patent applications and over 140 pending patent applications. We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011, involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:-6px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A third party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We will develop additional proprietary technologies that are patentable. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The patents of others will not have an adverse effect on our business. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We currently license patent rights from Northwestern University and may in the future license patent rights from third party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. We may also license additional third party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutics. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">inter alia</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We or our licensors, or any current or future strategic partners, may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future strategic partners, may be subject to third party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is also possible that we have failed to identify relevant third party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third party intellectual property rights. Any of these events, even if we </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we are unable to pr</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">otect the con</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">fidentiality of our trade secrets, our business and competitive position would be harmed.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Northwestern University license agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Third parties may independently develop similar or superior technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University license agreements. The Northwestern University license agreements indicate that the rights licensed to us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or the Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to the Company&#8217;s knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. In addition, because there may be therapeutic candidates approved for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the therapeutic candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third party payors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Certain of our product candidates may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of our product candidates may require companion diagnostics to identify appropriate patients for those product candidates in certain indications. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. We may rely on third parties for the design, development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics. If these parties are unable to successfully develop companion diagnostics for these product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected and we may not be able to obtain marketing authorization for these product candidates. Furthermore, our ability to market and sell, as well as the commercial success, of any of our product candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic and supply such companion diagnostic will harm our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although we do not currently have any products on the market, once we begin commercializing our therapeutic candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others: </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse regulatory inspection findings; </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">warning or untitled letters; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, marketing our therapeutics; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">suspension of review or refusal to approve pending applications or supplements to approved applications; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion from participation in government-funded healthcare programs; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion from eligibility for the award of government contracts for our therapeutics; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">FDA debarment; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">suspension or withdrawal of therapeutic approvals; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seizures or administrative detention of therapeutics; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions; and </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">civil and criminal penalties and fines. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Any therapeutics we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product is typically furnished incident to a physician&#8217;s services; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use); and </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product has been approved by the FDA. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under current law, as a condition of receiving Medicare Part B reimbursement (the Medicare program that generally covers physician-administered, outpatient drugs) for a manufacturer&#8217;s eligible drugs or biologicals, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program, the Veterans Health Administration program, and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Reimbursement rates under Medicare Part B would depend in part on whether the newly approved therapeutic would be eligible for a unique billing code. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that the efforts of governments and third party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Among the provisions of the ACA addressing coverage and reimbursement of pharmaceutical products, of importance to our potential therapeutic candidates are the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; In February 2018, Congress passed the Bipartisan Budget Act of 2018, which, beginning in 2019, increased the discount to be paid by pharmaceutical companies from 50% to 70% of a brand-name drug&#8217;s negotiated price and added biosimilars to the coverage gap discount program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Separately, pursuant to the health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in recent years, the U.S. Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures. For example, as a result of the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015, an annual 2% reduction to Medicare payments took effect on April&#160;1, 2013 and has been extended through 2027. These across-the-board spending cuts could adversely affect our future revenues, earnings, and cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing coverage, reimbursement, and marketing of products regulated by CMS or other government agencies. In addition to new legislation, CMS coverage and reimbursement policies are often revised or interpreted in ways that may significantly affect our business and our products. In particular, we expect that the new administration and the U.S. Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated that it </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law. Congress has also enacted legislation that repeals certain portions of the ACA, including the Tax Cuts and Jobs Act, passed in December 2017, which included a provision that eliminates the penalty under the ACA&#8217;s individual mandate, effective January 1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things, repealed the Independent Payment Advisory Board that was established by the ACA and was intended to reduce the rate of growth in Medicare spending. There is still uncertainty with respect to the impact President Trump&#8217;s Administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The healthcare industry is heavily regulated in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">the</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a healthcare company, our operations, clinical trial activities and interactions with healthcare providers may be subject to extensive regulation in the U.S., particularly if the company receives FDA approval for any of its therapeutics in the future. For example, if we receive FDA approval for a therapeutic for which reimbursement is available under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g., the False Claims Act), prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g., the federal Anti-Kickback Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals, or Open Payments. We are not able to predict how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices and activities under one or more of these laws. If our past or present operations are found to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Similarly, HIPAA prohibits, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">obtain</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or the BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place, beginning in January 2013, although the American Taxpayer Relief Act of 2012 delayed the BCA&#8217;s automatic cuts until March&#160;1, 2013. While the Medicare program&#8217;s eligibility and scope of benefits are generally exempt from these cuts, Medicare payments to providers and Part D health plans are not exempt. The BCA did, however, provide that the Medicare cuts to providers and Part D health plans would not exceed two percent. President Obama issued the sequestration order on March&#160;1, 2013, and cuts went into effect on April&#160;1, 2013. Additionally, the Bipartisan Budget Act of 2015 extended sequestration for Medicare through fiscal year 2027. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. federal budget remains in flux, which could, among other things, cut Medicare payments to providers. Although the BBA passed in February 2018 enacts a two-year federal spending agreement and raises the federal spending cap on non-defense spending for fiscal years 2018 and 2019, the Medicare program is frequently identified as a target for spending cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. In addition, we cannot predict any impact President Trump&#8217;s administration and the U.S. Congress may have on the federal budget. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we could be sued and held liable for harm caused to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the therapeutic may become less competitive; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Significant developments stemming from the United Kingdom&#8217;s recent referendum on membership in the European Union could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June&#160;23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union. This referendum has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and this uncertainty may last for years. Any business we conduct, now and in the future, in the United Kingdom, the European Union, and worldwide could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom&#8217;s referendum. The referendum, and the likely withdrawal of the United Kingdom from the European Union it triggers, has caused and, along with events potentially occurring in the future as a consequence of the United Kingdom&#8217;s withdrawal, including the possible breakup of the United Kingdom, may continue to cause significant volatility in global financial markets, including in global currency and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">debt markets. This volatility could cause a slowdown in economic activity in the United Kingdom, Europe, or globally, which could adversely affect our operating results and growth prospects. In addition, our business could be negatively affected by new trade agreements between the United Kingdom and other countries, including the U.S., and by the possible imposition of trade or other regulatory barriers in the United Kingdom. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is currently unclear how regulations affecting clinical trials, the approval of our future therapeutic candidates, and the sale of these therapeutic candidates will be affected by this referendum either in the United Kingdom or elsewhere in Europe. These possible negative impacts, and others resulting from the United Kingdom&#8217;s actual or threatened withdrawal from the European Union, may adversely affect our operating results and growth prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by&#160;non-affiliates&#160;exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in&#160;non-convertible&#160;debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a market for our common stock develops, its market price could fluctuate substantially due to a variety of factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; in this report and the following: </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of competitive therapeutics or technologies; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our therapeutics; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the recruitment or departure of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">announcement and expectation of additional financing efforts; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">speculation in the press or investment community; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">trading volume of our common stock; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the concentrated ownership of our common stock; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in accounting principles; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest; </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">natural disasters and other calamities; and </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general economic, industry and market conditions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The future issuance of equity or of debt securities that are convertible into equity may dilute your investment and reduce your equity interest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. To the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities. For example, we have filed, and the SEC has declared effective, a registration statement to register the resale of up to 39,714,143 shares of our common stock issued in connection with the Merger and the Private Placement or held by pre-Merger stockholders of us. This registration statement will permit the resale of these shares at any time for up to five years from the effective date of the registration statement. The resale of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Furthermore, we expect that, because there will be a large number of shares registered pursuant to this registration statement, selling stockholders will continue to offer shares covered by this registration statement for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to this registration statement may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our&#160;debt obligations expose us to risks that could adversely affect our business, operating results and&#160;financial condition and may result in further dilution to our stockholders. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have entered into a loan and security agreement with Hercules pursuant to which we may borrow in an aggregate principal amount of up to $10.0&#160;million from Hercules at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The Wall Street Journal</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) minus 3.50%. We were required to make interest only payments on the amounts borrowed until June 2017. Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019. Pursuant to an amendment dated January 15, 2018, amortization payments due for the thirteen (13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, shall begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to eighteen (18) consecutive months. Any remaining obligations under the loan agreement and other loan documents (other than the warrant) are due and payable on the maturity date. On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement. To the extent we desire to prepay the indebtedness prior to maturity, we will be obligated to pay a prepayment penalty to Hercules ranging from 1% to 3% of the amounts being prepaid, depending on when such prepayment occurs. The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets. Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing. Hercules has not yet exercised this right to participate. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to make payments on this indebtedness depends on our ability to generate cash in the future. We expect to experience negative cash flow for the foreseeable future as we fund our operations and capital expenditures. There can be no assurance that we will be in a position to repay this indebtedness when due or obtain extensions of the maturity date. We anticipate that we will need to secure additional funding in order for us to be able to satisfy our obligations when due. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If that additional funding involves the sale of equity securities or convertible securities, it would result in the issuance of additional shares of our capital stock, which would result in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dilution to our stockholders. The indebtedness is secured by substantially all of our assets other than intellectual property, on which we have given Hercules a negative pledge. In addition, under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without the prior consent of Hercules. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This level of debt could have important consequences to you as an investor in our securities. For example, it could: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limit our flexibility in planning for the development, clinical testing, approval and marketing of our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">place us at a competitive disadvantage compared to any of our competitors that are less leveraged than we are; </font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase our vulnerability to both general and industry-specific adverse economic conditions; and </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limit our ability to obtain additional funds. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The employment agreements with our executive officers may require us to pay severance benefits to officers in connection with termination of employment or upon a change of control of us, which could harm our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of David A. Giljohann, our Chief Executive Officer, Ekambar Kandimalla, our Chief Scientific Officer, David S. Snyder, our Chief Financial Officer, and Matthias G. Schroff, our Chief Operating Officer, is entitled to receive cash severance equal to twelve months, six months, six months, and six months, respectively, of his base salary if his employment is terminated by us without cause (as such term is defined in his employment offer letter). In addition, our 2015 Plan, which was assumed by us in the Merger, generally provides for accelerated vesting of equity awards upon the involuntary termination of an employee within the twelve month period following a change in control (as defined under the plan) and accelerated vesting of equity awards upon a change of control (as defined under the plan) for each of our executive officers. This vesting acceleration is intended to provide each of our executive officers with the full benefit of their equity awards and reward them for a successful outcome for our stockholders. The accelerated vesting of equity awards could result in dilution to our existing stockholders and harm the market price of our common stock. The payment of these severance benefits could harm our financial condition. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">There is currently no market for our common stock and we cannot assure you that any market will ever develop. You may therefore be unable to re-sell shares of our common stock at times and prices that you believe are appropriate. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock is not listed on a national securities exchange or any other exchange, or quoted on an over-the-counter market. Therefore, there is no trading market, active or otherwise, for our common stock and our common stock may never be included for trading on any stock exchange, automated quotation system or any over-the-counter market. Accordingly, our common stock is highly illiquid and you will likely experience difficulty in re-selling such shares at times and prices that you may desire and without depressing the market price for the shares or at all. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our common stock may not be eligible for listing or quotation on any securities exchange. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not currently meet the initial quantitative listing standards of any national securities exchange. We</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cannot assure you that we will be able to meet the initial listing standards of any national securities exchange, or, if we do meet such initial listing</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">standards, that we will be able to maintain any such listing. Further, the national securities exchanges are adopting so-called &#8220;seasoning&#8221; rules that</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">will require that we meet certain requirements, including prescribed periods of time trading over-the-counter and minimum filings of periodic reports</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with the SEC, before we are eligible to apply for listing on such national securities exchanges. We have contacted an authorized market </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">maker for</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an over-the-counter quotation system for sponsorship of our common stock, but we cannot guarantee that such sponsorship will be approved and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our common stock listed and quoted for sale. Even if our common stock is quoted for sale on an over-the-counter quotation system, buyers may</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">be insufficient in numbers to allow for a robust market and it may prove impossible to sell your shares. In addition, an investor may find it difficult</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain accurate quotations as to the market value of our common stock. In addition, if we fail to meet the criteria set forth in SEC regulations,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our common stock, which may further</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">affect its liquidity. This would also make it more difficult for us to raise additional capital. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The designation of our common stock as a &#8220;penny stock&#8221; would limit the liquidity of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock may be deemed a &#8220;penny stock&#8221; (as that term is defined under Rule 3a51-1 of the Exchange Act) in any market that may develop in the future. Generally, a &#8220;penny stock&#8221; is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share. Prices often are not available to buyers and sellers and the market may be very limited. Penny stocks in start-up companies are among the riskiest equity investments. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">document prepared by the SEC. The document provides information about penny stocks and the nature and level of risks involved in investing in</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the penny stock market. A broker must also provide purchasers with bid and offer quotations and information regarding broker and salesperson</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">compensation and make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">agreement to the purchase. Many brokers choose not to participate in penny stock transactions. Because of the penny stock rules, there may be</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">less trading activity in penny stocks in any market that develops for our common stock in the future and stockholders are likely to have difficulty</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">selling their shares. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, and because we will not be listed on a national securities exchange, security analysts of brokerage firms may not provide coverage of our Company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development. The failure to receive research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the beneficial ownership of our common stock as of March 31, 2018, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;47.7 percent of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate documents and the DGCL contain provisions that may enable our board of directors to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">stagger the terms of our board of directors and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">authorize our board of directors to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources and divert management&#8217;s attention.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations. In the future, we may also be subject to the listing requirements of the NASDAQ Stock Market. Despite recent reforms made possible by the JOBS Act, compliance with these rules and regulations nonetheless increases our legal and financial compliance costs, makes some activities more difficult, time-consuming or costly, and increases demand on our systems and resources, particularly after we will no longer be an &#8220;emerging growth company.&#8221; The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of disclosure of information in this report and in other filings required of a public company, our business and financial condition are more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business, brand and reputation and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also expect that being a public company and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may incur significant costs from class action litigation due to our expected stock volatility. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of current or future collaborators or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. This risk is especially relevant to us because pharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. The Merger, our prior equity offerings and other changes in our stock ownership may have resulted in ownership changes. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div><a name="s325AD1559EB95ACD84031E94E3A6CF57"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Sales of Unregistered Securities of Exicure</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2018, Exicure issued 98,800 shares and 46,666 shares of common stock at $3.00 per share, restricted in accordance with Rule 144 of the Securities Act, to two consultants for a value of $296,400.00 and $139,998.00, respectively, pursuant to a restricted stock purchase agreement in connection with a consulting agreement entered into by us and each consultant. We deemed these issuances of common stock to be exempt from registration under the Securities Act pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act. Each of the consultants represented that (a) it was an &#8220;accredited investor&#8221; as defined in Rule 501 of Regulation D promulgated by </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the SEC under the Securities Act and (b) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the shares of common stock were being acquired&#160;solely for investment&#160;for its own account and not with a view to, or for resale in connection with, any distribution thereof in violation of the Securities Act.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None of the securities described in this Item 2 were sold through an underwriter and, accordingly, there were no underwriting discounts or commissions involved.</font></div><div><a name="sD587154A20295929A0A619991FE2F340"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None</font></div><div><a name="s4628008496A85BA1B834B077A738D450"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sAEA079C5FB045A439533AB8168552A81"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None</font></div><div><a name="s230230A0E4C75A6F88B7605392AB2F2F"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1(1)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicureexhibit101-33118.htm"><font style="font-family:Times New Roman;font-size:10pt;">Offer Letter dated as of January 18, 2018 by and between Exicure, Inc. and Matthias G. Schroff, Ph.D.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31.1(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicureexhibit311-33118.htm"><font style="font-family:Times New Roman;font-size:10pt;">Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31.2(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicureexhibit312-33118.htm"><font style="font-family:Times New Roman;font-size:10pt;">Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicureexhibit321-33118.htm"><font style="font-family:Times New Roman;font-size:10pt;">Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.INS(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.SCH(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.CAL(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.DEF(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.LAB(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.PRE(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+  Indicates&#160;a&#160;management&#160;contract&#160;or&#160;compensatory&#160;plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Filed herewith. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><a name="s0F73A67C62D05262A4B1B60D9014FE5E"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Date: May </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, 2018</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:44.44444444444444%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">EXICURE, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exicureexhibit101-33118.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1d10448ee0274e6482c7efa68c8f7575"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;text-indent:192px;font-size:10pt;"><img src="exicureimage1a01.gif" alt="exicureimage1a01.gif" style="height:49px;width:206px;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:422px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exicure, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:422px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8045 Lamon Avenue, Suite 410</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:422px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Skokie, IL 60077</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:422px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(847) 673-1700</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">January 18, 2018</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dr. Matthias Schroff, Ph.D.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Bunzlauer Str. 7, 30853 Langenhagen, Germany</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Via email: maschroff@hotmail.com</font></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Matthias,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We are pleased to offer you a position with Exicure, Inc. (the "Company"). This letter ("Agreement") will confirm our arrangement with respect to the terms of your employment by the "Company. We have agreed as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Term of Employment and Duties: </font><font style="font-family:inherit;font-size:11pt;">We are pleased to offer you employment with the Company as Chief Operating Officer, reporting to Dr. David Giljohann, Chief Executive Officer, subject to government approval of Visa status in the United States. Your first day of employment will be agreed upon based on the approval of your O-1 Visa. During the term of your employment, you agree to devote your best efforts and all of your business time, attention and skills to the affairs of the Company as required by its business needs. As an executive officer of the Company, you understand that you will deemed to be subject to the requirements of Section 16 of the</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">U.S. Securities Exchange Act of 1934, as amended, including the Form 3 and Form 4 filing and short-swing trading requirements, and your compensation information will be publicly disclosed, as required by applicable U.S. securities laws.</font></div><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Compensation:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Base salary and bonus: </font><font style="font-family:inherit;font-size:11pt;">Your annualized salary will be $275,000. This will be paid according to the Company's regular payroll schedule. You will receive annual performance reviews or more frequently as circumstances and your performance suggest. You may be eligible for increases to your salary according to your performance and the Company's normal compensation review cycle. You will be eligible to receive a maximum annual performance bonus of up to 25% of your annual salary, which will be prorated in 2018 for the portion of the year in which you are employed. This bonus is payable at the discretion of the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") and will be based upon achievement of performance goals established by the Compensation Committee. This bonus will be payable at the Compensation Committee's sole discretion and in the form selected by the Compensation Committee. Your annual bonus will be subject to the terms of the Exicure Incentive Bonus Plan or any successor annual bonus program adopted by the Compensation Committee or the Board. Any bonus payable to you will be paid to you promptly following the conclusion of the performance year (but in any event no later than March 15th of the year following the conclusion of the</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:37px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 2 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:109px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">performance), subject to your continued employment through the date of payment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholdings and Taxes: </font><font style="font-family:inherit;font-size:11pt;">The Company will deduct from the payments to be made to you under this Agreement any authorized withholdings and any Federal, State or local withholding or other taxes or charges which the Company is from time to time required to deduct under applicable law, and all amounts payable to you under this Agreement are stated before any such deductions.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Stock Options: </font><font style="font-family:inherit;font-size:11pt;">While you are an employee of the Company, you will be eligible to participate in the Company's equity incentive plan, as determined by the Compensation Committee. In connection with the commencement of your employment, you will be eligible to receive a one-time option grant to purchase 345,000 shares of Company common shares, with an exercise price equal to the fair market value as of the date of the grant. (the "Sign-On Grant"). Ordinarily, as long as you remain an employee of the Company, 25% of the shares subject to the Sign-On Grant shall vest on the one-year anniversary  of your employment start date, and 1/48</font><font style="font-family:inherit;font-size:7pt;">th  </font><font style="font-family:inherit;font-size:11pt;">of the shares subject to the Sign-on Grant shall vest each month thereafter on the same day of the month as your employment start date (or if there is no corresponding day, on the last day of such month), subject to your continued employment with the Company through such date. Should the Company effect a Change in Control (as defined in the Company's 2017 Equity Incentive Plan (the "Equity Plan")) and should your employment be terminated by the Company within a year of the Change in Control other than for Cause (as defined in the underlying option award Agreement for purposes of this letter Agreement), such termination will result in immediate vesting of any unvested options subject to the Sign-On Grant ("Double Trigger" vesting). The Sign-On Grant will be subject to the terms of the Equity Plan and the formal option award agreement, which will be provided separately and which will include the definitive vesting schedule, termination benefits and other details regarding your Sign-On Grant.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Benefits and Expenses:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Expenses: </font><font style="font-family:inherit;font-size:11pt;">The Company will pay or reimburse you for all reasonable travel expenses ordinarily and necessarily incurred by you in furtherance of the Company's business, subject in each case to the Company's reimbursement policy. In addition to specific limitations set forth in the policy, you will be required to submit an itemized account of such expenditures and such proof as may be necessary (in accordance with the Company's policy and IRS regulations) to establish to the satisfaction of the Company that such expenses were ordinary and necessary expenses incurred by you in furtherance of the business of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:37px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 3 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Fringe Benefits: </font><font style="font-family:inherit;font-size:11pt;">During the term of your employment, you will be entitled to participate in any paid time off, health insurance, disability insurance, retirement, and other similar fringe benefit plans of the kinds and in the amounts provided generally to other exempt employees of the Company. You acknowledge that you have no rights in any such plans except as expressly provided under the terms of such plans and that such plans may be terminated, modified or supplemented at any time. Copies of any plans or other documents describing these benefits will be provided to you upon request. When you commence employment with the Company, you will be eligible to receive three weeks of vacation and use up to five days of sick leave each calendar year (with vacation time prorated for any partial year of employment), subject to change pursuant to the terms of the Company's paid time off policy and applicable law.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:84px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Relocation benefits: </font><font style="font-family:inherit;font-size:11pt;">The Company will pay you $50,000 to cover costs associated with relocation and other expenses reasonably incurred to relocate you and your family to the Chicago area. This payment is subject to a two&#173; year quarterly graded claw back in the event that you terminate your employment voluntarily or are terminated by the Company for Cause within two years from your employment start date, with such repayment to be paid by you within 30 days following such termination of employment. Such relocation payments will be made to you first to reimburse you for those deductible moving expenses as defined in Section 217 (b)(l) of the Internal Revenue Code of 1986, as amended (the "Code"), upon submitting a satisfactory accounting and receipts for the same. For the avoidance of doubt, the Company will reimburse you up to an aggregate of $50,000 notwithstanding the actual amount of reimbursable expenses incurred. Should the aggregate reimbursement of deductible moving expenses be less than</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:109px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$50,000 then the difference between $50,000 and such reimbursement will be</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">paid to you promptly as a lump sum in accordance with the ordinary payroll practices of the Company and will be included in your gross income. It is expected that you will be full time in Chicago as of your start date. The relocation payment is subject to completion of your relocation by August 1, 2018. The Company will also pay pre-approved expenses (business class airfare) for up to two house-hunting trips to Chicago. The Company will provide for six weeks of commuting (economy class airfare) and six weeks of temporary housing expenses in Chicago prior to your relocation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidentiality, Non-Compete, Non-Hire, Non-Disparagement, and Work Product Agreement and Company Security Trading Policy: </font><font style="font-family:inherit;font-size:11pt;">As consideration for your employment at the Company, you will be required to sign the Company's Confidentiality, Non-Compete, Non-Hire, Non-Disparagement, and Work Product Agreement and the Company Security Trading Policy. Copies of these documents are enclosed for your signature. Please contact me if you have any questions.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Termination: </font><font style="font-family:inherit;font-size:11pt;">Your employment by the Company is at will and may be terminated at any time by you, with 14 days prior written notice, or by the Company. Nothing</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 4 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:58px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">contained in this letter or the Confidentiality, Non-Compete, Non-Hire, Non&#173; Disparagement, and Work Product Agreement will be construed as conferring upon you any right to remain employed by the Company or affect the right of the Company to terminate your employment at any time for any reason. Upon your termination of employment, the Company will pay you your salary through your date of termination and such other benefits in which you are vested or are otherwise entitled to under the terms of such benefit plans through the date of your termination. Except as expressly provided in this paragraph or by law, the Company will have no further obligations to you following your termination of employment. Subject to your execution of a customary release of claims in favor of the Company within 30 days following your termination of employment, in the event that you are terminated by the Company other than for Cause, you will be entitled to a severance benefit in the amount of 6 months' salary continuation or, in the case of "Double Trigger" as set forth above, 6 months' salary plus full bonus target, payable in a lump sum payment within 30 days following your termination of employment (except to the extent prohibited by Section 409A of the Code, in which case the Double Trigger severance will be paid during the six-month period following your termination of employment). If you resign from the Company for any reason, are terminated by the Company due to disability or for Cause or in the event of your death, you will not be entitled to severance.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:58px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:33px;"><font style="font-family:inherit;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Other Employment Matters</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:81px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement will be binding on the Company and its successors and will insure to the benefit of and be enforceable by your personal or legal representatives, heirs and successors.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:82px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement and all questions of its interpretation, performance and enforcement and the rights and remedies of parties will be determined in accordance with the laws of the State of Illinois without application of conflict of law principles.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:82px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement supersedes any and all prior agreements, whether written or oral, between the Company or any representative thereof and you relating to the services performed by you for the Company or your compensation for such services, and all such prior agreements are null and void. This Agreement shall be subject to the terms and conditions of the option award agreement as well as the Equity Plan (or successor plan) and other Company plans and policies.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:81px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">This parties agree that this Agreement shall be cancelled in the event permission to work in the United States via a visa is not obtained by July </font><font style="font-family:inherit;font-size:12pt;">1st, </font><font style="font-family:inherit;font-size:11pt;">2018.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:81px;"><font style="font-family:inherit;font-size:10pt;">e.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any notice required or permitted to be given under this Agreement will be in writing and  will be deemed  given by:  (a) upon personal  delivery to the party to be notified, (b) when sent by confirmed facsimile or email to which sender receives a non-automated response if sent during normal business hours of the</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 5 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:106px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one </font><font style="font-family:Arial;font-size:11pt;">(1) </font><font style="font-family:inherit;font-size:11pt;">day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt at the following addresses or to such other addresses either party shall specify by like notice:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">if to the Company:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Financial Officer Exicure, Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8045 Lamon Ave</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:130px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Skokie, IL 525 Science Drive</font></div><div style="line-height:232%;padding-top:0px;text-align:left;padding-left:101px;text-indent:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: dsnyder@exicuretx.com, info@exicuretx.com</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">And if to you:</font></div><div style="line-height:232%;padding-top:0px;text-align:left;padding-left:101px;text-indent:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:130px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dr. Matthias Schroff, Ph.D.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:130px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Schlossstr. 1 4133 Pratteln Switzerland</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:130px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Email: maschroff@hotmail.com</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:81px;"><font style="font-family:inherit;font-size:10pt;">f.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Agreement may be amended or modified only upon the written consent of the Company and you.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:106px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:82px;"><font style="font-family:inherit;font-size:10pt;">g.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You hereby represent and warrant to the Company that: (a) neither the execution of this Agreement by you nor the performance of any of your obligations or duties hereunder will conflict with or violate or constitute a breach of the terms of any employment or other Agreement to which you are a party or by which you are bound; (b) you are not required to obtain the consent of any person, firm, corporation or other entity in order to enter into this Agreement or to perform any of your obligations or duties hereunder; (c) you are not subject to any restrictive covenants with respect to employment and (d) you will not, during the course of your employment with the Company, seek to utilize any trade secrets or confidential or proprietary information belonging to any of your prior employers or take any action that would breach any obligation you may have to your prior employers.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:106px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:81px;"><font style="font-family:inherit;font-size:10pt;">h.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Also included in this letter is an offer to you to self-disclose as a person with a disability. It is a government requirement that the Company provides this opportunity to you, and your completion of the form is strictly voluntary. Any information you provide is confidential. Upon your acceptance of this offer, we will forward upon request an invitation to make such disclosure.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:106px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:106px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:81px;"><font style="font-family:inherit;font-size:11pt;">i.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This letter Agreement is intended to comply with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent. The payments to your are also intended to be exempt :from Section 409A of the Code to the maximum extent possible, under either the</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:37px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 6 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">separation pay exemption pursuant to Treasury regulation &#167;l.409A-l(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation &#167;l.409A-l(b)(4), and for such purposes, each payment to you under this letter Agreement shall be considered a separate payment. To the extent any amounts under this letter Agreement are payable by reference to your "termination of employment" such term and similar terms shall be deemed to refer to your "separation from service," within the meaning of Section 409A of the Code. Notwithstanding any other provision in this letter Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section 409A of the Code, then (a) each such payment which is conditioned upon your execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (b) if you are a specified employee (within the meaning of Section 409A of the Code) as of the date of your separation from service, each such payment that is payable upon your separation from service and would have been paid prior to the six-month anniversary of your separation from service, shall be delayed until the earlier to occur of (i) the first day of the seventh month following your separation from service or (ii) the date of your death. Any reimbursement payable to your pursuant to this letter Agreement shall be conditioned on the submission by you of all expense reports reasonably required by Company under any applicable expense reimbursement policy, and shall be paid to you within thirty (30) days</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:108px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which you incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this letter Agreement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Matthias, we are impressed with your accomplishments to date. We are confident that you will make a significant contribution to the Company and are excited to have you join our executive team. We are strongly committed to our employees and firmly believe that your acceptance of employment will provide you with an excellent opportunity to enhance your professional career while contributing significantly to our success.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:37px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Please indicate your written acceptance by signing this letter and returning it to me at your earliest convenience. The terms of this letter, if not earlier accepted, will expire at 5:00 P.M. CST on January 29th, 2018. If you have any questions, please do not hesitate to contact me at 847-673-1702.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:37px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">We look forward to you joining us at Exicure</font><font style="font-family:inherit;font-size:12pt;">!</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sincerely yours,</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Accepted by:</font></div><div style="line-height:120%;padding-top:15px;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Exicure Inc.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Page 7 of 7</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:35%;"></td><td style="width:12%;"></td><td style="width:4%;"></td><td style="width:35%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18 Jan 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Matthias Schroff, Ph.D.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18 Jan 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Date)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthias Schroff, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Date)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exicureexhibit311-33118.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFEE9F53243385FAE9CD46B02C5ECA951"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David A. Giljohann, Ph.D., certify that: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 15, 2018 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.42063492063492%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exicureexhibit312-33118.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD2DA5C1EBA6F5E3C87F0552E8542B2F3"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David S. Snyder, certify that: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 15, 2018 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.42063492063492%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exicureexhibit321-33118.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8F0EE4D631035DECAB8DADC21EBF3EA1"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 1350 CERTIFICATIONS* </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), David A. Giljohann, Ph. D., President and Chief Executive Officer of Exicure, Inc. (the &#8220;Company&#8221;), and David S. Snyder, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: May 15, 2018 </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:46%;"></td><td style="width:2%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:100%;padding-bottom:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Quarterly Report on Form 10-Q, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>xcur-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:37B17304E9AF53009211BC1E83FE7C67,x:fcb646c218614cf18ab1b4fba5e176e2-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xcur="http://www.exicuretx.com/20180331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="xcur-20180331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Sep26-Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-11-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_xcur_ImmaterialErrorCorrectionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">xcur:ImmaterialErrorCorrectionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-02</xbrli:startDate>
			<xbrli:endDate>2016-12-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec02-02_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-02</xbrli:startDate>
			<xbrli:endDate>2016-12-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan15-15_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-15</xbrli:startDate>
			<xbrli:endDate>2018-01-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q2Jan01-Jun30_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Dec12-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="vote_per_share">
		<xbrli:measure>xcur:vote_per_share</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="target">
		<xbrli:measure>xcur:target</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q1YTD" id="Fact-53A4A3704E185E6EABFD56D3932A397C">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q1YTD" id="Fact-D3A0C4A9ECFE55608111F0B45E712066">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q1YTD" id="Fact-BB66B127C14655F58C34AC024253FE19">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q1YTD" id="Fact-DDA0226C36415E24AE42F393A81658A4">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q1YTD" id="Fact-F42089F970A9583A8D6A65620C68581A">2018-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q1YTD" id="Fact-A3399041F8235AEC8A6305CF3AB290EC">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q1YTD" id="Fact-16499C900F1F50DBA82F440FD8E4A61B">0001698530</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q2Apr30" decimals="INF" id="Fact-B4AE3B0DA24C543282F293823E8150BD" unitRef="shares">39454821</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2018Q1YTD" id="Fact-A6B64ED98A8C53F49AE5D680CF6CB855">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q1YTD" id="Fact-B762DB95B1665D5781E187380381127A">EXICURE, INC.</dei:EntityRegistrantName>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BE38C245A98758CFACFBF81B80832D42" unitRef="usd">1049000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-55B6E572D77F5B758D116C8244A29629" unitRef="usd">974000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-32978B0CE38856D89F7FA19BE0644719" unitRef="usd">1273000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_xcur_ImmaterialErrorCorrectionsMember" decimals="-3" id="Fact-6E43A1C8245EB2E5464261D5BFD943A7" unitRef="usd">-96000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-DB3407A20F2E521F95AD6016CDB5D09E" unitRef="usd">1265000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AA4C665FEE955302B56A8E8B581D230F" unitRef="usd">251000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-D3D3D02535515D269B28DAD3E81B30BC" unitRef="usd">514000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2012Q1" decimals="-3" id="Fact-8DFE6E4513AE5680B2B45390C8DB393A" unitRef="usd">52000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-479D4CE803A6555EA2504E3B14A3F511" unitRef="usd">48000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2018Q1" decimals="-3" id="Fact-57539437F4935D7B87FFDBCF6C5BE018" unitRef="usd">46000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-AA43307969C95C59AB459FF86C175CB8" unitRef="usd">849000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q1" decimals="-3" id="Fact-C13A7AA19AD95B3CB4F939ED45D2E562" unitRef="usd">918000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-36924AB01CC053098E07DD4FD395DFD7" unitRef="usd">53586000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q1" decimals="-3" id="Fact-B934B02184965473B60BB0E8D0EBCD16" unitRef="usd">54394000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1YTD" decimals="-3" id="Fact-E093D0B5987454AA95C977F3D3BE5AB9" unitRef="usd">365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8EBFB733272C5644A09EDF04CA6CEE2B" unitRef="usd">365000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-BA9D5D0C4C6A55FD98C1DE436814164B" unitRef="usd">380000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-89FCEFF404825750806811273243C14D" unitRef="usd">336000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-9A9CDF2F0EEF53E48404EA2CDA5D1648" unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-136104C0402550789CFF334418ADFCD3" unitRef="usd">269000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F7BCA54FB082528A9E79EF70B5101EE3" unitRef="usd">96000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-C68E3C5CF1B55487A01EC9C2D62BD21A" unitRef="usd">365000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2017Q1QTD" decimals="-3" id="Fact-4220B75FB8EC52AFBE15664163EE52F3" unitRef="usd">50000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2018Q1YTD" decimals="-3" id="Fact-00F64A8F85065B37A71C16E90ADF1FFB" unitRef="usd">24000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-BE9F8AF050115FC98C3254AC41205DA2" unitRef="shares">3683826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-86062027350E52F3B14B4577A55F5355" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-311E7AAC0117582386441FAF4D0D0AEE" unitRef="shares">4335729</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-8761144CB3D85C319CC49C403FB8155B" unitRef="shares">413320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-52616DE7B5E2544DBB048BD069763382" unitRef="usd">28987000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q1" decimals="-3" id="Fact-9039EA667D65538190350F2313C9FFC5" unitRef="usd">24354000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C0662F4B96785CA09E55E6D5E6B371BB" unitRef="usd">27638000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-DECE67A8600E555286D683E274BAAE21" unitRef="usd">23047000</us-gaap:AssetsCurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-2B21358A1D225B8E86D7D0FE896D6ABB" unitRef="usd">19623000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-3" id="Fact-96B6A5F8537E5190A6547EAAD53C2D34" unitRef="usd">12424000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-27AB17BFD9395A6FAD6816C941472B02" unitRef="usd">25764000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-3" id="Fact-0CE668A1D37B5C8086A2DD899763ECB9" unitRef="usd">21124000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1QTD" decimals="-3" id="Fact-77CF76A4D0765C76A9B819BF99850EF1" unitRef="usd">-7199000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-3" id="Fact-908344E681465205BC64FAABD533D4D8" unitRef="usd">-4640000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-9FAC6110DCC15A97BBB2198FFE05CE6D" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-2160BC59EEA55977960930511E622FC8" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-735FA5FA2DF15CC6A413455F12CDE18D" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q1" decimals="INF" id="Fact-65EBFBA01FBF5999B28A38F20F43B811" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-0D6485B4952B5A569F1A50F914B467F7" unitRef="shares">39300823</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q1" decimals="INF" id="Fact-C75850B8D06951728D05DA07B2ACE379" unitRef="shares">39454821</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-4F45A3541F335D9A8ECEED9083E8522B" unitRef="shares">39300823</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q1" decimals="INF" id="Fact-BBF89F44369252E096C3224DDF0E83D4" unitRef="shares">39454821</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-1C82422C036E51C9BB9B9508C98F6BE6" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q1" decimals="-3" id="Fact-C6AC54CB122656469CB858C88C4BB544" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2017Q4" decimals="-3" id="Fact-115CB83A88D90B0C522F216E88342E17" unitRef="usd">1034000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-EADE873ADA0741472DD9216E88383C5A" unitRef="usd">1034000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2018Q1" decimals="-3" id="Fact-A2A26159842F5906A289683A085E63CF" unitRef="usd">4999000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2018Q1" decimals="-3" id="Fact-715121DAAB5C5787A8BAEED6B517F126" unitRef="usd">108000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2017Q1QTD" decimals="-3" id="Fact-F998F81F619D592D1279217502A97C53" unitRef="usd">268000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9C80DB9A1B1A4EA00E77217502A8E292" unitRef="usd">45000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q1" decimals="-3" id="Fact-2A8C1CA0F05358EDA8836709DB701994" unitRef="usd">12000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-887A11430F7F50869C789EEC341E8DD5" unitRef="usd">1034000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-3A7A001D2CDAE273E953218B4E4F82EF" unitRef="usd">1034000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-3826F9F98DBB5873B362EC234BC77A87" unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q1QTD" decimals="-3" id="Fact-95197DF5206B5E34B7019FE725166212" unitRef="usd">38000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2018Q1YTD" decimals="-3" id="Fact-52B0B3E5546D5F5DBC46988CDFC67997" unitRef="usd">86000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-14B0B79864C652EBB0C995C6B76DFF76" unitRef="usd">17000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-DDA4C18C80B5505A91F0380A7E4D1780" unitRef="usd">17000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-ED3BB513D3E75FD290C29E5CC22A6117" unitRef="usd">21000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-D42783B2885C51819F6D58DD4B1A5439" unitRef="usd">21000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-918A58508D1B5103B94173632BBC2BAB" unitRef="usdPerShare">-15.62</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q1YTD" decimals="2" id="Fact-615A3DFB0F0A5A6BACD4232A7E62CC0D" unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q1QTD" decimals="2" id="Fact-F776A2DCDCA55D8C9872F40DE9B81110" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q1YTD" decimals="2" id="Fact-CC9F4336B1325EC1A20E91A04C15799D" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F713F1BDF711532398F37E41E4167DE3" unitRef="usd">718000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-448EC96F7AD25C1091DC6CB702B0869D" unitRef="usd">329000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q1" decimals="-3" id="Fact-6C5E5121F9DE53F6A9D002C6E4480C61" unitRef="usd">2997000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q1YTD" id="Fact-1C084CD5A3195453ACA359569B76C8FA">P2Y9M0D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C257A467565B534D9CB6D4F145B72B30" unitRef="usd">-38000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9D7EA6130AAB57FFA19C3CDA0BC9B079" unitRef="usd">128000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2018Q1YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-997FBF8E5753562BA94AC92AA536FA7E" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2018Q1YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" id="Fact-5A3BBE4439635F78828057602743BF82">P3Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q1YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="3" id="Fact-CB461C885E945719A18556342F8B5827" unitRef="number">0.781</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q1YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-8B3B17179BA55AAD969960444ED0066D" unitRef="number">0.0238</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q1YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-460982AB8DD85A77A9842ED015095854" unitRef="usd">128000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-84759DD9FE6C53C68080E1191EDA879C" unitRef="usd">523000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3EA86987712157ACA753367BC6489FD3" unitRef="usd">651000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-9092683EBCE45BD3B93341D61DBCCEA1" unitRef="usd">1426000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-712CC75F79075D0DA6C9C94708F157E3" unitRef="usd">2045000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1QTD" decimals="-3" id="Fact-E671B27308B15EB2ADC5CDA5C6CCE240" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="-3" id="Fact-2C2A2F04AC3F5ED18EF446D814AC887C" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q1QTD" decimals="-3" id="Fact-AD8B4B2D3BDC5289A95AAAF72874DA8F" unitRef="usd">58000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q1YTD" decimals="-3" id="Fact-0BF19FDD44E55319BEE007381934A70A" unitRef="usd">-120000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-69BD936BC53F55579C2DF4076BAC6A81" unitRef="usd">-1581000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-8DE912B9BFAB5A2684701AFCA91C42CD" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2017Q1QTD" decimals="-3" id="Fact-82B5DC53BE86790E07FF217C6935AF6E" unitRef="usd">241000</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2018Q1YTD" decimals="-3" id="Fact-D6D389B43875C019005E217C69374E0B" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B7BDBC8FB9FCBD827A75217785D3D427" unitRef="usd">-1982000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2018Q1YTD" decimals="-3" id="Fact-81B45EB373B4C98D72FB2177861F8B12" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0B20374F0E0E5F71B539F4C509426BDB" unitRef="usd">5000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2018Q1YTD" decimals="-3" id="Fact-395E074C0B50519593271E8E85E5C3F0" unitRef="usd">4000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2017Q1QTD" decimals="-3" id="Fact-152AB105F8C5FB4BDB1B21C7D4EA5A6B" unitRef="usd">19000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2018Q1YTD" decimals="-3" id="Fact-3027219A645A0B7C089121C7D4ECC6CE" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-BC9FEB733D635178AEB290FF08889FE7" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-F784E0D7358F55CD9B640B68EE167AB0" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q1QTD" decimals="-3" id="Fact-A91C2B05E94C5690B7D519F5D01683D6" unitRef="usd">556000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q1YTD" decimals="-3" id="Fact-A0E302E5109051C5BEE35153B34D25C6" unitRef="usd">-311000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0E3DB6C044595330A6A39D6F67627129" unitRef="usd">449000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2018Q1YTD" decimals="-3" id="Fact-5D2FD06BB1A4515E94C4C9087A2E9FEC" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:InterestExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-09271E52D08A5C2CB2ECE147991E8F9B" unitRef="usd">204000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-832823EDA9C8542D826FCE9A642972D2" unitRef="usd">161000</us-gaap:InterestExpense>
	<us-gaap:InterestPaid contextRef="FD2017Q1QTD" decimals="-3" id="Fact-1428063711B45E33B5F3D17F4B786B1B" unitRef="usd">153000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BEB2BB9934B555648229CD96B190D2C1" unitRef="usd">136000</us-gaap:InterestPaid>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="FD2014Q4QTD" id="Fact-B319D63136D05B638D840AC849350B86">P6Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-0E3719851B6F569CBF23387DAD546626" unitRef="usd">9012000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q1" decimals="-3" id="Fact-CF87FDBBB91355399A3EB5E497BCCC75" unitRef="usd">8046000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-0FBC145205855D838BBFE255B845C44C" unitRef="usd">28987000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-815FC03EDD94540AA30E91545E3E7230" unitRef="usd">24354000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C5C2FFDBEB9B547DB824B0CB54DEA9DC" unitRef="usd">3356000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-DE518D884A485C19814D0D46884E8884" unitRef="usd">3015000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-3" id="Fact-AF12649CDE70EC56BA1D457D8E7907D4" unitRef="usd">4855000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q1" decimals="-3" id="Fact-06AE3456179F59D695F32D2F03C1D3F6" unitRef="usd">4879000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-06B3562E183D50FB977ECB8E9ECEF60A" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-AF9F6164C3455F62A94269D897300900" unitRef="usd">776000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2018Q1" decimals="-3" id="Fact-15724C502F6657A4A9987023ECBFCA20" unitRef="usd">4999000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2018Q1" decimals="-3" id="Fact-70CD896A04EE5AECB3F6880556E6246E" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7E1A82E74FF65A05AC609ED135C33D7D" unitRef="usd">4855000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q1" decimals="-3" id="Fact-816DC9F3055D571A93944BA7F56E6291" unitRef="usd">4103000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-62D79077638752699A5349A9A76CA703" unitRef="usd">43000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-D16C6B8BCAD8570C980313FBDB43DF9D" unitRef="usd">7000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-B45E04B441DB54F28ACAC66831352647" unitRef="usd">-245000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-62C77A9CAD075A1DB83C9533C8F30D4D" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1QTD" decimals="-3" id="Fact-7A14204512A15C7ABB044B46CC5E291E" unitRef="usd">-6997000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q1YTD" decimals="-3" id="Fact-B919DC11FBA950609E83EFF6BD4E0153" unitRef="usd">-4647000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-63BF0F350A675BC99A376C79090890E2" unitRef="usd">-2652000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-00713CC6B11E4801DFD84B54C516C55A" unitRef="usd">-5509000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD" decimals="-3" id="Fact-3613E4B016895FB7A164C366E4CFB065" unitRef="usd">-5509000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-0E2641E9B3A11A9D2C3264506BF4E3ED" unitRef="usd">1034000</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-CFFBCD7092435EB98EB77BA3BCF5E4B0" unitRef="usd">-170000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-61A32D7D036D5C33AF1AE0CAA7873353" unitRef="usd">-225000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD" decimals="-3" id="Fact-8A86862FECE655A7ABE6C8A059AAC44A" unitRef="usd">4914000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BD7CB22A2D22599593087410C1CF78F3" unitRef="usd">5320000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-68F5CCDF147451BA9CB25B645F1BE312" unitRef="usd">-2482000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD" decimals="-3" id="Fact-50CEF7A40E425BCB9D4C1525B4F1A86D" unitRef="usd">-5284000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-BE46F891DD04614782FF645483DCCD02" unitRef="usd">1034000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q1" decimals="-3" id="Fact-85EAA96FD0D0582D8FCA56027EC34812" unitRef="usd">1015000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2018Q1" decimals="-3" id="Fact-30A001D06195515A92A0C7F7CC89E2B5" unitRef="usd">59000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q1" decimals="-3" id="Fact-F8C582CA56CC5CBEBBBA70209159F8F6" unitRef="usd">353000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q1" decimals="-3" id="Fact-FA87F086EA7751ACB51879A1CCC085C0" unitRef="usd">347000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2018Q1" decimals="-3" id="Fact-0FF043E08BB35BEFA8948B5F795CEBD7" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2018Q1" decimals="-3" id="Fact-D71785EF28605C4F94E450680C00626D" unitRef="usd">256000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2017Q1QTD" decimals="-3" id="Fact-19EAF2DA05E55904BD8F6FAD578E8A2A" unitRef="usd">77000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2018Q1YTD" decimals="-3" id="Fact-746E55AD6A4E59F6BDA3B7CB1AA140B1" unitRef="usd">89000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2017Q1QTD" decimals="-3" id="Fact-F147131D666F5FEB827701A8C6663D67" unitRef="usd">83000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2018Q1YTD" decimals="-3" id="Fact-70ACDD1153695D079350058D8DBBF36D" unitRef="usd">83000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C844F7E03C06588C86402CC6A22448C8" unitRef="usd">160000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2018Q1YTD" decimals="-3" id="Fact-41AFDBF150495593874F93A5DB1A6AF3" unitRef="usd">172000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0B8B342F2FDA5457A4714DF6DFC112CA" unitRef="usd">304000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-E5AE8771551855BABACB5473C7E51683" unitRef="usd">422000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C58F214711B8584BBB428F7BA51B1A57" unitRef="usd">32000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q1" decimals="-3" id="Fact-D14849FB32E95F72A355F16576BEB06F" unitRef="usd">32000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-347311C8B065553B9F8F8183D9DCDF7A" unitRef="usd">278000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q1" decimals="-3" id="Fact-C76B42A6E66050FB930A468B5AD3D7A8" unitRef="usd">277000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-EE084441241D5225840197FA939D57A1" unitRef="usd">34000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9AC0704ED8435CEC8E7431BB34C0C377" unitRef="usd">-64000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C57A24D0F09CDFC4DC64656822B6DDAF" unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
	<us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="FD2018Q1YTD" decimals="-3" id="Fact-F4C78946DC82A90D070E656822B0A85C" unitRef="usd">73000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q4Sep26-Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-A6F8749327847B90D81E4CA875AAA3ED" unitRef="usd">3966000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0E12F2C21D1A5A90BECC959011CFCE13" unitRef="usd">245000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q1YTD" decimals="-3" id="Fact-E9A8CE45BB675793811CB52E27F936AD" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-BE14D64B8CD894C350BF21CAC95C867E" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-E758782A970D9C98DB7721D107FB71C4" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-646FC81D9C0776D88D7721CAE1F6A491" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q1" decimals="INF" id="Fact-E1B11DCED11E9A14D08B21D0D7361AF6" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-6A59DF091CB7844D514521CAFA97AFB3" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q1" decimals="INF" id="Fact-B3371D97EF65D0772DD121D17D3B4789" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-FF0C467C2916ACE9530C21CB0DEB508A" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q1" decimals="INF" id="Fact-733DD2E2537B68907B5D21CB0DF4B7FD" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3E27A1BA36AD5DF1A7009527B1FB140F" unitRef="usd">1844000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_xcur_ImmaterialErrorCorrectionsMember" decimals="-3" id="Fact-EBEABB70C051A87325B461D583D199BC" unitRef="usd">933000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-F637923F8AB251F7A0F9F35DC20B56CE" unitRef="usd">1897000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0DF2CF08200A53718D6D64D14F7206DA" unitRef="usd">43000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q1YTD" decimals="-3" id="Fact-C68F21D3038C5547AAB17E08B2B613BE" unitRef="usd">7000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-D961975CD4205E95BC44CF561E571125" unitRef="usd">2166000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-FD95B917A134572385B1BF0F0BBFF405" unitRef="usd">120000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-BA6AAD9CD77F51D995D0BF8785590C7B" unitRef="usd">1797000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-D93A660993995AFB8027935AFCBB399F" unitRef="usd">31000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-F60D6A5DDAEB53D78676325CCB2B986A" unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember" decimals="-3" id="Fact-161BD8DDDBFF5D1697BE2161DADB61A5" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1" decimals="-3" id="Fact-AB8D994CEB1F5450AAC437220E4C0C59" unitRef="usd">2193000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-6CBA88BC25A05C15B02858FB5DEF2EE4" unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-5B6D4C0E4B4253B9AAB6D9A3895FDD2F" unitRef="usd">1906000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-93DC8CBF098656A4A3E886A39F069B85" unitRef="usd">31000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-95335433D1AD5DDFAF0F30C358619D8B" unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember" decimals="-3" id="Fact-F1630733D2135014BEC5C9428ADA70EE" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-C004005E3A345E598AF3E78416E9D93B" unitRef="usd">1317000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q1" decimals="-3" id="Fact-25F5EBDA00C2506BB399815671E3B912" unitRef="usd">1275000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2017Q1YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-3" id="Fact-856DE0239FC45183AA33CA6B58F93D87" unitRef="usd">25000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q1YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-3" id="Fact-E8BCAAAACBA5549A89F2DAF17CB1B814" unitRef="usd">25000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="FD2017Q1QTD" decimals="-3" id="Fact-A676DD4000FC5C3981FC1069D2943EEA" unitRef="usd">363000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD" decimals="-3" id="Fact-FA901CBCD8495CC08355A275EFBA2D3A" unitRef="usd">3488000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q1YTD" decimals="-3" id="Fact-6A65DB2E6F175CE0B57ABE5A7AF00043" unitRef="usd">3275000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-595FAE476704500C8E5F417624351C63" unitRef="usd">-33615000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_xcur_ImmaterialErrorCorrectionsMember" decimals="-3" id="Fact-76A5A67EDAA1C0C5809161D5F0B2CB06" unitRef="usd">1028000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q1" decimals="-3" id="Fact-B721F2DCA1995B2ABCDA62CB4FC97A0B" unitRef="usd">-38090000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-BE0F6B237A8F5171A9BA483F443A4632" unitRef="usd">5000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-39BFB0CEABFF53DC9EE5E2D4635FF6C3" unitRef="usd">2000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-4E404B1D3E6D5327B8AEEE2C21CEEAEC" unitRef="usd">3000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-D6B58817EC02578A8CD68CE6FE5C7429" unitRef="usd">4000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-9E3DB4233ACF5114850466F1287B35E4" unitRef="usd">1000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q1YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-0DAD64DB1F345777B276F3BB3817B743" unitRef="usd">3000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:Revenues contextRef="FD2017Q1QTD" decimals="-3" id="Fact-FA3F11F3822A510D8FC05B778A417CD2" unitRef="usd">2432000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD" decimals="-3" id="Fact-A03B6A6D63F05BB79E0AC961473034FB" unitRef="usd">36000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-3" id="Fact-7A545E6898FD053D1BEE6457439133DF" unitRef="usd">-1034000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q4Sep26-Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-9A1B3033C337548AC8754CA828D60DE7" unitRef="usd">31513000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Sep26-Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-EF14F6868E5A42430B984CA71964AD32" unitRef="shares">10504196</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q4Nov2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-E442F6CC005DCBDD08F34CA7C496ADDD" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1QTD" decimals="-3" id="Fact-F155951EEDB75DBAA89A9B5FBA9F865C" unitRef="usd">380000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-3" id="Fact-EE5895F5C8BE5F8F9F96BEF98C7E987A" unitRef="usd">365000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2017Q1" decimals="2" id="Fact-3E4928AF0EC325CBBAC821E5DB669758" unitRef="usdPerShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-37BBBB64EA905A75A94C128290CE0362" unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q1QTD" decimals="2" id="Fact-6E5D6A7AA64F573A909EF5CBD7B6079A" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q1YTD" decimals="2" id="Fact-D8E4A51D4F1252D6AAE7065116712375" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-F6E7BC570FC85B8395280E87B40CCA50" unitRef="number">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-1B230601F60D513EBB55039D42A5EE0B" unitRef="number">0.808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="3" id="Fact-E0D3EBCC8F2E503C9800C221D9ABC75A" unitRef="number">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q1YTD" decimals="3" id="Fact-0443B5BA6A065682B9B9CE7B2A2A6F42" unitRef="number">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-BC23F65CB8325A03882E5027FF3EDA37" unitRef="number">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-B1E0D0AABC195B80B55EDEDF8016235A" unitRef="number">0.0197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="4" id="Fact-3697452FF87355C98488F15EFC6951C6" unitRef="number">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q1YTD" decimals="4" id="Fact-7CA5644BB43F5681B26EA5BEF5EFF97B" unitRef="number">0.0272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2018Q1_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="INF" id="Fact-094C8A9ECB815DAD8CE3786AAE214C10" unitRef="shares">1498264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q1" decimals="INF" id="Fact-26CE6F2A158B5BDABED9B6F0DC2F416F" unitRef="shares">2597078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-DC910188FEC3531A9EBA7632B01AE3EB" unitRef="usdPerShare">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q1QTD" decimals="-3" id="Fact-85A0997FE3FC5A9BA0374BDEC64FCF75" unitRef="usd">202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q1YTD" decimals="-3" id="Fact-E1FB36C5D84959ECAE3EC6E96985E421" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q1YTD" decimals="INF" id="Fact-27FD97F5CBEA5D8B9FEEE42EC6AC6DD8" unitRef="shares">2638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q1YTD" decimals="INF" id="Fact-C9419A7EA7F058FFAE0FE2EB819CEB63" unitRef="shares">674279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q1QTD" decimals="2" id="Fact-5AEE9CE8E0845E1F8A51BE88B24995FC" unitRef="usdPerShare">2.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q1YTD" decimals="2" id="Fact-AEAD0D7DBA5D5CC5B7CC9BC74DD4733C" unitRef="usdPerShare">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-7AAA4A7EB9AC52788E55B344A7AFCB00" unitRef="shares">3672620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q1" decimals="INF" id="Fact-B68FA1960320539CAF555F3B3995E4D6" unitRef="shares">4335729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-6AA750A108A75FDCA32C5CD66C6DD15B" unitRef="usdPerShare">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-6738BFF98F64524296D6945B36E0DACA" unitRef="usdPerShare">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2018Q1" decimals="-3" id="Fact-D2E63E437D3E5FFB96D1755D589A0B87" unitRef="usd">5190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-C0367104D99451738CC0D0468F8C65BA" unitRef="usd">5221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2018Q1" decimals="-3" id="Fact-B02D8FF683675A6C875F4813BBADEEBF" unitRef="usd">5221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2018Q1" decimals="INF" id="Fact-A6E08FE217A75EE78E3FF56A630A9F30" unitRef="shares">3916640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2018Q1" decimals="2" id="Fact-05A38FE1BB7B5891BDA1FA72088148D2" unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-1BE97C24E03D56FC8A98CF1B609037DE" unitRef="usdPerShare">0.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-AEEC687326B25D9D97ACCAD464822610" unitRef="usdPerShare">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q1YTD" decimals="2" id="Fact-1CE976D517DB52EB9DD7C6AA630C968C" unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2017Q1" decimals="2" id="Fact-1F06EBA2D7B058B421BA21E5D9DADDD1" unitRef="usdPerShare">4.21</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2018Q1" decimals="2" id="Fact-0F9316F3EDA0528AA06C1FD91E075D1D" unitRef="usdPerShare">3.00</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-3989DF2CBD885E1D981F366CC0C102F0">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-70D48A645E585FE5B8BB2297AFFE856E">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-718811F63BA755959DCD115205E6AB4C">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C6A972DE341359739F8B4F779BD642C5">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2018Q1" decimals="-3" id="Fact-623151C251C550ACA6C6A9A657C7B49F" unitRef="usd">4245000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q1YTD" id="Fact-99E2F5ED41985D24A3372BD5AF7AC01A">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-42054D2A8B4753E88A7CF7622C3EF414">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q1YTD" id="Fact-54541C5668F659EE8ED8BAD75B573D76">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q1YTD" id="Fact-37EB45EC897A5F4D9B091B927001DC81">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F466CA263F185270B46AAE297DFA7122" unitRef="shares">39300823</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BE84F1D9A6F45C198E516933AE476B03" unitRef="shares">39454821</us-gaap:SharesOutstanding>
	<us-gaap:StockIssued1 contextRef="FD2017Q1QTD" decimals="-3" id="Fact-178154C461B779841CBE656CA3AD512F" unitRef="usd">0</us-gaap:StockIssued1>
	<us-gaap:StockIssued1 contextRef="FD2018Q1YTD" decimals="-3" id="Fact-BA835CBBB9968C18E762656CA3AD255C" unitRef="usd">436000</us-gaap:StockIssued1>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E364A91680E251FAA648E987F0787354" unitRef="shares">145466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q1YTD" decimals="INF" id="Fact-2D20230CBCAB552284DF13B9C9953F05" unitRef="shares">8532</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4557C50FA1BB5BBD961403E2F1E00BFD" unitRef="shares">8532</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1YTD" decimals="-3" id="Fact-06C7A8236BBC53638E6345FC0968C6D0" unitRef="usd">436000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-454AE3C6B1095FEA95D1A2959DD61249" unitRef="usd">436000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1YTD" decimals="-3" id="Fact-D0457F0AE64051BFAE5B6149EC756DA2" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FE0552E7842D55C3A80BB7A7B513DFE5" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-E594423B60BF58CB87BB866FDDF55898" unitRef="usd">19975000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6DD983DEEA8D57A6ACB80B1B330EBC38" unitRef="usd">53586000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DD4C54B1212F55BEA52734DAC90D7F37" unitRef="usd">4000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C1BBF3302D0553B0A1035DC235769842" unitRef="usd">-33615000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-4E172003DCC65FE0B6BF4048FE7A4059" unitRef="usd">16308000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3DE82FC560DD56FE987672591462B823" unitRef="usd">54394000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-499C59D81D9258EA81BB1042CB492013" unitRef="usd">4000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-7A5343A7FDDC55508BC3B9CBC296EA93" unitRef="usd">-38090000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 contextRef="FI2017Q4" decimals="-3" id="Fact-F1D273C7E8EEE00F6DE1216E2F244C9B" unitRef="usd">21009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D050A3085F965D04C6B9216E2F3421FD" unitRef="usd">53586000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-CEE3F70FD1B61EB975D3216E2F2B58F3" unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-33D8542A672C70333F76216E2F18C932" unitRef="usd">-32581000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-230334B66044543C9265ED76C4B615E8" unitRef="usd">13000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2018Q1" decimals="-3" id="Fact-B5300E22AE6D506E8C9CA83F1CDE0FA8" unitRef="usd">5000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1QTD" decimals="0" id="Fact-E945291C818C5A5899303ED077CE9843" unitRef="shares">169794</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q1YTD" decimals="0" id="Fact-FF3AE2BF452756868D9B4EDB6D3654B2" unitRef="shares">39357289</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<xcur:AdjustmentToAdditionalPaidInCapitalConversionOfCapital contextRef="D2015Q3Jul09-09_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-70DEFCC8745B5DAB83118661A49CC0EF" unitRef="usd">18837000</xcur:AdjustmentToAdditionalPaidInCapitalConversionOfCapital>
	<xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-7BD18E8C032B571C88F34BBF3234F82C" unitRef="target">3</xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets>
	<xcur:CollaborationAgreementRevenue contextRef="FD2017Q1QTD" decimals="-3" id="Fact-357FF147D3F55C3B97BE49F6C9489631" unitRef="usd">2432000</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2018Q1YTD" decimals="-3" id="Fact-3DDE5EF80C8F5FCAA14A1773CCB6D341" unitRef="usd">36000</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementUpfrontPayment contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-0A833621AA785C6F8B8DC21A0B4BF386" unitRef="usd">10000000</xcur:CollaborationAgreementUpfrontPayment>
	<xcur:CommonStockVotingRightsforEachShare contextRef="FI2018Q1" decimals="INF" id="Fact-890A35B4D2122E5B446221D086C2CB2D" unitRef="vote_per_share">1</xcur:CommonStockVotingRightsforEachShare>
	<xcur:CommonStockWarrantLiability contextRef="FI2017Q4" decimals="-3" id="Fact-4C7F2FE79CCD571F8BB7CCF12AE5CE16" unitRef="usd">523000</xcur:CommonStockWarrantLiability>
	<xcur:CommonStockWarrantLiability contextRef="FI2018Q1" decimals="-3" id="Fact-FEC967213DA75E74B6482E45AFA47307" unitRef="usd">651000</xcur:CommonStockWarrantLiability>
	<xcur:DebtInstrumentPeriodicPaymentConsecutivePeriod contextRef="D2020Q2Jan01-Jun30_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" id="Fact-E82862C320D48C34BE7C21A0AEE882EB">P18M</xcur:DebtInstrumentPeriodicPaymentConsecutivePeriod>
	<xcur:DebtInstrumentPeriodicPaymentDeferralPeriod contextRef="D2018Q1Jan15-15_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" id="Fact-D2917371092B613F299321A0672330CE">P13M</xcur:DebtInstrumentPeriodicPaymentDeferralPeriod>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate contextRef="FD2018Q1YTD" decimals="-3" id="Fact-47B4691B567A5EA1808E526D308BCC62" unitRef="usd">50000</xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock contextRef="FD2018Q1YTD" decimals="-3" id="Fact-3A41974832A454AB9505DB0DC531487E" unitRef="usd">94000</xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock>
	<xcur:PaymentsforLicenseAgreements contextRef="D2018Q1Dec12-Mar31" decimals="-3" id="Fact-B8C7AFF8F40954409603EFADA682C516" unitRef="usd">3419000</xcur:PaymentsforLicenseAgreements>
	<xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty contextRef="D2016Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-60E5B2247D425612831CD23DEFD7F709" unitRef="usd">8000</xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty>
	<xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty contextRef="D2017Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-EC3CE4906BAC505990E335EE8498F316" unitRef="usd">3000</xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty>
	<xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate contextRef="FI2018Q1" decimals="-3" id="Fact-06D6B8339C911B9BA82645649E4BF923" unitRef="usd">-56927000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-CA07D8EF61BC576CB4A6A99F7A59D21C" unitRef="usd">350000000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-D6F4CA7B08B657EC9166069CFA5A846A" unitRef="usd">410000000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-DAA89897E8525543A3215D8B3AA095A1" unitRef="usd">16500000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent contextRef="D2016Q4Dec02-02_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="2" id="Fact-6B71BAE68E17513D892D5BE97C339181" unitRef="number">0.10</xcur:RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-B6CEE94DF7D55EE18DD9905656C7CB97" unitRef="usd">776500000</xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2017Q1QTD" decimals="2" id="Fact-4A33D007116A527B8B315A64068AE3B3" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2018Q1YTD" decimals="2" id="Fact-44788C73F4995302A35EB0DEEACB0EB7" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2017Q1QTD" decimals="-3" id="Fact-DD16CD6D16B9FDDD8ADD2175029C6DCE" unitRef="usd">733000</xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2018Q1YTD" decimals="-3" id="Fact-9BE9348E1B3D27113DCB217502A5C62E" unitRef="usd">0</xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-1A638F9D814954EFAF08F1BDA9A9BD5E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and December 31, 2017, and for the three months ended March 31, 2018 and 2017, have been presented in conformity with generally accepted accounting principles in the United States (&amp;#8220;GAAP&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2018Q1YTD" id="Fact-8718C2175F13526595416CE3647830C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Description of Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Exicure, Inc. (&amp;#8220;Parent&amp;#8221;) is a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;clinical-stage&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&amp;#8217;s proprietary Spherical Nucleic Acid (&amp;#8220;SNA&amp;#8221;) technology. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;We believe the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; design of the Company&amp;#8217;s SNAs gives rise to chemical and biological properties that &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&amp;#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Throughout this Quarterly Report on Form 10-Q, the terms &amp;#8220;the Company&amp;#8221; and &amp;#8220;Exicure&amp;#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;References to the &amp;#8220;Merger&amp;#8221; refer to the September 26, 2017 transaction whereby Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation, or Max-1, merged with and into Exicure Operating Company (f/k/a Exicure, Inc.), a privately-held Delaware Corporation referred to herein as Exicure OpCo, with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 (which then changed its name to Exicure, Inc.).  References to the &amp;#8220;Private Placement&amp;#8221; refers to the transactions following the Merger that occurred in several closings on September 26, 2017, October 27, 2017 and November 2, 2017 in which we sold to accredited investors approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$31,513&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; worth of shares of common stock (before deducting placement agent fees and expenses which are approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,966&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;), or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,504,196&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares, at a price of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a privately-held Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these notes to unaudited condensed consolidated financial statements as the corporate conversion.   In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$18,837&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was reclassified to Additional paid in capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and December 31, 2017, and for the three months ended March 31, 2018 and 2017, have been presented in conformity with generally accepted accounting principles in the United States (&amp;#8220;GAAP&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Going Concern&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018, the Company has generated an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56,927&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&amp;#8217;s current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Unaudited Interim Financial Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying interim consolidated balance sheet as of March 31, 2018, the interim consolidated statements of operations for the three months ended March 31, 2018 and 2017, the interim consolidated statement of changes in stockholders&amp;#8217; equity for the three months ended March 31, 2018, and the interim consolidated statements of cash flows for the three months ended March 31, 2018 and 2017, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&amp;#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and the results of its cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in these notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, or any other interim periods, or any future year or period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&amp;#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Revision of Prior Period Financial Statements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We have revised the accompanying comparative financial statements to correct the immaterial errors. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The correction of the errors increased prepaid expense and other current assets by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$933&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, decreased accrued expenses by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$96&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and decreased accumulated deficit by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,028&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; at December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-749E8F1E317754258F55D8E1D14E84C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Purdue Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma, L.P. (&amp;#8220;Purdue&amp;#8221;) and referred to herein as the &amp;#8220;Purdue Collaboration.&amp;#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&amp;#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In addition, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$776,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$410,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$350,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;See Note 13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, for recent developments related to the Purdue Collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the adoption of ASC 606, the upfront payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, the Company recorded the unamortized deferred revenue of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as an adjustment to the beginning balance of retained deficit at January 1, 2018.  See Note 2, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, for more information related to the adoption of ASC 606.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company identified multiple performance obligations as part of the Purdue Collaboration agreement, including the upfront payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, discussed above, and the research and development services.  The Company determined that the performance obligations should not be combined, the license should be recognized at the time the license is granted and the research and development services at the time the service is performed.  The Purdue Collaboration agreement includes contingent promises related to specified research, development and regulatory milestones and sale-based milestones.  Each contingent promise related to contingent and milestone payment is evaluated to determine whether it represents a material right.  The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which it is determined that the revenue is not subject to a significant reversal.  To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration agreement as revenue.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the three months ended March 31, 2018, the Company recognized collaboration revenue of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which consisted entirely of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the three months ended March 31, 2017, the Company recognized collaboration revenue of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,432&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which included &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$363&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-FB6D401310415965B18C1DBE6B968D33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$52&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$46&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$48&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of March 31, 2018 and December 31, 2017, respectively, calculated on the basis of the extended lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of March 31, 2018 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Northwestern University license agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&amp;#8217;s 2009 license agreement with Northwestern University (&amp;#8220;NU&amp;#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &amp;#8220;assigned field&amp;#8221;); (2)&amp;#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&amp;#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&amp;#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&amp;#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &amp;#8220;restated license agreement&amp;#8221;). In February 2016, we obtained exclusive license as to NU&amp;#8217;s rights in certain SNA technology we jointly own with NU (the &amp;#8220;February 2016 license agreement&amp;#8221;). Our license to NU&amp;#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &amp;#8220;June 2016 license agreement&amp;#8221;). Our rights and obligations in these 2016 agreements&amp;#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &amp;#8220;the Northwestern University License Agreements&amp;#8221;).  As of March 31, 2018, the Company has paid to NU an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,419&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in consideration of each of the obligations described above.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-43A87E3190075E46B117BC31FD3BC8D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-5A080632B5F5533AAC1820A2EE3C1BE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On January 15, 2018, the Company and Hercules Technology Growth Capital Limited (&amp;#8220;Hercules&amp;#8221;) amended its loan agreement so that amortization payments due for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;thirteen&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&amp;#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, shall begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;eighteen&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (18) consecutive months.  Any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At March 31, 2018 and December 31, 2017, the carrying value of the current and non-current portion of long-term debt is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,879&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,855&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At March 31, 2018, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company paid interest on debt of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$136&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$153&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during the three months ended March 31, 2018 and 2017, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q1YTD" id="Fact-14367C8512D45527B9F42860E43EB9AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,498,264&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Unamortized equity-based compensation expense at March 31, 2018 was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,997&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which is expected to be amortized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.8 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.9 to 6.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.3 to 6.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.97% to 2.17%; weighted avg. 2.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;82.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;80.8% to 83.1%; weighted avg. 81.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The expected term is based upon the &amp;#8220;simplified method&amp;#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &amp;#8220;simplified method&amp;#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2018 and 2017 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Three months ended March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Three months ended March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. At March 31, 2018, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which is the per share price paid by outside investors in the Private Placement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2018 and 2017 was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.13&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.92&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per common stock option, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Outstanding - December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,672,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;674,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(8,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Outstanding - March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,335,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Exercisable - March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,597,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Vested and Expected to Vest -&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,916,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value of common stock options exercised during the three months ended March 31, 2018 and 2017 was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$18&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$202&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-947A19D208965BC3900E551950D645B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-5063A8ED5DD95883BAE58D7E51157362">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2018 and 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the three months ended March 31, 2018 and 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(5,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,357,289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;169,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&amp;#8217;s net loss per share during the periods ending on the dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,335,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,683,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;413,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-40929FB83E8C567AA3ABEDB231DADB98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the common stock warrant liability at March 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;78.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q1YTD" id="Fact-3E55E7171E335BB38A26E2AF6D8C7344">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the market approach and Level 1 inputs to value its cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&amp;#160;2 of the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s common stock warrant liability is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the common stock warrant liability at March 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;78.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; change in the estimate of expected volatility at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  A &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; change in the estimate of fair value of the common stock at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$94&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended March 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Balance at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q1YTD" id="Fact-96C669ECD38256D8BAC3D2DE3CF8C7A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended March 31, 2018:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Balance at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-01D0F41F67525AD5937D2FEDE15DFAB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company incurred a pretax loss in each of the three months ended March 31, 2018 and 2017, which consists entirely of loss in the U.S. and resulted in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; provision for income tax expense during the periods then ended. The effective tax rate is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in each of the three months ended March 31, 2018 and 2017 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-5090B1761CCB50048A05FA1AF61A4BC1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company adopted ASC 606 on a modified retrospective basis.  See above &amp;#8220;Revenue Recognition&amp;#8221; for a discussion of the Company&amp;#8217;s updated policies related to revenue recognition effective January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Impact of adoption of ASC 606&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of the date of adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2018; (ii) there were no impacts to the balances of the accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; each in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&amp;#8217;s statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q1YTD" id="Fact-AAB70E2BB0D950789E2B26E90386E3B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-7DE7F01395EB5DE59AC4F6A87013782B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Related-Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC, our former parent and largest stockholder.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&amp;#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The amounts due from AuraSense, LLC in connection with the above mentioned activities were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$17&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; at March 31, 2018 and December 31, 2017, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Direct costs of AuraSense LLC paid by the Company&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in each of the three months ended March 31, 2018 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-54AC22DAF8B651C28EE144A4451C7872">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;(ASC 605).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Identify the contract with the customer.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&amp;#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&amp;#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&amp;#8217;s intent and ability to pay, which is based on a variety of factors including the customer&amp;#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Identify the performance obligations in the contract.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Determine the transaction price.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&amp;#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Allocate the transaction price to performance obligations in the contract.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recognize revenue when or as the Company satisfies a performance obligation.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&amp;#8217;s performance, (ii) the entity&amp;#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&amp;#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Licenses of intellectual property&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&amp;#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Milestone payments:&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalties&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018, the Company&amp;#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-21A8E0F1CBBE531A8D1830790BF5C3BB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll-related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-B9CA8C2CBF715B6CAF967F94A6E25276">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&amp;#8217;s net loss per share during the periods ending on the dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,335,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,683,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;413,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2018Q1YTD" id="Fact-A330C651E0A55D0389413A12562ACCA7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q1YTD" id="Fact-989938AEB4435FFE8F79131B156A2403">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the three months ended March 31, 2018 and 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(5,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,357,289&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;169,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(0.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-F0F965B4694E592FA1DBEBD82B83A5E9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of March 31, 2018 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2018Q1YTD" id="Fact-902A3796C84B5D0794FA09314B217AF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At March 31, 2018, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-11DD4FBA2D2F5628AA9794A85ECADB14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Direct costs of AuraSense LLC paid by the Company&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
	<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="FD2018Q1YTD" id="Fact-77B80976D3A852F19FA2180CBA125848">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q1YTD" id="Fact-31669D3DCAD9554595D70A0566BF2BD2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Outstanding - December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,672,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;674,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(8,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Outstanding - March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,335,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Exercisable - March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,597,078&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Vested and Expected to Vest -&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,916,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-AB9A6143A0145F36B0F6B739677777F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2018 and 2017 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Three months ended March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Three months ended March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.9 to 6.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.3 to 6.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.97% to 2.17%; weighted avg. 2.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;82.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;80.8% to 83.1%; weighted avg. 81.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q1YTD" id="Fact-DA5C901893B9506581A5E321F506A1EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;There have been no changes to the significant accounting policies disclosed in the Company&amp;#8217;s most recent Annual Report on Form&amp;#160;10-K, except as required by recently adopted accounting pronouncements, as discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;(ASC 605).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Identify the contract with the customer.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&amp;#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&amp;#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&amp;#8217;s intent and ability to pay, which is based on a variety of factors including the customer&amp;#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Identify the performance obligations in the contract.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Determine the transaction price.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&amp;#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Allocate the transaction price to performance obligations in the contract.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recognize revenue when or as the Company satisfies a performance obligation.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&amp;#8217;s performance, (ii) the entity&amp;#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&amp;#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Licenses of intellectual property&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&amp;#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Milestone payments:&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalties&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&amp;#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018, the Company&amp;#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company adopted ASC 606 on a modified retrospective basis.  See above &amp;#8220;Revenue Recognition&amp;#8221; for a discussion of the Company&amp;#8217;s updated policies related to revenue recognition effective January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Impact of adoption of ASC 606&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of the date of adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2018; (ii) there were no impacts to the balances of the accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; each in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&amp;#8217;s statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-B585939C4DCF56238DF6FAF98049FFD3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018 and December 31, 2017, the Company had authorized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;200,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock, par value &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As of March 31, 2018, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;39,454,821&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares issued and outstanding.  As of December 31, 2017, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;39,300,823&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The holders of shares of the Company&amp;#8217;s common stock are entitled to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&amp;#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&amp;#8217;s board of directors (the &amp;#8220;Board&amp;#8221;) out of funds legally available for that purpose. In the event of the Company&amp;#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&amp;#160;non-assessable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of March 31, 2018 and December 31, 2017, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of preferred stock, par value &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q1YTD" id="Fact-5EB28E359BD959D5BA85199FA5A98F70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In April 2018, Purdue notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that, other than the recent developments related to the Purdue Collaboration disclosed above, there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2018Q1YTD" id="Fact-417C35EF1BC7537599A87B4D96CE5702">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Supplemental Balance Sheet Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$86&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$38&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the three months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; ended March 31, 2018 and 2017&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll-related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q1YTD" id="Fact-A56E16DD698B567F9A15FFCFEC4501CB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&amp;#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Revision of Prior Period Financial Statements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We have revised the accompanying comparative financial statements to correct the immaterial errors. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The correction of the errors increased prepaid expense and other current assets by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$933&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, decreased accrued expenses by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$96&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and decreased accumulated deficit by &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,028&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; at December 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>xcur-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exicuretx.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xcur="http://www.exicuretx.com/20180331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies">
        <link:definition>2131100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2431402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
        <link:definition>2431404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfRentExpenseDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails">
        <link:definition>2431403 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2331301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exicuretx.com/role/Debt">
        <link:definition>2113100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails">
        <link:definition>2413402 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesOfLongTermDebtDetails" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails">
        <link:definition>2413403 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exicuretx.com/role/DebtTables">
        <link:definition>2313301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentationDetails" roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails">
        <link:definition>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails">
        <link:definition>2401402 - Disclosure - Description of Business and Basis of Presentation  - Schedule of Error Corrections (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.exicuretx.com/role/EquityBasedCompensation">
        <link:definition>2119100 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails">
        <link:definition>2419404 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails">
        <link:definition>2419405 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationNarrativeDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails">
        <link:definition>2419402 - Disclosure - Equity-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleOfCompensationExpenseDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails">
        <link:definition>2419403 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails">
        <link:definition>2419406 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables">
        <link:definition>2319301 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exicuretx.com/role/FairValueMeasurements">
        <link:definition>2128100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2428402 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2428404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails">
        <link:definition>2428403 - Disclosure - Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables">
        <link:definition>2328301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exicuretx.com/role/IncomeTaxes">
        <link:definition>2122100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails">
        <link:definition>2422401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.exicuretx.com/role/LossPerCommonShare">
        <link:definition>2125100 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2425403 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationOfEarningsPerShareDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails">
        <link:definition>2425402 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables">
        <link:definition>2325301 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PurdueCollaboration" roleURI="http://www.exicuretx.com/role/PurdueCollaboration">
        <link:definition>2107100 - Disclosure - Purdue Collaboration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PurdueCollaborationDetails" roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails">
        <link:definition>2407401 - Disclosure - Purdue Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions">
        <link:definition>2134100 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2434402 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails">
        <link:definition>2434403 - Disclosure - Related-Party Transactions - Schedule of Revenue from Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables">
        <link:definition>2334301 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies">
        <link:definition>2104100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404402 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exicuretx.com/role/StockholdersEquity">
        <link:definition>2116100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCurrentCapitalizationDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails">
        <link:definition>2416401 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exicuretx.com/role/SubsequentEvents">
        <link:definition>2135100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2110100 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails">
        <link:definition>2410403 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails">
        <link:definition>2410402 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2310301 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity">
        <link:definition>1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" name="AdjustmentToAdditionalPaidInCapitalConversionOfCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_AuraSenseLLCMember" name="AuraSenseLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" name="CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementRevenue" name="CollaborationAgreementRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementUpfrontPayment" name="CollaborationAgreementUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_CommitmentsandContingenciesAbstract" name="CommitmentsandContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CommonStockVotingRightsforEachShare" name="CommonStockVotingRightsforEachShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_CommonStockWarrantLiability" name="CommonStockWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="xcur_ComputersandSoftwareMember" name="ComputersandSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConsultingServicesMember" name="ConsultingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod" name="DebtInstrumentPeriodicPaymentConsecutivePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_DebtInstrumentPeriodicPaymentDeferralPeriod" name="DebtInstrumentPeriodicPaymentDeferralPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_DirectCostsMember" name="DirectCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ExicureInc.2017EquityIncentivePlanMember" name="ExicureInc.2017EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" name="FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" name="FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_HerculesTechnologyGrowthCapitalMember" name="HerculesTechnologyGrowthCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ImmaterialErrorCorrectionsMember" name="ImmaterialErrorCorrectionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_PaymentsforLicenseAgreements" name="PaymentsforLicenseAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_QuarterlyFeeForIndirectCostsMember" name="QuarterlyFeeForIndirectCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" name="RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" name="RetainedEarningsAccumulatedDeficitInceptiontoDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" name="RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" name="StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SupplementalBalanceSheetInformationAbstract" name="SupplementalBalanceSheetInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>xcur-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20180331.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20180331.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20180331.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:href="xcur-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20180331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20180331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20180331.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20180331.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20180331.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_5fcb8627-b558-5566-1abf-864642e66a13" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_5fcb8627-b558-5566-1abf-864642e66a13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_f9f96586-cf02-591c-086f-9aaf67596c0b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_f9f96586-cf02-591c-086f-9aaf67596c0b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_0af4cf4f-dd4e-4a27-50f3-b3447f0d9b89" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_0af4cf4f-dd4e-4a27-50f3-b3447f0d9b89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_01d226b5-d89e-45e6-1279-541e7b5bf1df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_01d226b5-d89e-45e6-1279-541e7b5bf1df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_22C277AFD9872E2A0F6D3ECE3FF2BC72" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_xcur_CommonStockWarrantLiability_22C277AFD9872E2A0F6D3ECE3FF2BC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_59b4758f-0619-f6f0-6034-8dc07dd59c92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_59b4758f-0619-f6f0-6034-8dc07dd59c92" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_525fb2d2-5bf5-6d13-be2b-a6879de902da" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_59b4758f-0619-f6f0-6034-8dc07dd59c92" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_525fb2d2-5bf5-6d13-be2b-a6879de902da" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9b039144-dc24-2381-1de5-20fa04e9b091" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9b039144-dc24-2381-1de5-20fa04e9b091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_6cd34f19-57d8-aa6f-5d3a-fb8e0fc91b31" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_6cd34f19-57d8-aa6f-5d3a-fb8e0fc91b31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_566fd81d-ab31-e2a8-2025-7a0dce40b34d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_566fd81d-ab31-e2a8-2025-7a0dce40b34d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_e044e8e2-5c45-7b11-95e2-5c6b268cc854" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_e044e8e2-5c45-7b11-95e2-5c6b268cc854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_3F55313F06E9F18342DB7A654AA9DC54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_xcur_CollaborationAgreementRevenue_3F55313F06E9F18342DB7A654AA9DC54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>xcur-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20180331.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20180331.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20180331.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:href="xcur-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20180331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20180331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20180331.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20180331.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20180331.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:to="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:to="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:to="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:to="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:to="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentDeferralPeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:to="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:to="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:to="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ImmaterialErrorCorrectionsMember" xlink:label="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:to="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:to="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6E5286287C8663DE7308565D00AF03D5_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:to="loc_us-gaap_RangeMember_6E5286287C8663DE7308565D00AF03D5_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:to="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D7E7B6ADB6915833979277DAF79CA4DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_MinimumMember_D7E7B6ADB6915833979277DAF79CA4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CB41838EEF3956F2A677448F9E61EA1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_MaximumMember_CB41838EEF3956F2A677448F9E61EA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_7F01F8C6C8E0584B9FFDD4DEBBAF8EEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_WeightedAverageMember_7F01F8C6C8E0584B9FFDD4DEBBAF8EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:to="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:to="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:to="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:to="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:to="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_F55DA2C5CC30B18BECF74563A3B70609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:to="loc_us-gaap_MinimumMember_F55DA2C5CC30B18BECF74563A3B70609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:to="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:to="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_D137A482A3BC01AA159B4563A3BD02AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_SharePrice_D137A482A3BC01AA159B4563A3BD02AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A554A1E71DC63F0747DF565493FA1FF6_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A554A1E71DC63F0747DF565493FA1FF6_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:to="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:to="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:to="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:to="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:to="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:to="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8DDCF2EEDB7B1DB2CA784B5621DDB9D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:to="loc_us-gaap_CommonStockMember_8DDCF2EEDB7B1DB2CA784B5621DDB9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_0057420AB7096E0007484B5621DD4A0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:to="loc_xcur_WarrantLiabilityMember_0057420AB7096E0007484B5621DD4A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_341D80F17D08F89FDCAD938610013B7A_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_341D80F17D08F89FDCAD938610013B7A_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_59F6953EDB34558498CAA202F32C874B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:to="loc_xcur_WarrantLiabilityMember_59F6953EDB34558498CAA202F32C874B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D511AC597C1AEE340A649372EB97DBE7_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:to="loc_us-gaap_ClassOfStockDomain_D511AC597C1AEE340A649372EB97DBE7_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:to="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DB03063331B65E84A0F478B42A2635AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:to="loc_us-gaap_CommonStockMember_DB03063331B65E84A0F478B42A2635AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_D95EE3F3571F53AFAE63676B1A5D67C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_D95EE3F3571F53AFAE63676B1A5D67C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0766A0ED7DAA53EE8357D0DF63590C91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0766A0ED7DAA53EE8357D0DF63590C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F45586E0F0B7500C8C6EE845D34DFCFD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F45586E0F0B7500C8C6EE845D34DFCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_623DE43AC83E5EAFAE69EACC02602639" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_623DE43AC83E5EAFAE69EACC02602639" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280265F3217F6C29744674FD342244F0_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280265F3217F6C29744674FD342244F0_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:to="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:to="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:to="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7774EC4D916A5748B1EC4563A412C4A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:to="loc_us-gaap_MaximumMember_7774EC4D916A5748B1EC4563A412C4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:to="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_969E316A5B483B7703AC7A1A68D55E58_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_969E316A5B483B7703AC7A1A68D55E58_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:to="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_96294427A55E6A76DF8F7A1A68D56E9B_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:to="loc_us-gaap_RelatedPartyDomain_96294427A55E6A76DF8F7A1A68D56E9B_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:to="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:to="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_EEF63C3A09BA21E490137A1A68D5CCC8_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_EEF63C3A09BA21E490137A1A68D5CCC8_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:to="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:to="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_A0847D563C02D76A614021EAF0DBB11B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:to="loc_xcur_AuraSenseLLCMember_A0847D563C02D76A614021EAF0DBB11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:to="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:to="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:to="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:to="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:to="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:to="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1581C08B0F679F0E974BA6D7B76606AA_A22EABD71E7359059CC834392BA48F00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1581C08B0F679F0E974BA6D7B76606AA_A22EABD71E7359059CC834392BA48F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="loc_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="loc_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="loc_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:to="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:to="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:to="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1A65F6C67CDCAC5B44766453FCEC157A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_CommonStockMember_1A65F6C67CDCAC5B44766453FCEC157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_40190F97DB1DD25283C06453FCEC4519" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_RetainedEarningsMember_40190F97DB1DD25283C06453FCEC4519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9F5A6D6276DDF571AB3D6453FCEC0E18" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9F5A6D6276DDF571AB3D6453FCEC0E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_54DF2085701FF5815AFB6453FCEC36F7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_NetIncomeLoss_54DF2085701FF5815AFB6453FCEC36F7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>xcur-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_441025016DC682A3675858E34453E6F2_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_241DA0C126690B0E5B5158E356D76FE2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_241DA0C126690B0E5B5158E356D76FE2_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_905D786DA45532E194CF7A1A68D47233_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_B6A9F7FB074E0C8D59C07A1A68D4C788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_B6A9F7FB074E0C8D59C07A1A68D4C788_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_6079D9A6B0AAB99B16127A1A68D4A1B6_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_6079D9A6B0AAB99B16127A1A68D4A1B6_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:to="lab_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_969E316A5B483B7703AC7A1A68D55E58_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_969E316A5B483B7703AC7A1A68D55E58_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="arc" />
    <link:label id="lab_xcur_AuraSenseLLCMember_53F6389EBBAC2058AF2D7A1A68D5C63C_terseLabel_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AuraSense</link:label>
    <link:label id="lab_xcur_AuraSenseLLCMember_53F6389EBBAC2058AF2D7A1A68D5C63C_label_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AuraSense, LLC [Member]</link:label>
    <link:label id="lab_xcur_AuraSenseLLCMember_53F6389EBBAC2058AF2D7A1A68D5C63C_documentation_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AuraSense, LLC [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:to="lab_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2BDD6810BFC978A45A187A1A68D57D26_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2BDD6810BFC978A45A187A1A68D57D26_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_96294427A55E6A76DF8F7A1A68D56E9B_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_96294427A55E6A76DF8F7A1A68D56E9B_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:to="lab_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_457EE4D6E333B4DD581C7A1A68D54B70_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_us-gaap_DirectorMember_457EE4D6E333B4DD581C7A1A68D54B70_label_en-US" xlink:label="lab_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:to="lab_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_F66F33DD95A6E546D0137A1A68D55F89_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_F66F33DD95A6E546D0137A1A68D55F89_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_EEF63C3A09BA21E490137A1A68D5CCC8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_EEF63C3A09BA21E490137A1A68D5CCC8_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="arc" />
    <link:label id="lab_xcur_ConsultingServicesMember_EDA65FCF668755C219E07A1A68D5B2B1_terseLabel_en-US" xlink:label="lab_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_EDA65FCF668755C219E07A1A68D5B2B1_label_en-US" xlink:label="lab_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_EDA65FCF668755C219E07A1A68D5B2B1_documentation_en-US" xlink:label="lab_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:to="lab_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_D21117D9F7AAA7567DEC7A1A68D5EDB9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_D21117D9F7AAA7567DEC7A1A68D5EDB9_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:type="arc" />
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_6A2857AD42E8BE4E00A57A1A68D5C311_terseLabel_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly revenue from related party for indirect costs</link:label>
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_6A2857AD42E8BE4E00A57A1A68D5C311_label_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Quarterly Revenue From Transactions With Related Party</link:label>
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_6A2857AD42E8BE4E00A57A1A68D5C311_documentation_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Quarterly Revenue From Transactions With Related Party</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:to="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_1DD4D8DEC0347CB484CF7A1A68D552AB_verboseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_1DD4D8DEC0347CB484CF7A1A68D552AB_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_D7C4A968210E8DDA89747A1A68D56DA9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_D7C4A968210E8DDA89747A1A68D56DA9_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary of Common Parent</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary of Common Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:to="lab_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="arc" />
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99_terseLabel_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit generated, since inception</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99_label_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99_documentation_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:to="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="arc" />
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802_terseLabel_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount reclassified in connection with corporate conversion</link:label>
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802_label_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Conversion Of Capital</link:label>
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802_documentation_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Conversion Of Capital</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:to="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:to="lab_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037_label_en-US" xlink:label="lab_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:to="lab_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C_label_en-US" xlink:label="lab_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="lab_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B_label_en-US" xlink:label="lab_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:to="lab_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881_label_en-US" xlink:label="lab_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:to="lab_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE_label_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:to="lab_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Underlying Common Stock (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03_label_en-US" xlink:label="lab_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:to="lab_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price of Common Stock Option (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="arc" />
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771_label_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771_documentation_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:to="lab_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BDD90823B27AECE8A0F15A020BF2207F_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BDD90823B27AECE8A0F15A020BF2207F_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="arc" />
    <link:label id="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E_terseLabel_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E_label_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E_documentation_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:to="lab_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:to="lab_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:to="lab_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="arc" />
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of 10% change in expected volatility rate</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="arc" />
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of 10% change in the estimate of fair value of the common stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5FBBD48365F6F687EAA85AE5DEA38CB3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5FBBD48365F6F687EAA85AE5DEA38CB3_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_16D515E866069973EC50B7257D2D4BE4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_130DCA55EF80FDA20FD1B7257D2DB179_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purdue Collaboration</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_130DCA55EF80FDA20FD1B7257D2DB179_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8CEC53AA3515553FE3C1A6D7B7666B94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8CEC53AA3515553FE3C1A6D7B7666B94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_771FBBC5B50E5C5EA8AA3213003CED07" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C746C29E8DCED77D9DB8A6D7B766C8D4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C746C29E8DCED77D9DB8A6D7B766C8D4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E23612E2E58957338B0746F8B140B472" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1581C08B0F679F0E974BA6D7B76606AA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1581C08B0F679F0E974BA6D7B76606AA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_50BED20E6D275CCBB5EF5DC4C0D10739" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_88686D382D7A2812D07EA6D7B76675AE_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_88686D382D7A2812D07EA6D7B76675AE_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:to="lab_us-gaap_EquipmentMember_38E157381EF959B19AA587D62DA4E141" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7649015B3307384C5134A6D7B7667145_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7649015B3307384C5134A6D7B7667145_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_54C41B9A62C756CE8E81722F97895023" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_489E56F7ACB0397BA5F6A6D7B76675C7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_489E56F7ACB0397BA5F6A6D7B76675C7_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_23C1A1D9AD4F5C2DBA3EE6AAF90E5123" xlink:type="arc" />
    <link:label id="lab_xcur_ComputersandSoftwareMember_1297FC1240647133DF83A6D7B7662E21_terseLabel_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_1297FC1240647133DF83A6D7B7662E21_label_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_1297FC1240647133DF83A6D7B7662E21_documentation_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:to="lab_xcur_ComputersandSoftwareMember_4DF9D615DF1E5A9C8D5A7D99B1983D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_F9D225A5C9999F9199DBA6D7B766E5D0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_F9D225A5C9999F9199DBA6D7B766E5D0_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:to="lab_us-gaap_ConstructionInProgressMember_294B1F282464538E943C7E35861677BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_44DD932CC04F49CD065CA6D7B766E2DE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_44DD932CC04F49CD065CA6D7B766E2DE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0D245013601F535A852AB105B9938A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_B3A65C632F1F1D014B18A6D7B7665293_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_B3A65C632F1F1D014B18A6D7B7665293_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_E1EDEA268447590497A62CF1DE277332" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AFDFBAF8683282F84D75A6D7B7664264_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AFDFBAF8683282F84D75A6D7B7664264_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_FE181774B8C952DA9355E3B29A838B4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D81A98D9E7F3D5C8DB5FA6D7B7660C2C_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D81A98D9E7F3D5C8DB5FA6D7B7660C2C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D3455094C26452118FF75DB2FB326194" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_5BA3B13080440417629EA6D7B7677B6D_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_5BA3B13080440417629EA6D7B7677B6D_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet_1E018347B3305172996ABB5A0B0E717F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_34F562C739BEAD2F7CE55AFDAD64A0EA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5F288A76A2FA859D80585AFDFFD77F1D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5F288A76A2FA859D80585AFDFFD77F1D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_986064C17803108D8E4A4747827A8586_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:to="lab_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_CC14EE70F8BC3967EE0B4747BB227473_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_CC14EE70F8BC3967EE0B4747BB227473_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:to="lab_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:to="lab_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:to="lab_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting standard - ASC 606</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:to="lab_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6_label_en-US" xlink:label="lab_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:to="lab_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:to="lab_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:to="lab_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1357BABB646CABEAC01B51262E39A14D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7E7FF6951BB348A7DF8451264658E9E1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7E7FF6951BB348A7DF8451264658E9E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8E600D6094FC4AD11B07474A0E13A5AA_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8E600D6094FC4AD11B07474A0E13A5AA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_681EA84496BB7EB73F3B63090E602215_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:to="lab_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55AF2C95F0C658ABBD6D63090E604BB3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_55AF2C95F0C658ABBD6D63090E604BB3_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_031202FDFDDC1E33347563090E60B621_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_031202FDFDDC1E33347563090E60B621_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_879088A33D0ABA73669C512EA28D6412_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_879088A33D0ABA73669C512EA28D6412_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B979D58DC2C810370B2651287A107224_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B979D58DC2C810370B2651287A107224_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:to="lab_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purdue Collaboration</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:to="lab_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional collaboration targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:to="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment received for research agreement</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B_label_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:to="lab_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate research milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate regulatory milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate commercial milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial sales royalty, percent</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:to="lab_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2_label_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Revenue</link:label>
    <link:label id="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Revenue</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:to="lab_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursable research and development activities</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3527B8748CE571A78BDD5FE08462FAAF_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3527B8748CE571A78BDD5FE08462FAAF_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:type="arc" />
    <link:label id="lab_xcur_CommitmentsandContingenciesAbstract_2DDA3F9986BF71C30834A6E4DAE08679_label_en-US" xlink:label="lab_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_xcur_CommitmentsandContingenciesAbstract_2DDA3F9986BF71C30834A6E4DAE08679_documentation_en-US" xlink:label="lab_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommitmentsandContingenciesAbstract" xlink:label="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:to="lab_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_6B3E93694267A7DCAE3FA6E4DAE0B594_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended lease term</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_6B3E93694267A7DCAE3FA6E4DAE0B594_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_E5FF281F70C69476CAC9A6E4DAE03206_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent liability</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_E5FF281F70C69476CAC9A6E4DAE03206_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:to="lab_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:type="arc" />
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_6610005DB21FAD7D490AA7499B163DC5_terseLabel_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate consideration paid to NU for agreement obligations</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_6610005DB21FAD7D490AA7499B163DC5_label_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_6610005DB21FAD7D490AA7499B163DC5_documentation_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_PaymentsforLicenseAgreements" xlink:label="loc_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:to="lab_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_01C2B4A2EFE9487C48744739A092D659_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_01C2B4A2EFE9487C48744739A092D659_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_69F3E55DA79686A4DCD15FC891E1A47E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions used to Estimate Fair Value of Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_69F3E55DA79686A4DCD15FC891E1A47E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1679C90A721BD04140D95FCB3C5E3B84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1679C90A721BD04140D95FCB3C5E3B84_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0F0EF5AA5AE8EB0AC0AE565D829147A8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0F0EF5AA5AE8EB0AC0AE565D829147A8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_334E30C121FBDCB64933565DF7BF84AB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_334E30C121FBDCB64933565DF7BF84AB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04C1770391FD94123D95565ED2F56B4B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04C1770391FD94123D95565ED2F56B4B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EF322FE1588B2ECFC27156612CDDA5FD_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EF322FE1588B2ECFC27156612CDDA5FD_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EF322FE1588B2ECFC27156612CDDA5FD_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8379203229F55250BE61565F93E50B07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8379203229F55250BE61565F93E50B07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="lab_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:to="lab_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:to="lab_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:to="lab_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:to="lab_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:to="lab_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656_label_en-US" xlink:label="lab_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:to="lab_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:to="lab_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per common share (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation Expense Classification in Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions Used to Determine Fair Value of Common Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DC9C83809F3F6C6A1C67A6D78AF0FD4F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1FF50E00643B57E9B7E0B2D096B232E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DC9C83809F3F6C6A1C67A6D78AF0FD4F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1FF50E00643B57E9B7E0B2D096B232E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1FF50E00643B57E9B7E0B2D096B232E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1FF50E00643B57E9B7E0B2D096B232E5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1FF50E00643B57E9B7E0B2D096B232E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A996C10A7F9FD2779CD7A6D78AF0088A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_373A2C185DB55D58AE2FE0E1AB46410A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A996C10A7F9FD2779CD7A6D78AF0088A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_373A2C185DB55D58AE2FE0E1AB46410A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_373A2C185DB55D58AE2FE0E1AB46410A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_373A2C185DB55D58AE2FE0E1AB46410A" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_373A2C185DB55D58AE2FE0E1AB46410A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_0E811A6C3AD884424E7355E630FAB941_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:to="lab_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_DC676B8D4DD84137FF9D55E6605EFAEE_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_DC676B8D4DD84137FF9D55E6605EFAEE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:to="lab_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0F021027A85254FE7A219372EB9750BF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0F021027A85254FE7A219372EB9750BF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6CD1346252D254DF79229372EB97E15D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6CD1346252D254DF79229372EB97E15D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:type="arc" />
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81_terseLabel_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, voting rights for each share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81_label_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81_documentation_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommonStockVotingRightsforEachShare" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:to="lab_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:to="lab_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Error Corrections [Axis]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Error Corrections [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Error Correction [Domain]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Error Correction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="arc" />
    <link:label id="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148_terseLabel_en-US" xlink:label="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immaterial Error Corrections</link:label>
    <link:label id="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148_label_en-US" xlink:label="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immaterial Error Corrections [Member]</link:label>
    <link:label id="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148_documentation_en-US" xlink:label="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immaterial Error Corrections [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ImmaterialErrorCorrectionsMember" xlink:label="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:to="lab_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="arc" />
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6C3B3FEC38E4C3618F4263090E602056_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6C3B3FEC38E4C3618F4263090E602056_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B25468FC7A02F1A031416387E8064791_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B25468FC7A02F1A031416387E8064791_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42B3C2D86B5F0118FD1E74FD3421E003_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_42B3C2D86B5F0118FD1E74FD3421E003_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_100DC38CFABEEDB7A5E974FD34217777_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_100DC38CFABEEDB7A5E974FD34217777_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_280265F3217F6C29744674FD342244F0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_280265F3217F6C29744674FD342244F0_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_AB7F1BFF3C2D3FAF585B74FD3422BE1E_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_AB7F1BFF3C2D3FAF585B74FD3422BE1E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:to="lab_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_99CFD3599C075C56187B74FD34229BD6_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_99CFD3599C075C56187B74FD34229BD6_label_en-US" xlink:label="lab_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:to="lab_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7A8121DACDA8514A7F4D74FD34222B8D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7A8121DACDA8514A7F4D74FD34222B8D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5D29E11BF902013A51C274FD342258CE_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5D29E11BF902013A51C274FD342258CE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:to="lab_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:to="lab_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="arc" />
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89_terseLabel_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89_label_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89_documentation_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:to="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:to="lab_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:to="lab_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FC1B0CDA9C2A7C85C9FFA6D73CCEB0F2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1E331713F3DA5A9DBE6E5958EF305B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FC1B0CDA9C2A7C85C9FFA6D73CCEB0F2_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1E331713F3DA5A9DBE6E5958EF305B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1E331713F3DA5A9DBE6E5958EF305B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1E331713F3DA5A9DBE6E5958EF305B7E" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1E331713F3DA5A9DBE6E5958EF305B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:to="lab_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of long-term debt issuance costs and fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue receivable and accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Unbilled Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:to="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for professional services</link:label>
    <link:label id="lab_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB_label_en-US" xlink:label="lab_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:to="lab_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:type="arc" />
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB_terseLabel_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB_label_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB_documentation_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:to="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Principal balance outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:to="lab_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:to="lab_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF_label_en-US" xlink:label="lab_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:to="lab_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in- Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:to="lab_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:to="lab_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:to="lab_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, adjusted</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:to="lab_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:to="lab_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:to="lab_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:type="arc" />
    <link:label id="lab_xcur_DocumentAndEntityInformationAbstract_D08AD05AF39565F3E7505ABEDAE53C53_label_en-US" xlink:label="lab_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_xcur_DocumentAndEntityInformationAbstract_D08AD05AF39565F3E7505ABEDAE53C53_documentation_en-US" xlink:label="lab_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DocumentAndEntityInformationAbstract" xlink:label="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="lab_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_CE67979EF454675209A15ABEDAE814B2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_CE67979EF454675209A15ABEDAE814B2_label_en-US" xlink:label="lab_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:to="lab_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_F68EF6AA2D2F159C81735ABEDAE89A15_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_F68EF6AA2D2F159C81735ABEDAE89A15_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:to="lab_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_82F53AB350A4B1BA33705ABEDAE9A32F_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_82F53AB350A4B1BA33705ABEDAE9A32F_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:to="lab_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_368ACBCB825B4E3D79B05ABEDAE991A5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_368ACBCB825B4E3D79B05ABEDAE991A5_label_en-US" xlink:label="lab_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:to="lab_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_0871E57CE4F6395F5EA55ABEDAE93666_terseLabel_en-US" xlink:label="lab_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_0871E57CE4F6395F5EA55ABEDAE93666_label_en-US" xlink:label="lab_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:to="lab_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_7BFC235E6E6F2F8422ED5ABEDAE9EBAD_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_7BFC235E6E6F2F8422ED5ABEDAE9EBAD_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:to="lab_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_B8FA6126C5BC9BF6044B5ABEDAE955F0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_B8FA6126C5BC9BF6044B5ABEDAE955F0_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:to="lab_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5A8EBFCC11D52178DF515ABEDAE928F3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5A8EBFCC11D52178DF515ABEDAE928F3_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:to="lab_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_2156BBC35C520E5E22805ABEDAE9FAA1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_2156BBC35C520E5E22805ABEDAE9FAA1_label_en-US" xlink:label="lab_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:to="lab_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_19AB0242994952147D6F5ABEDAE90FE3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_19AB0242994952147D6F5ABEDAE90FE3_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_B1433D7331D71064B3D060186E9097DD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight-line rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_B1433D7331D71064B3D060186E9097DD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_399073225EC160FBFB256018C740F119_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_399073225EC160FBFB256018C740F119_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Contingent Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_101F8CB5ABFEE74725D6601927BC644D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_101F8CB5ABFEE74725D6601927BC644D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_BAF1854D505EFD3D1DB84748A21E9C98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_BAF1854D505EFD3D1DB84748A21E9C98_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_8F8558B25EE8EFD40BDC5FE9A1D1F536_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from Related Party</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_8F8558B25EE8EFD40BDC5FE9A1D1F536_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C709945477716887BDAC5652F51358F8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C709945477716887BDAC5652F51358F8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_A554A1E71DC63F0747DF565493FA1FF6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_A554A1E71DC63F0747DF565493FA1FF6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7CAEB4731276C7AF0D015653403599EF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7CAEB4731276C7AF0D015653403599EF_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_BDB59C5851BBDC29C25D565371660516_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_BDB59C5851BBDC29C25D565371660516_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4CE4103C0C1A54C621475651EFE15F6C_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4CE4103C0C1A54C621475651EFE15F6C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="lab_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:to="lab_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:to="lab_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:to="lab_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:to="lab_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:to="lab_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="arc" />
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569_terseLabel_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569_label_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569_documentation_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:to="lab_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:to="lab_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="lab_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:type="arc" />
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt payments deferred, consecutive period</link:label>
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9_label_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Deferral Period</link:label>
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Deferral Period</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentDeferralPeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:to="lab_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="arc" />
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of principal and interest, consecutive period</link:label>
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D_label_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Consecutive Period</link:label>
    <link:label id="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Consecutive Period</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:to="lab_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:to="lab_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC_label_en-US" xlink:label="lab_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:to="lab_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_AB1F4A28CB53A15E374B93771716FE2A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_AB1F4A28CB53A15E374B93771716FE2A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:to="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_24C051F64E7477450D4B9372EB8FAFB6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_24C051F64E7477450D4B9372EB8FAFB6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2018</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss included in other income (expense), net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29694F305EF4E6ACEBC0B593CB35D998_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29694F305EF4E6ACEBC0B593CB35D998_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0A7CFBC966E594D98907B593CB357957_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, beginning period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0A7CFBC966E594D98907B593CB357957_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19BEFEF99036DA8ECD7BB593CB35AC37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19BEFEF99036DA8ECD7BB593CB35AC37_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D2767DDA1DE20C63DA60B593CB35DA12_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_61B45AF79185DE0023DAB593CB3584B6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_61B45AF79185DE0023DAB593CB3584B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6199F072B2E5FAF33E0AB593CB359ABC_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, ending period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_01A9F9155A5471A11301B593CB35B5C5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_01A9F9155A5471A11301B593CB35B5C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_75CBCEC4F131E0D8B6BEB593CB35C366_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, beginning period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_75CBCEC4F131E0D8B6BEB593CB35C366_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6A2EA2E1E9424A7B5939B593CB359B4A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6A2EA2E1E9424A7B5939B593CB359B4A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EE8F312EF8DA95C422DB593CB3661FA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6EE8F312EF8DA95C422DB593CB3661FA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37DD12774B99AE81CD3DB593CB363B0F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, forfeitures (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37DD12774B99AE81CD3DB593CB363B0F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01DC7F2DF6C73B8478CCB593CB3606A6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, ending period (dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D40336FBDFA27417F488B593CB36B9E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D40336FBDFA27417F488B593CB36B9E4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A1765B60D28FCCB17DE6B593CB3689EB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A1765B60D28FCCB17DE6B593CB3689EB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FC7D1A1F70AF506999B2B593CB364F82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_FC7D1A1F70AF506999B2B593CB364F82_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD0D0C30812B1D571399B593CB36380A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD0D0C30812B1D571399B593CB36380A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5B7AFC8CA660B057D97EB593CB36E83A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-Average Exercise Price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5B7AFC8CA660B057D97EB593CB36E83A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BE7BBEE36D96DFE8CB4AB593CB363E14_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BE7BBEE36D96DFE8CB4AB593CB363E14_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4DDBEE22046905E6ED12B593CB36C202_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4DDBEE22046905E6ED12B593CB36C202_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D3DAE604B3FDCA3F939B593CB3667A3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D3DAE604B3FDCA3F939B593CB3667A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7F193336FD75309CEB6AB593CB360268_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Weighted-Average Exercise Price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7F193336FD75309CEB6AB593CB360268_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_A4047CEA3D12CE3A9985B593CB36D6F5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_A4047CEA3D12CE3A9985B593CB36D6F5_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_C5673E094C1205363607B593CB3667DB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Aggregate Intrinsic Value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_C5673E094C1205363607B593CB3667DB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:type="arc" />
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B_terseLabel_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly fee for indirect costs</link:label>
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B_label_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Fee For Indirect Costs [Member]</link:label>
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B_documentation_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Quarterly Fee For Indirect Costs [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:to="lab_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="arc" />
    <link:label id="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B_terseLabel_en-US" xlink:label="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct costs of AuraSense LLC paid by the Company</link:label>
    <link:label id="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B_label_en-US" xlink:label="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Costs [Member]</link:label>
    <link:label id="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B_documentation_en-US" xlink:label="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Costs [Member]</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:to="lab_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:to="lab_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:to="lab_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="lab_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:to="lab_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C_label_en-US" xlink:label="lab_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:to="lab_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:to="lab_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:to="lab_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:to="lab_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:type="arc" />
    <link:label id="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:to="lab_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB_label_en-US" xlink:label="lab_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:to="lab_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:to="lab_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 39,454,821 issued and outstanding, March 31, 2018; 39,300,823 shares issued and outstanding, December 31, 2017</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:to="lab_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:to="lab_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:to="lab_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>xcur-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20180331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="xcur-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20180331.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20180331.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:href="xcur-20180331.xsd#DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20180331.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20180331.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20180331.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20180331.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:href="xcur-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20180331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20180331.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20180331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20180331.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20180331.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20180331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20180331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20180331.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20180331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20180331.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="xcur-20180331.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FF55124EC97E595E801282612DDB9261" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3EC3246BCFE650AC917BD9C6DBE261EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommitmentsandContingenciesAbstract" xlink:label="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E4656338F8F950F9B661BAF804F361AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_B6181987F4055A2EB67245E1152D7E12" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_PaymentsforLicenseAgreements" xlink:label="loc_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_B6A66E3C8FE3584C8539E71A5F4B8CFD" xlink:to="loc_xcur_PaymentsforLicenseAgreements_30BEC621D19A5F8F9E0AA0FA37E56E4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_65B01C0647139A9398B4217E08E45A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_268885730416EF12A624217E08E47805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F50B5B578376021E5D4821E912E33985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_73E75579164ED2C8569021E913C1C1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_50EC9B5B7E84C92E045A217E08E40418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7E45A6370A0F53C2B8D8217E08E46C5F" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FA4212A91B448219DB6F217E08E558EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F931D9C40B29546F979C5C8DE9D2C449" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F931D9C40B29546F979C5C8DE9D2C449" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_EEF4523845BC5944AEDB702FF8D08CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F931D9C40B29546F979C5C8DE9D2C449" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_D3EB5D88EBC659B4B5F3193E2F214620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F931D9C40B29546F979C5C8DE9D2C449" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_6D8AA79321DD55E9B60CF6133C005B01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ACED0D2E435E5CA89FDC3A57D32B4CD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ACED0D2E435E5CA89FDC3A57D32B4CD2" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_928E3E1B12B45EA5810055B9FB1CDFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ACED0D2E435E5CA89FDC3A57D32B4CD2" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_FAAB7A9014135A88907B69EF44264885" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3E68F9EC06EC3D53C6956453FD2B02F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3E68F9EC06EC3D53C6956453FD2B02F8" xlink:to="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_687A6EF15FA39D3E3BE46453FD2BDE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_99FC339ACA4A115D83766453FD2B5175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_0A7C1D81173C9318F01A6453FD2B4986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B43E9E25DB33A383D0ED6453FD2B2C71" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B43E9E25DB33A383D0ED6453FD2B2C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54DC4CA68C1F7C67DB056453FD2BA544" xlink:to="loc_us-gaap_AssetsCurrent_70E8AAB2FCD73C9F76D16453FD2C6CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7B858F592977E65D1EAC6453FD2CACAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_05358BA65308A9B2CB736453FD2C1F99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_DBBCC5B35BAE4CDBA0766453FD2B4ABA" xlink:to="loc_us-gaap_Assets_D476D17CD5502F0B43356453FD2C5D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3E68F9EC06EC3D53C6956453FD2B02F8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="loc_us-gaap_LongTermDebtCurrent_C9B1FD917421D94831106453FD2C21E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="loc_us-gaap_AccountsPayableCurrent_F4B0F5781E26C830CBDA6453FD2C645A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6B7ECCAD940F6DB7BFC36453FD2CAF95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_5E9163D4544636494CC36453FD2C6964" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="loc_us-gaap_DeferredRevenueCurrent_5E9163D4544636494CC36453FD2C6964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E7008B084E2BF3E6C0AA6453FD2C3C53" xlink:to="loc_us-gaap_LiabilitiesCurrent_6D959C01ABA8B3B8180D6453FD2C7201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3FA14DE22E1B501B86826453FD2C3774" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_xcur_CommonStockWarrantLiability_F7C1473AB9BC6400EC4B6453FD2CA84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_EC2BEA00FBD52DA213BC6453FD2C7A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_Liabilities_CEE651052AA7B64712A46453FD2CAEFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:to="loc_us-gaap_CommonStockValue_2D6C2CC1F18A3470E1B56453FD32F5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C9159053AC19D7D3F0986453FD32950C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1BF34692169403CD8D66453FD32885E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1BF34692169403CD8D66453FD32885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43A9A94D62160ACE167F6453FD2C5715" xlink:to="loc_us-gaap_StockholdersEquity_71A9A5E1CD84CF3012F76453FD32B65D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8504BF4FA4FE4C7CF1A56453FD2C55DC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_93122F5F00766EA637076453FD328EB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7642FF0E1B0C043D7E256453FCFBEB8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_EAF484C8B0A52A968E956453FD0B6B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:to="loc_us-gaap_CommonStockSharesIssued_4A73B34B79A66F0636386453FD0B79F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E96934129BDBE014FDF76453FCFB5794" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7D2F908EBA395FA6BC786453FD0B0C37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C5EE2A7824035BA5B648E66BCE92A18A" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_39A23405F9495981B5229FFF0FC26849" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D10317FC5B6B20774B964563A3E47607" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D10317FC5B6B20774B964563A3E47607" xlink:to="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_7934A6B7C38692BEB85C4563A3E43688" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F8766F281D9FC70D6D7E4563A3E43117" xlink:to="loc_us-gaap_ScenarioForecastMember_5A019EC058F6A0BBC39D4563A3E4EC4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1C4F8DA1E1AA8C06BB654563A3E41769" xlink:to="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3C26EFDCE7506EB119ED4563A3E40983" xlink:to="loc_us-gaap_SecuredDebtMember_B15B47B709707F8A60014563A3E45E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_968ADADAE64139AE7FF34563A3E4E145" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_78C836991F434F429F6D4563A3E5888D" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_E9B5946672EB9006A48F4563A3E5F569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BCADF65E85CB25F2839E4563A3E536C5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3885056EDB397D74DC284563A3E569A1" xlink:to="loc_us-gaap_LoansPayableMember_D674F35618014EB97F954563A3E5F8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_AA9B49D49B8ABADD6A204563A3E484BB" xlink:to="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentDeferralPeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod_C2B7067BDECEBAE8D43B4563A3E528E9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod" xlink:label="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod_A35E63083BD323B503C24563A3E5C25D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_us-gaap_LongTermDebt_7594CCD87CB5F140B66A4563A3E50E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_FEFE06BF687F93B5992B4563A3E57AAE" xlink:to="loc_us-gaap_InterestPaid_148C397F136335D05AC84563A3E5EDEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_B2B8BF9E0A2C3E85EF8D217E09528817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_29AA0B7FCCBEB757D7A0217E0952EE73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_118D62F5788581652176217E09530FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_633EFB42864B160ACC88217E0953176F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_EFA2F28742DBA3961B71217E09538E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_LongTermDebt_07E091C59FD7E720A285217E095344DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_LongTermDebtCurrent_29C470313361A14F1124217E09536703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DFD5A3D5471A524CAD30217E0952AD7C" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_CC3D9410C72EE6BA9EF7217E09535488" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5173A57DEC6153A38F9318606D1B1F0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5173A57DEC6153A38F9318606D1B1F0A" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_34861BCAD8815C6C95FD8BC775D55C3E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FD5C463D78F1572FA2C8BF33CBC951E0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8260885DC86853AAA6F0129D8EC1F34A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5DCE0BF366B454BF7E336453FCDCF398" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5DCE0BF366B454BF7E336453FCDCF398" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E9EE8EC6CD5B9D18FC8D6453FCDC7662" xlink:to="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_CCDBFA027D4DEA43D6266453FCDCFBEF" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_CDA020237A3911B3EB886453FCDC3A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_34156F9B125707E1F12A6453FCDCB374" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12F9B68208DB9117BF2A6453FCDC1D7A" xlink:to="loc_us-gaap_PrivatePlacementMember_E57FF691C433A2B7087E6453FCDCC693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ADF280337EA12DA47CCE6453FCDC51E5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F8AFBB8EF046270423426453FCDC0F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_32C323152E10257F1B726453FCDC8507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5940DB55CDE826DBE4CB6453FCDCDA01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_AC8B700CE532A5178FAC6453FCDCE720" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_0D17FB23461D610975546453FCDC9E99" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9D8BC513B2A6A012C01D6453FCDC0C5E" xlink:to="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_B23ACB5DE45901EE4DB36453FCDC5802" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D2FC78E3216CC7D05D6B649C860539EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D2FC78E3216CC7D05D6B649C860539EB" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_3CFC2BFED3B2343D21BD649C8A100452" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ImmaterialErrorCorrectionsMember" xlink:label="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_EE3AACE1147F354814A2649C8A108E2D" xlink:to="loc_xcur_ImmaterialErrorCorrectionsMember_0178A4E9AA9C1663C3D4649C8A431148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_D4D64FDF321F6483303D649C898536B2" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E63222344110DBC74E08649C89B100C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C31BE5DD91156086F373649C89D36D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_AFD650F96BADC615324F649C89858524" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66FC146C0C2EB946E1FD649C89EF329B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DocumentAndEntityInformationAbstract" xlink:label="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_EntityRegistrantName_F74E6C9B14F15E31AA15A86CCF1099FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_EntityCentralIndexKey_AC5D410B308354F191DE1709B3342BE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_CurrentFiscalYearEndDate_D67D5C3A84C85373AFB713495F35422F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_EntityFilerCategory_01CEC62D55F25EC4B8AA14599B5BD202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_DocumentType_37F7EBE3732C59ECAD1906383C8F3B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_DocumentPeriodEndDate_13A6CD6A65FD5939A2A89583177A3609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_DocumentFiscalYearFocus_A1C083CDA5A05342B14CCBB01EA35030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_DocumentFiscalPeriodFocus_977E435B8B835A7D82D13CA6DD0E00C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_AmendmentFlag_54920FDBEF825B2AA19F24D49F6624B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_B846B12E024E5FC88CED9857A11FC04E" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_00C6E2EEC39659619C2737807FA787EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B91DBD30C0D59B6A58972461DC71B2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B91DBD30C0D59B6A58972461DC71B2E" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20E639FDC001502D8F3859B63E6313DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C018DA843BA593FBD0F8741F771A2B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C018DA843BA593FBD0F8741F771A2B2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:to="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_4EBD6AE8A6E0512D899A5C696667B185" xlink:to="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D7E7B6ADB6915833979277DAF79CA4DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_MinimumMember_D7E7B6ADB6915833979277DAF79CA4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_CB41838EEF3956F2A677448F9E61EA1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_MaximumMember_CB41838EEF3956F2A677448F9E61EA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_7F01F8C6C8E0584B9FFDD4DEBBAF8EEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0D60B05D28465779BE223CCBD9C65EB9" xlink:to="loc_us-gaap_WeightedAverageMember_7F01F8C6C8E0584B9FFDD4DEBBAF8EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90546F7868B6566BBBA3E056F7455A1C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_A32A5479EE91511CA25442463B438CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_499310D4274B5029AC2880DD46D83877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9B2266F9A09C567B91F1586332B4EBA7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_8DB94B36D64D5DFDA7E77D2D41BEECB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77FB1DCBCA4D51ED99F93BDB79BEF893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8F243CA244C352448445D3CEBF191D83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B1E57E3B0D0765BD068B4563A39BB257" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:to="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_01F3D763FF2AFBDAD8084563A39B7037" xlink:to="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_MinimumMember_5D886FBDC0A32928FC2F4563A39CB29B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_MaximumMember_3AC3F58CF915B17C158A4563A39CC881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_08BF2D8FEED76303E95E4563A39BE25C" xlink:to="loc_us-gaap_WeightedAverageMember_E3CDEAC0B1FF67AD6A1A4563A39C13AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D9D6DA037E4AB00727D04563A39BB40A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="loc_us-gaap_SharePrice_D57EA4917229094B88A34563A39C7A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8AB2DE939CA2BE6001AD4563A39CA968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_DC02AFBD065D07B459AA4563A39C767C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FC15DD0DC84330DED9494563A3B77052" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FC15DD0DC84330DED9494563A3B77052" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B053CBE9421865DC2D7E4563A3B7E7BE" xlink:to="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_F55DA2C5CC30B18BECF74563A3B70609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E9D3F19708A59899EB944563A3B7C186" xlink:to="loc_us-gaap_MinimumMember_F55DA2C5CC30B18BECF74563A3B70609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D07D01519F742D18D6B04563A3B71234" xlink:to="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3CE41C6BD29D21D9982E4563A3B7E23D" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_D0AFC9E240B5F77AFF0B4563A3BD8B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_19BA6AE3104F313C16B94563A3BDFDC1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0B0B2D3BB084CE00846C4563A3BD7008" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6B31E492468F22AECF94563A3BD857C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E04E653528A33C16E844563A3B7C8FA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_D137A482A3BC01AA159B4563A3BD02AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_SharePrice_D137A482A3BC01AA159B4563A3BD02AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0400FAFC755D3F34B79E4563A3BDBDFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_12E07B9FFEB4212893474563A3BDC499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_BC4EEC6BDA883FBDD0D14563A3BD5D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FB9640F6F1998CB1D0E04563A3BEAEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7A634DE4EFE52F8D8B9B4563A3BDF7FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0FE9DBF5EEB19E4CCC354563A3BEF34F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33101716FDFB590F8EAFFDB5802BC253" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33101716FDFB590F8EAFFDB5802BC253" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D4C4C7D5CB352F88D551FA919DE8F29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02D3FCCFB7CE5F47BC9F97EEE7EC00F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DE7CADBC9ACA59948835B3E412F616D3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_DEFADDFB76A65B33A8A9C9F2F2552A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C90B42F0BBB255F392269DE42148490D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279686AA1E615635B66C9704F614AA2D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_163047EE5A43571B9C2757E794DCC3AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F88B77CC6715FD7AEF78F264499C0E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F88B77CC6715FD7AEF78F264499C0E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D7019D1B4D8E5616906ED96BCBE538ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0167C9C9560754BC9E44819124D7EE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_433447A000185C75AAB7D0A20752831D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_968FEF3389665FE8865D55C4984299CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ED8EC2551AEC52C3B7700B9370FCA934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68C26D3278D55FA19B0F676EB103F677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F88B77CC6715FD7AEF78F264499C0E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59D0770A1F2F5B6BB2C0D13C7B070411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DDC00C24FD295C149FF1764DFBD220BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3526CEDDACCE5D5C8FC89A89E74DD235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F8A57D63009B5439B7D0B78835A73D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8624E653CF7B557888E3C630C06993EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B1356D26F38C5696BF511F0FC393F08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8F88B77CC6715FD7AEF78F264499C0E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E1361B94E51458358A2AAD3281DEFAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_AF2912AD8CA05E0FB9DF38FDC7F0FDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E30F66A529B356D88A16337A86A7574B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_93346B42F80B56FDAE71DE42B1BBBCF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50F9F06CEA4E5F8683518900493EC723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_39EC2C7091A351CD87F5D6FDFB801E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_897138EF4DE0531FBF984C690D0B4DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49FEFBC3B87C5840939FD20D5D993B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_FC6E8AAA8F8050EEAEE72B4B0C2F5C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_752B1B01A04E5E5A9C6222C2877DC027" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_B0D090A62CB751A9AF7E345A2D459A25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958B8744BB4524AB9EEB6453FCBD6161" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958B8744BB4524AB9EEB6453FCBD6161" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6632A8F4706F237F1A206453FCBD1300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958B8744BB4524AB9EEB6453FCBD6161" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_712F9ECF2F27F36ECD8F6453FCBD5D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958B8744BB4524AB9EEB6453FCBD6161" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0A2A6EF9E9697AE36C966453FCBDAA7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5C3FD7CB5F6C561A9EF8A8CC9A106A01" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5C3FD7CB5F6C561A9EF8A8CC9A106A01" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_EF6C6EFC2DEE577D85F192418D5EEBA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7D523337BD1A5C1259F21EAF0FFEE87" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_C26133466ED7F774FF0121EAF1001394" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_F64098DAA9E69C3D71BB21EAF100C8C7" xlink:to="loc_xcur_WarrantLiabilityMember_14A4CECFD0DEFF11C3B621EAF100B52E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0C1380F5D88F95878F0721EAF100A32B" xlink:to="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9235DB9E1696A79C04D121EAF1001378" xlink:to="loc_us-gaap_CommonStockMember_1A01F6D746DFA6147C0321EAF1002969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_CA1EDEE969EF81DC9CBF21EAF0FF0ACE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_B6AF33F67AFA604C9A8421EAF1002946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_AC4C2A6100146BE37D3421EAF100F9D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9B6FB4EACBBC4608F0FC21EAF101CDD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_82C6F35C1498E72381ED21EAF101DC75" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_2A4750929649CA9337BA21EAF1017676" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2877ED0ABFBCCD667AF421EAF100295C" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_D33200E21C22507CF5B421EAF10163A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2923E90A328A802B2C774B5621DD8BDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2923E90A328A802B2C774B5621DD8BDF" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E1E764F41477F2DFDAC04B5B725F2186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16175E9A20A73A34A1064B5B72643D99" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F3989D2F1AECC1EB09884B5BA4FB50AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29C3DC6DE6284FAE80A94B5621DDF57F" xlink:to="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8DDCF2EEDB7B1DB2CA784B5621DDB9D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_94515853EF6874450BCC4B5621DD13F3" xlink:to="loc_us-gaap_CommonStockMember_8DDCF2EEDB7B1DB2CA784B5621DDB9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_F5F88C1772599A7B7DC04B5621DDA585" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_0057420AB7096E0007484B5621DD4A0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5A1DD25FF8D16C88BED54B5621DD5209" xlink:to="loc_xcur_WarrantLiabilityMember_0057420AB7096E0007484B5621DD4A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09EAFE6CF4E1FF2940B74B5621DD2A3B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_FADBDB7B0D9AA16F50284B5621DDA429" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2FC5CEEC705002F8682F4B5621DDD07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_558899B18457538DC3FA4B5621DD1E53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_CF7C13DD8C9131B31ACF4B5621DDC61F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_203F2AE05F94438166D64B5621DDD3E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D3F43EA64A7D55C7AAC5224AA9E3F6A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D3F43EA64A7D55C7AAC5224AA9E3F6A7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_30A61901B21958AEBD15D9432AE5FB6D" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_59F6953EDB34558498CAA202F32C874B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6EAD3DD5B4AD58D0BA3A149680EAF8A6" xlink:to="loc_xcur_WarrantLiabilityMember_59F6953EDB34558498CAA202F32C874B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4E90CBA21B12586EAF0E56E2E739FE8A" xlink:to="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_DB03063331B65E84A0F478B42A2635AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A876A726F9B65A67B777617C34E406CA" xlink:to="loc_us-gaap_CommonStockMember_DB03063331B65E84A0F478B42A2635AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_631741E7379F5B508A11312CF862C68A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_D95EE3F3571F53AFAE63676B1A5D67C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_D95EE3F3571F53AFAE63676B1A5D67C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0766A0ED7DAA53EE8357D0DF63590C91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_0766A0ED7DAA53EE8357D0DF63590C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F45586E0F0B7500C8C6EE845D34DFCFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_F45586E0F0B7500C8C6EE845D34DFCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_623DE43AC83E5EAFAE69EACC02602639" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8476086ED32250BCAEEC5D1D0AE27A00" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_623DE43AC83E5EAFAE69EACC02602639" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D11D27965B0A56468A3671FFBBA5926A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D11D27965B0A56468A3671FFBBA5926A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1DB6A40D1EB453C68D5C426D61481714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D11D27965B0A56468A3671FFBBA5926A" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_A06EE07940FA54C4883381BC6631393A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40B71DC9B286528E94399D0B313B8757" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_74F60203F5175B6F97525C43976DE83F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18CF48E398375E298AACC09C142124D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18CF48E398375E298AACC09C142124D0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_56D567AE51685EF68C6AE9A3C2E332F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18CF48E398375E298AACC09C142124D0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3EC760BCF2BA583F9BDD3742445DACEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E264BF497EEF593CBC8E1D086B9647DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E264BF497EEF593CBC8E1D086B9647DD" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_481F453D5CE65D3D9CFD4E535B47A36A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7ECE29CBA13C5FAFB6CE90B6708352CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7ECE29CBA13C5FAFB6CE90B6708352CB" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8645161BCDBA5E88AD43DF693F180387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5B80AFC3DFDD597FBADF558D011BFDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F73369F0784B5EE6A34C317A4B185F82" xlink:to="loc_us-gaap_WarrantMember_A8E67AE92C5E5C548B94C3CC8F21EC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_B37D5F79ACF95AE6B8BFA9FA6743DEC2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C3E629DB39465F4F827171CD63DF78E1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0479016D6A655479A404C2F44DADCE33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E9AF4F7F9AEC50A483D470F42FE88F05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:to="loc_us-gaap_NetIncomeLoss_E9AF4F7F9AEC50A483D470F42FE88F05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15D096C948685C78B0F78B1ED39BA195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08BC9F837AD9568DB6C182C463A95F57" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_10D3A775FEC85325B9564C20C55B335D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_05808759A0005154BFDE59221FE4B077" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05808759A0005154BFDE59221FE4B077" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7738F9CE9E7F5A359B525A3F4827DC9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05808759A0005154BFDE59221FE4B077" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E2D0BF0AF267506BA62FFD3DFDF9B2A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_F3F94374ACCF5BFEA711EE32242C0684" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_F52C5F20BD1150289188A294BC50D0D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_FC4F7E18A77B3547CFCD4563A412BBC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_FC4F7E18A77B3547CFCD4563A412BBC4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_FDB649A2A113E46A0E2E4563A41232CB" xlink:to="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7774EC4D916A5748B1EC4563A412C4A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_53EA37B8741CA458A5744563A412A02B" xlink:to="loc_us-gaap_MaximumMember_7774EC4D916A5748B1EC4563A412C4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6D28871C2FC51634FD1C4563A41213BF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894058784374060CDCD44563A4126B45" xlink:to="loc_us-gaap_CollaborativeArrangementMember_78397CB1A05E66B3B1B94563A4125D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57647036B93EBEDF4F324563A4127448" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_4C01CF9494CCC861B0734563A412B1EC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_7C0AAFC6A5CA1CC818C54563A412977B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_C94D0CC0BD93D9ED5ED24563A412646B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_3FF1C35A59EB2CBC49774563A41266FE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_4E41802B631E55F1BE1F4563A412CCA8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_12B0F124916021109E2E4563A413B831" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_D1DAADEC583CBA32D7D34563A4134C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_8B5093E683BE00C4EE664563A41328F6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_xcur_CollaborationAgreementRevenue_BBD672ABFAECE6CEBA1F4563A4138FD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1ECA42D70500F5F9BA214563A412CB2B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_7FB6AD74D6EF1CDA7C324563A4139186" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1BCDAD8ECDE45ECC9CE32C1157911523" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1BCDAD8ECDE45ECC9CE32C1157911523" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D06DB980BACC5054907144E7721B8690" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_924F8B56D1BA51F0B42E8B06F4426750" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_58AAEF0B4C3B536FB2BEC813A78DBCBF" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_9B79770A19F65EDDA59F6E5968B598A4" xlink:to="loc_xcur_AuraSenseLLCMember_BB5499C13F065F0DAFC587A915198E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_14C2C2F18A6E5E1280A8732718A759ED" xlink:to="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_51FAB2350E6C5050AD15DD7EE8DC6DFB" xlink:to="loc_us-gaap_DirectorMember_1F1F4FE94F065725A583E46C9D942C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_BA620E80BA57511298F65EB4988B9EA3" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2AF0FA408C865C259386D58AF6A93859" xlink:to="loc_xcur_ConsultingServicesMember_C4830363A2055826A8D7B77BCDCE4184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403009FCFD785211B46745D9CE330460" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_089401097F9F513096B4DC48F9272769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_1E055408E1E85F3CB939ECC6F96ABD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_35BF52669D2E572AB5333C2B70B924F1" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_E02EE3AF15E855019EA345D6D0F221FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_46C806AF2166F9E8F4C021EAF0DBBA53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_46C806AF2166F9E8F4C021EAF0DBBA53" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:to="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_C9004D6148D8A4D331FF21EAF0DB8FE1" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_A0847D563C02D76A614021EAF0DBB11B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C5C25B0E947FF154ECC521EAF0DB8583" xlink:to="loc_xcur_AuraSenseLLCMember_A0847D563C02D76A614021EAF0DBB11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5F2C21D85FEAA9569EC721EAF0DC280B" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:to="loc_xcur_QuarterlyFeeForIndirectCostsMember_40C6F190E2D5B593BDE221EAF0DC6B1B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A2C2F7304A51CC27A0421EAF0DCD168" xlink:to="loc_xcur_DirectCostsMember_354B0DA2BB9801B2F41021EAF0DC023B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9B0AAF6423E828E2EA7C21EAF0DBF818" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_CFF36D33CA96399C774E21EAF0DC7511" xlink:to="loc_us-gaap_RevenueFromRelatedParties_717BADA102AE3BA2FF1121EAF0DCE2C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8DAEF61B18635D939B0543B6D3DE3480" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8DAEF61B18635D939B0543B6D3DE3480" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2BB0BD47FFE554BC8A600384A4C0C411" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BDDC5EC62D4C5E8C9F8C6605FB1CF7CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BDDC5EC62D4C5E8C9F8C6605FB1CF7CA" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_31DCE4B7DEE559F68ED36F60801754B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BF54F80FDC9A03DC9C6D6450073E9093" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BF54F80FDC9A03DC9C6D6450073E9093" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3947FDAAA645490D009E64500741768A" xlink:to="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35692C6668DB4510A3FE645007415690" xlink:to="loc_us-gaap_RetainedEarningsMember_4B154E41E0029B3596F6645007417639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_913F4CCAE7B6FF88BA82645007410046" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_B1AB7BDCB10BDF42C37264500741B3EA" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_2FD30EB0FF388C4E5278645007425F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3F68BFA630248C35B34264500742E5B9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_05D91D8F5EAA155E857F64500742E833" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_0273C82BEAD39B5580106450074268F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_316A87E1BFFE35493CFB64500740DC93" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_AE697CD7A9FB0C68E2C2645007421C37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_55A64F5812C014D2A7BF64500742B66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F7C48D51BCBD6CA13A3264500742CBBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_Revenues_063D73799C5464F3F3496457F3077DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_OperatingIncomeLoss_E05596BF7BF3CCA86A5B6454CD25254A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4AF91E36D20DB4D608A06450074275A0" xlink:to="loc_us-gaap_NetIncomeLoss_1940C669A86EE1A6A30964506BB67E31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0B239CE493EEE1932EAB217E0981F60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_14D5F45FAF439518B5FB217E098181DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_UseOfEstimates_C86EBED505E7447110F0217E0981EA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7AF0B2DF1AAA7C6DC9F0217E0981C20B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1450D3801B8B95D90754217E098287C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_173ACD5258BC7D844CA1217E0980918F" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_09C2C57BD1600F17E705217E09824927" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_05699D0F15585152ADCEEE4C6014BB89" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25F31BF95D4F5AE28B97287F889EBB45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_927DC5C5C9522B05E29D217E094C5CC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_927DC5C5C9522B05E29D217E094C5CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_EF0C693697B0D2BCBD36217E094CBE0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_EF0C693697B0D2BCBD36217E094CBE0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CB1D9356666C125EC83C217E094CA8B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_CommonStockSharesIssued_CB1D9356666C125EC83C217E094CA8B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6381AF0DCBED1A82EA90217E094CE9AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6381AF0DCBED1A82EA90217E094CE9AE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CommonStockVotingRightsforEachShare" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_xcur_CommonStockVotingRightsforEachShare_B5690C0EEE7D324EE0B6217E094C3D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_F1E8E6BC79B749A249C7217E094C0CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_23B4F9616A9DAF24E935217E094C8C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9515CEA6AF4EB0163F6A217E094C8373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C57678BD67590C176D217E094ADE22" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78A0AD995D630F14C202217E094C4D71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_681377F2CE884C83413A21EAF0D7F44A" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_A39E701BE11CE86B2C5B21EAF0D75399" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_93DD751310D75D35B2EFE2DB947CD51B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D9390A1ABFA852BFABEF6B2DE3E6EF39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_93DD751310D75D35B2EFE2DB947CD51B" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_D9390A1ABFA852BFABEF6B2DE3E6EF39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2325E535D64273D55943217E0965630F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8C5F4C323D588042D0A0217E0965AC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43F90FEDA2C6D02A9A53217E096513AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_21F9A880A8835CA1C624217E09649771" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_FF8D333B737048E20419217E096555AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_8AC1808FE19F55D5A2B964B4205D6C1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D6E4B703DC355273ADAA11F908F5912A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_8AC1808FE19F55D5A2B964B4205D6C1A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D6E4B703DC355273ADAA11F908F5912A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D04C3F4B984D581BA425475B055DC8D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D6E4B703DC355273ADAA11F908F5912A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D04C3F4B984D581BA425475B055DC8D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_D04C3F4B984D581BA425475B055DC8D3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_C6227461A1225739BC0146AF53482FD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:to="loc_us-gaap_EquipmentMember_C6227461A1225739BC0146AF53482FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_E6F6102C5B27531089B9C6ACE88FCBA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_E6F6102C5B27531089B9C6ACE88FCBA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A03C6D613B7F5599BC5361AD8E8E8A76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_A03C6D613B7F5599BC5361AD8E8E8A76" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_EF2FA750BDB2580FADE966F2BAD825A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:to="loc_xcur_ComputersandSoftwareMember_EF2FA750BDB2580FADE966F2BAD825A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_EF7912A73FEC5AF0A535C6DBBE3A200D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CC195D58F323588B90BC581FABC3EBF7" xlink:to="loc_us-gaap_ConstructionInProgressMember_EF7912A73FEC5AF0A535C6DBBE3A200D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D6E4B703DC355273ADAA11F908F5912A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34D61E0AF8945D13AD2CD9959F152467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34D61E0AF8945D13AD2CD9959F152467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9DFB201CD8550088343A1A021781007" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_D9DFB201CD8550088343A1A021781007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_B2F8CCD213AD535589395B0EA81232C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_B2F8CCD213AD535589395B0EA81232C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_DA9C705FBAE85C6F8C2CEC36854E08B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1F669AB50FA35A49922B6916CE4CF218" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_DA9C705FBAE85C6F8C2CEC36854E08B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:href="xcur-20180331.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_9E22C46ACD0C5B5C98C0CF2A3D81A2A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_F77C2EB583925329A549B78914B6C306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_9E22C46ACD0C5B5C98C0CF2A3D81A2A6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_F77C2EB583925329A549B78914B6C306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6CF826E20195526EBB5CC110F99B9BA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_9E22C46ACD0C5B5C98C0CF2A3D81A2A6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6CF826E20195526EBB5CC110F99B9BA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_21F326ECC71835EA71B26453FCEC543C" xlink:to="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D4C7A1F2D6F35108132F6453FCECD3EE" xlink:to="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1A65F6C67CDCAC5B44766453FCEC157A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_CommonStockMember_1A65F6C67CDCAC5B44766453FCEC157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_FD3E8BEB172112FF2E546453FCECF6F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_40190F97DB1DD25283C06453FCEC4519" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8A696D90ED85B35CCA6F6453FCEC01B3" xlink:to="loc_us-gaap_RetainedEarningsMember_40190F97DB1DD25283C06453FCEC4519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0D773262A2147DFCBCF76453FCEC44EF" xlink:to="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8D8414230445F489C0E16453FCEC035A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_SharesOutstanding_712BFAF8BB6014AD316D6453FCECA9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockholdersEquity_04DD73E58DB73C713B6B6453FCEC65E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9F5A6D6276DDF571AB3D6453FCEC0E18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9F5A6D6276DDF571AB3D6453FCEC0E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_05617C4BCA2543C517936453FCECCCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3914B561F2071BC949B66453FCECA855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_AE1DEA69DD38091915E76453FCEC7537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76410A9B5D6D781A8A1C6453FCECBE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18355FD8774F899836176453FCECD069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6B0F0B03D4052C1190106453FCECDE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_54DF2085701FF5815AFB6453FCEC36F7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_NetIncomeLoss_54DF2085701FF5815AFB6453FCEC36F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_SharesOutstanding_CB42A328F8F9196F72836453FCEC611D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_46D312F980E6A76B43DC6453FCEC58A0" xlink:to="loc_us-gaap_StockholdersEquity_3D82596ECD48525D03AF6453FCECA132" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0C151EA93E53466BA9D7656756D821BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:to="loc_us-gaap_NetIncomeLoss_0C151EA93E53466BA9D7656756D821BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_55DDFD5757055AFC813E656756D9C845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_55DDFD5757055AFC813E656756D9C845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_ShareBasedCompensation_DA8481DFFA5572758E29656756D9CD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_BD6FC71B36E884E3566C656756D9312E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_DAF87430B10A1AE6220F6568255B5BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2841118BF3F503B41816656756D90470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9FC787839CFCF9A0E1B2656756D9C2D8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_F6A20F79094246238C4D656756DA91F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_8FC2904EE56393656755656756DADE7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75806030A47357F51AF0656756DAEC89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_95A2E1F0CFB0D91A3E79656756DA31D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1A7D26E7DB9160A307E1656756DA6C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F0B9FC1AC25C42825E9C656756DA1D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_172A860C3D1F527C3B82656756DADE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9767F18210490FB8DD1B656756DA879D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C620AC302ABF386AD091656756D96E35" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_BAF46AEF054233FC1F27656756DABF47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9915789BDCDC92D4E04D656756D68F12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53307DB284E31ACCAC2D656756DA0E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_983B80DEC67FA92F2F84656756DA03FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A0EBDFC601EBF0B605EF656756DAFA3E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ECDE2BB923D6A04BEC0656756DAE9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_45A3656D00C95E609A84656756DBEE1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7855255CF4330ABC3A99656756DA5ED6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3967FD4E005F7CF47B82656756DB88B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_218FD8F144A1C641C633656756DB3EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2FC4C380816EF789CC9E656756DB7A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AEC056399D5DF90635CD656756DB9CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_79A410A87C723A61AF3D656756D32BFC" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4A4E0BE72937971C20CA656756DB1DD4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:to="loc_us-gaap_StockIssued1_FDF10D91E068161F8650656CA77EA7DB" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:to="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_E59E563B206F1D200809656756DB1FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_21A543E4F9510C1BEC02656756DB1491" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77B7B274C3BB408A36A1656756DBD402" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20180331.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_BD657BB11DAB888EB10C6453FCECE535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:to="loc_xcur_CollaborationAgreementRevenue_BD657BB11DAB888EB10C6453FCECE535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_B4C93AEAADEAD21AB36E6453FCEC25AA" xlink:to="loc_us-gaap_Revenues_DEEF93D781EE9C1559116453FCEC5086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_753298DE23A7F64D68E46453FCECBAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_C82B5AA49010596F5A776453FCECE3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:to="loc_us-gaap_OperatingExpenses_A116CC69D83C3123D88F6453FCEC49C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_DACD0D0737E9A2E2582A6453FCEC3485" xlink:to="loc_us-gaap_OperatingIncomeLoss_440D8DEB4D9CA27C51736453FCEC9ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:to="loc_us-gaap_InterestExpense_4002F816FADC30BB1C716453FCEC5656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_064C2627E89CC4DBD53C6453FCECCE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4BC1D69C87CF897E1A856453FCECFC0A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_79870758656D7830613E6453FCEC02E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_NetIncomeLoss_6DF79EDE74778D6916416453FCECBC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A888C52D91FFB3FE8B956453FCEC6537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B26D92519FA23BBB23D46453FCEC6587" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1579D91BCA5DCDE3938B6453FCECBEE3" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exicureimage1a01.gif
<TEXT>
begin 644 exicureimage1a01.gif
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MV40/+L0%,I#!#'8Y@Y.0\("K=-_A,.:V_& P5\X*W_->:9 :U. &-\ !#G(
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$*R  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759178192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXICURE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001698530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,454,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759586608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,124<span></span>
</td>
<td class="nump">$ 25,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled revenue receivable</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">23,047<span></span>
</td>
<td class="nump">27,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,354<span></span>
</td>
<td class="nump">28,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,015<span></span>
</td>
<td class="nump">3,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">4,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,046<span></span>
</td>
<td class="nump">9,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 39,454,821 issued and outstanding, March 31, 2018; 39,300,823 shares issued and outstanding, December 31, 2017</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">54,394<span></span>
</td>
<td class="nump">53,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(38,090)<span></span>
</td>
<td class="num">(33,615)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,308<span></span>
</td>
<td class="nump">19,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 24,354<span></span>
</td>
<td class="nump">$ 28,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753172704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,454,821<span></span>
</td>
<td class="nump">39,300,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">39,454,821<span></span>
</td>
<td class="nump">39,300,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759465680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 2,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">3,275<span></span>
</td>
<td class="nump">3,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,284)<span></span>
</td>
<td class="num">(2,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (loss), net</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,509)<span></span>
</td>
<td class="num">$ (2,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (15.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">39,357,289<span></span>
</td>
<td class="nump">169,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763333248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in- Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of new accounting standard - ASC 606</a></td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,300,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">19,975<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 53,586<span></span>
</td>
<td class="num">(33,615)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Beginning balance, adjusted at Dec. 31, 2017</a></td>
<td class="nump">$ 21,009<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">53,586<span></span>
</td>
<td class="num">(32,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">8,532<span></span>
</td>
<td class="nump">8,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,454,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">$ 16,308<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 54,394<span></span>
</td>
<td class="num">$ (38,090)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765116928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,509)<span></span>
</td>
<td class="num">$ (2,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">128<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Unbilled revenue receivable and accounts receivable</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">311<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,647)<span></span>
</td>
<td class="num">(6,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase decrease in cash and cash equivalents</a></td>
<td class="num">(4,640)<span></span>
</td>
<td class="num">(7,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">25,764<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">21,124<span></span>
</td>
<td class="nump">12,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for professional services</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction', window );">Deferred offering costs (accounts payable and accrued expenses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Capital expenditures (accounts payable and accrued expenses)</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755837200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure, Inc. (&#8220;Parent&#8221;) is a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">clinical-stage</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> design of the Company&#8217;s SNAs gives rise to chemical and biological properties that </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Throughout this Quarterly Report on Form 10-Q, the terms &#8220;the Company&#8221; and &#8220;Exicure&#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">References to the &#8220;Merger&#8221; refer to the September 26, 2017 transaction whereby Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation, or Max-1, merged with and into Exicure Operating Company (f/k/a Exicure, Inc.), a privately-held Delaware Corporation referred to herein as Exicure OpCo, with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 (which then changed its name to Exicure, Inc.).  References to the &#8220;Private Placement&#8221; refers to the transactions following the Merger that occurred in several closings on September 26, 2017, October 27, 2017 and November 2, 2017 in which we sold to accredited investors approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$31,513</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> worth of shares of common stock (before deducting placement agent fees and expenses which are approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">), or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares, at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a privately-held Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these notes to unaudited condensed consolidated financial statements as the corporate conversion.   In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18,837</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was reclassified to Additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and December 31, 2017, and for the three months ended March 31, 2018 and 2017, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Going Concern</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the Company has generated an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,927</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, existing working capital at March 31, 2018 is not sufficient to sustain operations beyond March 31, 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Unaudited Interim Financial Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying interim consolidated balance sheet as of March 31, 2018, the interim consolidated statements of operations for the three months ended March 31, 2018 and 2017, the interim consolidated statement of changes in stockholders&#8217; equity for the three months ended March 31, 2018, and the interim consolidated statements of cash flows for the three months ended March 31, 2018 and 2017, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2018, the results of its operations for the three months ended March 31, 2018 and 2017, and the results of its cash flows for the three months ended March 31, 2018 and 2017. The financial data and other information disclosed in these notes related to the three months ended March 31, 2018 and 2017 are unaudited. The results for the three months ended March 31, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, or any other interim periods, or any future year or period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revision of Prior Period Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We have revised the accompanying comparative financial statements to correct the immaterial errors. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The correction of the errors increased prepaid expense and other current assets by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$933</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, decreased accrued expenses by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$96</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and decreased accumulated deficit by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> at December 31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635301216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form&#160;10-K, except as required by recently adopted accounting pronouncements, as discussed below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(ASC 605).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the contract with the customer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determine the transaction price.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Allocate the transaction price to performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recognize revenue when or as the Company satisfies a performance obligation.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Licenses of intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone payments:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the Company&#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company adopted ASC 606 on a modified retrospective basis.  See above &#8220;Revenue Recognition&#8221; for a discussion of the Company&#8217;s updated policies related to revenue recognition effective January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Impact of adoption of ASC 606</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of the date of adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2018; (ii) there were no impacts to the balances of the accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> each in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&#8217;s statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608634400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purdue Collaboration<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Purdue Collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma, L.P. (&#8220;Purdue&#8221;) and referred to herein as the &#8220;Purdue Collaboration.&#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, the Company is eligible to receive up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$776,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Note 13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for recent developments related to the Purdue Collaboration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the adoption of ASC 606, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, the Company recorded the unamortized deferred revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as an adjustment to the beginning balance of retained deficit at January 1, 2018.  See Note 2, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information related to the adoption of ASC 606.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company identified multiple performance obligations as part of the Purdue Collaboration agreement, including the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, discussed above, and the research and development services.  The Company determined that the performance obligations should not be combined, the license should be recognized at the time the license is granted and the research and development services at the time the service is performed.  The Purdue Collaboration agreement includes contingent promises related to specified research, development and regulatory milestones and sale-based milestones.  Each contingent promise related to contingent and milestone payment is evaluated to determine whether it represents a material right.  The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which it is determined that the revenue is not subject to a significant reversal.  To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration agreement as revenue.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the three months ended March 31, 2018, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which consisted entirely of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the three months ended March 31, 2017, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,432</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$363</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6634799568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Supplemental Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(918</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$86</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$38</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the three months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> ended March 31, 2018 and 2017</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597364208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 15, 2018, the Company and Hercules Technology Growth Capital Limited (&#8220;Hercules&#8221;) amended its loan agreement so that amortization payments due for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">thirteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, shall begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">eighteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (18) consecutive months.  Any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At March 31, 2018 and December 31, 2017, the carrying value of the current and non-current portion of long-term debt is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,879</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,855</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At March 31, 2018, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Principal balance outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Noncurrent portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$136</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$153</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during the three months ended March 31, 2018 and 2017, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908493552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018 and December 31, 2017, the Company had authorized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">200,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of March 31, 2018, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,454,821</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares issued and outstanding.  As of December 31, 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,300,823</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The holders of shares of the Company&#8217;s common stock are entitled to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&#160;non-assessable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018 and December 31, 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of preferred stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares issued and outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631903872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,498,264</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at March 31, 2018 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,997</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.8 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.9 to 6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.72%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">82.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2018 and 2017 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. At March 31, 2018, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is the per share price paid by outside investors in the Private Placement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.13</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.92</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,672,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">674,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercisable - March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,597,078</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vested and Expected to Vest -</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,916,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the three months ended March 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$202</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6610283600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company incurred a pretax loss in each of the three months ended March 31, 2018 and 2017, which consists entirely of loss in the U.S. and resulted in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> provision for income tax expense during the periods then ended. The effective tax rate is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in each of the three months ended March 31, 2018 and 2017 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651921216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2018 and 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three months ended March 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,357,289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">169,794</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,683,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">413,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629167776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s common stock warrant liability is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> change in the estimate of expected volatility at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> change in the estimate of fair value of the common stock at March 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$94</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755740480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$52</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of March 31, 2018 and December 31, 2017, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Future minimum lease payments as of March 31, 2018 are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, we obtained exclusive license as to NU&#8217;s rights in certain SNA technology we jointly own with NU (the &#8220;February 2016 license agreement&#8221;). Our license to NU&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of March 31, 2018, the Company has paid to NU an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,419</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in consideration of each of the obligations described above.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597364208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC, our former parent and largest stockholder.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> at March 31, 2018 and December 31, 2017, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in each of the three months ended March 31, 2018 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635301216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue notified the Company it has declined to exercise its option to develop AST-005 at this time, but that it also intends to retain rights relating to the TNF target, and Purdue reserves its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that, other than the recent developments related to the Purdue Collaboration disclosed above, there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754336064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and December 31, 2017, and for the three months ended March 31, 2018 and 2017, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revision of Prior Period Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We have revised the accompanying comparative financial statements to correct the immaterial errors. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The correction of the errors increased prepaid expense and other current assets by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$933</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, decreased accrued expenses by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$96</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and decreased accumulated deficit by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> at December 31, 2017. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(ASC 605).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the contract with the customer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determine the transaction price.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Allocate the transaction price to performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recognize revenue when or as the Company satisfies a performance obligation.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Licenses of intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone payments:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2018, the Company&#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company adopted ASC 606 on a modified retrospective basis.  See above &#8220;Revenue Recognition&#8221; for a discussion of the Company&#8217;s updated policies related to revenue recognition effective January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Impact of adoption of ASC 606</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of the date of adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2018; (ii) there were no impacts to the balances of the accompanying unaudited condensed consolidated balance sheet as of March 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> each in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&#8217;s statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635744912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(918</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,265</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755931056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Principal Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At March 31, 2018, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Principal balance outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Noncurrent portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604638496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Equity-Based Compensation Expense Classification in Statement of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Fair Value of Common Stock Option Grants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2018 and 2017 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Three months ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.9 to 6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.72%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">82.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Common Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,672,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">674,279</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercisable - March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,597,078</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vested and Expected to Vest -</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,916,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755843712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three months ended March 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,357,289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">169,794</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,335,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,683,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">413,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753095600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions used to Estimate Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended March 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759165104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of Rent Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Future minimum lease payments as of March 31, 2018 are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635321184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Revenue from Related Party</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763268928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th"><div>Nov. 02, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate', window );">Accumulated deficit generated, since inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56,927)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,504,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember', window );">Subsidiary of Common Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital', window );">Amount reclassified in connection with corporate conversion</a></td>
<td class="nump">$ 18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital, Conversion Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained Earnings (Accumulated Deficit), Inception to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763294352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation  - Schedule of Error Corrections (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="nump">$ 1,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (38,090)<span></span>
</td>
<td class="num">(33,615)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=xcur_ImmaterialErrorCorrectionsMember', window );">Immaterial Error Corrections</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=xcur_ImmaterialErrorCorrectionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=xcur_ImmaterialErrorCorrectionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765534064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of new accounting standard - ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (38,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 2,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,284)<span></span>
</td>
<td class="num">(2,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,509)<span></span>
</td>
<td class="num">$ (2,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of new accounting standard - ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765242064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purdue Collaboration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2016 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 2,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Reimbursable research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets', window );">Number of additional collaboration targets | target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue', window );">Potential milestone revenue</a></td>
<td class="nump">776,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue', window );">Aggregate research milestone revenue</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue', window );">Aggregate regulatory milestone revenue</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue', window );">Aggregate commercial milestone revenue</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent', window );">Commercial sales royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Number of Additional Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765629760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(849)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617627456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 1,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759414400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Hercules Technology Growth Capital | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod', window );">Debt payments deferred, consecutive period</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Secured Debt | Hercules Technology Growth Capital | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod', window );">Amortization of principal and interest, consecutive period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Consecutive Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentPeriodicPaymentConsecutivePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentPeriodicPaymentDeferralPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Deferral Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentPeriodicPaymentDeferralPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763294208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Principal Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2019</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance outstanding</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">less: unamortized discount</a></td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">less: unamortized debt issuance costs</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion</a></td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765243440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Current Capitalization (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>vote_per_share </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">39,454,821<span></span>
</td>
<td class="nump">39,300,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">39,454,821<span></span>
</td>
<td class="nump">39,300,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockVotingRightsforEachShare', window );">Common stock, voting rights for each share | vote_per_share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockVotingRightsforEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights for Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockVotingRightsforEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754775136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="nump">$ 2,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">1,498,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754727920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754528720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">82.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755792592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765331648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, beginning period</a></td>
<td class="nump">3,672,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">674,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares</a></td>
<td class="num">(8,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(2,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, ending period</a></td>
<td class="nump">4,335,729<span></span>
</td>
<td class="nump">3,672,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning period (dollars per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted (dollars per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised (dollars per share)</a></td>
<td class="nump">0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeitures (dollars per share)</a></td>
<td class="nump">1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending period (dollars per share)</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="nump">$ 5,221<span></span>
</td>
<td class="nump">$ 5,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares</a></td>
<td class="nump">2,597,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest, shares</a></td>
<td class="nump">3,916,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Expected to Vest, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Expected to Vest, Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and Expected to Vest, Aggregate Intrinsic Value (dollars per share)</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632497792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755863648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,509)<span></span>
</td>
<td class="num">$ (2,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">39,357,289<span></span>
</td>
<td class="nump">169,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (15.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755886544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">4,335,729<span></span>
</td>
<td class="nump">3,683,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">413,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755785312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate', window );">Impact of 10% change in expected volatility rate</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock', window );">Impact of 10% change in the estimate of fair value of the common stock</a></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">78.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635766800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details) - Warrant Liability - Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">78.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753185952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Common Stock - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at January 1, 2018</a></td>
<td class="nump">$ 523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss included in other income (expense), net</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2018</a></td>
<td class="nump">$ 651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617302608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">76 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommitmentsandContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Extended lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Deferred rent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsforLicenseAgreements', window );">Aggregate consideration paid to NU for agreement obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommitmentsandContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommitmentsandContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsforLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsforLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617657168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Rent Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Straight-line rent expense</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseContingentRentals', window );">Contingent rent expense</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseContingentRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increases or decreases in lease payments that result from changes occurring after the inception of the lease in the factors (other than the passage of time) on which lease payments are based, except that any escalation of minimum lease payments relating to increases in construction or acquisition cost of the leased property or for increases in some measure of cost or value during the construction or preconstruction period, are excluded from contingent rentals. Contingent rentals also may include amounts for which the triggering events have not yet occurred or the specified targets for which have not yet been achieved (such as sales based percentage rent), but which events are considered probable of occurring or which specified targets are considered probable of being achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77895616&amp;loc=d3e36728-112689<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=77910666&amp;loc=d3e35050-112683<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseContingentRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617354848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2018</a></td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754530208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Board of Directors | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">AuraSense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty', window );">Quarterly revenue from related party for indirect costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Quarterly Revenue From Transactions With Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629489152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Schedule of Revenue from Related Party (Details) - AuraSense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Quarterly fee for indirect costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Direct costs of AuraSense LLC paid by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_QuarterlyFeeForIndirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_QuarterlyFeeForIndirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_DirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_DirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]YP6#5RDGF[4G \M9%A(UH_M,9AZ=/$'4$L#!!0    ( +&(KTP RR+"?@,
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M-BK,1F#0)Q/\[K.JU+=(/".!0E)A2 )%H,!6&$H*Y:$3\* $2DJ%20F4@DH
MF1A&I>+$XX:')5!:*DQ+H"#4+FWLAE%E<>QQP^,2*"\UYB50%B8Q_IHQHMAW
M3 $>F$")J3$Q@?)0IO@SPHH\7Q')4U-2:FI,34EQF F-(<.H<@$>ADN>F9(R
M4_N.@)XS(&6FQLR4%(>84^]*WOK@B2DI,34FIJ0PC+7*B1=&IN+,LQLE#TU)
MH8E7<"LI#C^H3.285:Q.)>#9D9('IZ3@Q.>DK62HF"B184.,+,]3GQ^>GI+2
M4V-ZSIHW)WOF_,#)F/-#M+A=#=?=[T7[4#9=<&][=U$;KU-':WOCNA0W+KF3
MNV%?*Y4Y]D,Q=>5VNF9.E=Z>YRMT=+W';_X#4$L#!!0    ( +&(KTR!7]:2
M]@$  (L%   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC93;CILP$(9?
M!?$ L3EN-@*DAJIJI5:*MNKVVB%#0&MC:CMA^_:U#8L(<=OE I_^?_R-P9,-
M7+S(!D!YKXQV,O<;I?H=0K)J@!&YX3UT>J7F@A&EA^*,9"^ G*R)411BG")&
MVLXO,CMW$$7&+XJV'1R$)R^,$?%[#Y0/N1_X;Q-/[;E19@(564_.\!W4C_X@
M] C-44XM@TZVO/,$U+G_(=B5J=%;P7,+@UST/9/)D?,7,_ARRGUL@(!"I4P$
MHILKE$"I":0Q?DTQ_7E+8USVWZ)_LKGK7(Y$0LGIS_:DFMS?^MX):G*AZHD/
MGV'*)_&]*?FO< 6JY89$[U%Q*NW;JRY2<39%T2B,O(YMV]EV&%?2A\GF-H23
M(9P-0?Q/0S09HI4!C60VU8]$D2(3?/#$^+%Z8OZ)8!?IPZS,I#T[NZ:SE7KV
M6L2/&;J:.)-D/TK"A22\590.131+D-Y_A@B=$*'U1PM_@MW^R.F/K#]>^H-5
M$J-D:R6=E> -QG@E*_\KNZ&)G33Q/<WJP/:C)%ELH^_=^*R WJ.\84J<3,D]
M4[1B2NYVBA[C)-Z&ZS-R"2.,MW_[YJF3*+TGBE=$Z7N)7$(G$5I<"U.FOA%Q
M;COI';G2-\S>@YIS!3HHWNAXC:Z,\X!"K4SW0??%6!_&@>+]5/K07'^+/U!+
M P04    " "QB*],EAOXBNL"  #T"@  &    'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;'U686^;,!#]*XCO"]A@&ZHD4L,T;=(F59VV?::)DZ "9L9)NG\_
MVU!*[:-? C;OW;UGCLNM;T(^]V?.5?#2U&V_"<]*=7=1U._/O"G[E>AXJY\<
MA6Q*I9?R%/6=Y.7!DIHZPG%,HZ:LVG"[MGL/<KL6%U57+7^007]IFE+^V_%:
MW#8A"E\W'JO369F-:+ONRA/_R=6O[D'J531%.50-;_M*M('DQTUXC^X*Q S!
M(GY7_-;/[@-CY4F(9[/X=MB$L5'$:[Y7)D2I+U=>\+HVD;2.OV/0<,IIB//[
MU^A?K'EMYJGL>2'J/]5!G3=A%@8'?BPOM7H4MZ]\-$3"8'3_G5]YK>%&B<ZQ
M%W5O?X/]I5>B&:-H*4WY,ERKUEYO8_Q7&DS (P%/!)W[(T(R$I(W0FK-#\JL
MU<^E*K=K*6Z!'-Y65YJB0'>)/LR]V;1G9Y]IM[W>O6X)64=7$V>$[ 8(GD'0
MA(AT\"D#AC+LL$?'[Q,4/H)0.$,">D@L/YGS&<Q/07YJ^>F<GSEG,$"8A;06
MDE#'A0_!:8)A'03407P=N:-C@)"/=/B091T4U$&]\Z0QS&<@GWD^*')\,-\'
M9D[A%0 HS3)8208JR7PE3O'M,O^XXM15XH-0BA=J- >5Y+Z2Q%&2>TE(@F-'
MB0]*<Y3"2E ,?_*QKR5UO_G8R_.)X,R!%1 ,I]E"M:&%%H3\>B,+$< 6<X^P
M[XBZCK O%;EU64 H70\+:N!VA!)?#7/5)'X>]R44 "A9D@)W-N2W-NJVMA'S
MWC)VOP (A=A"6T!P?T-^@Z-N@QLQ[%WAD3AWY0 P3,E2X<%]#E%/#XM=/0,F
MGR>*5\A[50 ,D15=$@0W3N1W3N9V3@1TQ3PA#&?>&?E(1'.6NR44S6:%ALN3
M':OZ8"\NK3)_R[/=:72[QV;6</9W9J2S,\A;F&$>_%'*4]7VP9-0>I*Q\\91
M",6US'BE!9[U"#HM:GY4YI;I>SG,8<-"B6Z<,:-IT-W^!U!+ P04    " "Q
MB*],UF LL^8"   S"P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(U6
M76^;,!3]*XCW%G]@8ZHDTIIFVJ1-JCIM>W83)T$%S,!)NG\_8P@%VTGV$FQS
MSKWG7.,;STZR?FOV0JC@O<C+9A[NE:H>HJA9[T7!FWM9B5*_V<JZX$I/ZUW4
M5+7@&T,J\@@!0*."9V6XF)FUYWHQDP>59Z5XKH/F4!2\_OLH<GF:AS \+[QD
MN[UJ%Z+%K.([\4.HG]5SK6?1$&63%:)L,ED&M=C.PT_P805)2S"(7YDX-:-Q
MT%IYE?*MG7S=S$/0*A*Y6*LV!->/HUB*/&\C:1U_^J#AD+,ECL?GZ)^->6WF
ME3=B*?/?V4;MYR$+@XW8\D.N7N3IB^@-D3#HW7\31Y%K>*M$YUC+O#&_P?K0
M*%GT4;24@K]WSZPTSU,?_TSS$U!/0 ,!7B?@GH _"/@J(>X)\4! ["J!] 3R
M03"2HLZ[*>835WPQJ^4IJ+OOH>+M9P<?B-ZN=;MH=L>\T_5L].IQD:!9=&SC
M])#'#H+&$#R%+#V0> IY\D#(%++R0.@ B;2-P0OR>D&&C\?\Q,_'7CXV_'C,
M9U8M.DAB(*6!0( MJZL;H(F2V*LD=I6D5LD["!DEP2D&@"'L3T2\B8B3B '+
M,G$2P32U]VY)',_V!^ B"":,6K5SL]UA3"'QFZ)>4]0U!2U3U!&#( !VC5V4
M;8HZ<GVF7-0=1F0D:F(J\9I*_OOC9EX^<XMB'W3FR&0$6Z#E#=!$2>I5DKI*
MK'[RF#J%3ZS"IXZ,"]70C=K;]X"K(K8;'W#/&"5V7[L.FFJYT(.AJ\4^7SUF
M<@QC$M,+#1+Z.R1$;B9JNT9.IAA3V_5UT%2+O]M"M]W2U-:"W9-#B'U.5S=A
M4SW^G@O=ILL2>Q=\75=O T,7SC+TMUWHZ;OV7PUT&R:D&#!;TNW.ZX&06.NV
MJ^C"[C #*;"L1:.[17N=_,[K758VP:M4^IIB+A-;*970,<&]CKG7-]AADHNM
M:H>)'M?=-:Z;*%GU5]1HN"<O_@%02P,$%     @ L8BO3/+TV><.!   3!,
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R%F-MNXS80AE]%T+U7FJ&.
M@6T@=E&T0 L$6[2]5FS:%E8274F.MV]?ZA"O,C-,;V*)^8?\AX>/%-=WTW[K
M+EKWWO>Z:KJ-?^G[ZU,0=(>+KHONB[GJQO[G9-JZZ.UK>PZZ:ZN+XQA45P&&
M81+41=GXV_58]M)NU^;65V6C7UJON]5UT?Z[TY6Y;WSPWPN^EN=+/Q0$V_6U
M..L_=/_G]:6U;\&CEF-9ZZ8K3>.U^K3QG^%IKZ(A8%3\5>I[MWCVAE1>C?DV
MO/QZW/CAX$A7^M /513VYTWO=54--5D?_\R5^H\VA\#E\WOM/X_)VV1>BT[O
M3?5W>>PO&S_SO:,^%;>J_VKNO^@YH=CWYNQ_TV^ZLO+!B6WC8*IN_.L=;EUO
MZKD6:Z4NOD^_93/^WN?ZW\/D )P#\!%@V_XL0,T!ZD? V)O!Y&Q,]:>B+[;K
MUMR]=AJM:S%,"GA2MC,/0^'8=^/_;+:=+7W;9ODZ>!OJF26[28(+"3P4@:W\
MT0)*+>R0A>/'!O9<$2=R"TK,08WQ:A&?AW)\),9'8WRTB$]H'TR2=)0THV05
MQR%1[045)C'*7F+12\QS<?1V(L8G+)><=/=NDL0+EUE"$N$2E<DN4M%%REQD
M$7&1\B:2F-@0-)EC9#/11\9[0Q$?&6L#B=4]E\0.%[GH(N<N:&_DK(F4&-US
MB<,$A/)*#[F-F"[UD#4"F!$C@FCEFA[@H [P:>Y8\B!2Y1F09Y/2;)#/=)H+
MEZRB*'=8D?$#BEE!9D4)[5 O@B9V.)%!!IQD>4:=1'Q1 5 K7&1YYQHAF600
M<S-L:XD_F=2S%2Y98>1@(LA0!$Y%!=0*9QZSPB4K<,T5&8S R:C8(N386P$R
M,UP5NQ:A#$?@=%0)]<+9MV)K2-! G+F&2&8D<$A"&%(WGS%P-L,E=HPRQQZ,
M,BJ1HS*B\P4%"M)E)&@<S$:9DPA"KS G(+ EB5)J1I E^0*:'PW)V$5DX(;0
MU;DR+I'C$D*Z*R-G(1UI06+!X  FRL!$#DP(Z=Z,'(;,B\!+MQ>9E\B/?A"Z
MJI YAYQS$-(EC9QB;*IP2:0<3F3.(><<A'131(XPYH1+G$YDRB&G'(1T4T0!
M878)L6$69"GDCBT 9=*A1#JZ,2+'&,9I0H\,@@SR!!T]I&3:*4X[ (I>Q5&&
M .RH+,BL:"'[:$BFGN*G0P#'=J)D3BE^/+1N:4[\\!?1'7 OB!P,5XZO4X%W
M0'FG_I]W@B15KI&6<:<$W '%G>)?L1'],!,TF-#31["X@ZAU>QZO:SKO8&Y-
M/WSN+TH?5T+/.-QAD/(=/.VGBYT?U4SW3+\7[;EL.N_5]+VIQWN,DS&]MA[#
M+[:G+KHX/EXJ?>J'Q]0^M]/]SO32F^M\=Q4\+M"V_P%02P,$%     @ L8BO
M3!N=72VS 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q]4V%O
MVR 0_2N('U!B)VFKR+;4=)HV:96B5ML^$_MLHP+G 8[;?U_ CN=MUKX =]Q[
M]^XXL@'-JVT!''E34MN<MLYU!\9LV8+B]@8[T/ZF1J.X\Z9IF.T,\"J"E&3I
M9G/+%!>:%EGTG4R18>^DT' RQ/9*<?-^!(E#3A-Z=3R+IG7!P8JLXPV\@/O>
MG8RWV,Q2"07:"M3$0)W3A^1PW(7X&/!#P& 79Q(J.2.^!N-KE=--$ 022A<8
MN-\N\ A2!B(OX]?$2>>4 ;@\7]D_Q]I]+6=NX1'E3U&Y-J?WE%10\UZZ9QR^
MP%3/GI*I^&]P >G#@Q*?HT1IXTK*WCI4$XN7HOC;N L=]V&\V5]AZX!T J0S
MX#X"V)@H*O_$'2\R@P,Q8^\['IXX.:2^-V5PQE;$.R_>>N^E2))]QBZ!:(HY
MCC'I,F:.8)Y]3I&NI3BF_\#3=?AV5>$VPK=_*+Q=)]BM$NPBP>Z_):[%W/V5
MA"UZJL T<9HL*;'7<9(7WGE@']+X)K_#QVE_XJ81VI(S.O^RL?\UH@,O97/C
M1ZCU'VPV)-0N'._\V8QC-AH.N^D'L?D;%Q]02P,$%     @ L8BO3,:^;R&U
M 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6Q]4]MNVS ,_15!
M'U#%3M9E@6V@Z5!LP 8$'=8^*S9M"]7%E>2X^_M1LNMZJ]$72:1X#@\I*AN,
M?7(M@"<O2FJ7T];[[L"8*UM0W%V9#C3>U,8J[M&T#7.=!5Y%D)(LW6RNF>)"
MTR*+OI,M,M-[*32<+'&]4MS^.8(T0TX3^NJX%TWK@X,56<<;^ 7^=W>R:+&9
MI1(*M!-&$PMU3F^2PW$7XF/ @X#!+<XD5'(VYBD8WZN<;H(@D%#ZP,!QN\ M
M2!F(4,;SQ$GGE &X/+^RW\7:L98S=W!KY*.H?)O3/245U+R7_MX,WV"JYQ,E
M4_$_X (2PX,2S%$:Z>)*RMYYHR86E*+XR[@+'?=AO-FF$VP=D$Z = ;L8QXV
M)HK*OW+/B\R:@=BQ]QT/3YP<4NQ-&9RQ%?$.Q3OT7HHDV6?L$HBFF.,8DRYC
MY@B&['.*="W%,7T'3]?AVU6%VPC?_J/P>IU@MTJPBP2[#TM<B_GR7Q*VZ*D"
MV\1I<J0TO8Z3O/#. WL3'Y&]A8_3_I/;1FA'SL;CR\;^U\9X0"F;*QRA%C_8
M;$BH?3A^QK,=QVPTO.FF'\3F;US\!5!+ P04    " "QB*],'9I8M[,!  #2
M P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3VV[4,!#]%<L?4&>]
M2ZE62:1N$0()I%41]-F;3!*KO@3;V92_9^RD(4#@Q?:,YYPY,Q[GHW7/O@,(
MY$4KXPO:A= ?&?-5!UKX&]N#P9O&.BT"FJYEOG<@Z@32BO$LNV5:2$/+//G.
MKLSM$)0T<';$#UH+]^,$RHX%W=%7QZ-LNQ =K,Q[T<(7"%_[LT.++2RUU&"\
MM(8X: IZOSN>#C$^!7R3,/K5F<1*+M8^1^-C7= L"@(%58@, K<K/(!2D0AE
M?)\YZ9(R M?G5_;WJ7:LY2(\/%CU).O0%?2.DAH:,:CP:,</,-?SAI*Y^$]P
M!87A40GFJ*SR:275X(/5,PM*T>)EVJ5)^SC=[&]GV#: SP"^ .Y2'C8E2LK?
MB2#*W-F1N*GWO8A/O#MR[$T5G:D5Z0[%>_1>RQW/<G:-1'/,:8KAZY@E@B'[
MDH)OI3CQO^!\&[[?5+A/\/UO"O^1_[!)<$@$A_^6N!7SITJVZJD&UZ9I\J2R
M@TF3O/(N WO/TYO\"I^F_;-PK32>7&S ETW];ZP-@%*R&QRA#C_88BAH0CR^
MQ;.;QFPR@NWG'\26;US^!%!+ P04    " "QB*],2J.?KK,!  #2 P  &0
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M8@.^;.I_8VT E+*[P1'J\(,MAH(FQ.,]GMTT9I,1;#__(+9\X_(74$L#!!0
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M^]]H[<!+26[\"'7^@RV&@,:%XYT_FVG,)L/I?OY!9/G&Y6]02P,$%     @
ML8BO3'N_[=JS 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M?5/;;M0P$/T5RQ]0;RY M4HB=8L02""MBH!G;S))K/H2;&=3_IZQDX8 :5]L
MSWC.F3/C<3$9^^AZ $^>E-2NI+WWPY$Q5_>@N+LQ VB\:8U5W*-I.^8&"[R)
M("59>CB\98H+3:LB^LZV*LSHI=!PML2-2G'[ZP323"5-Z+/C072]#PY6%0/O
MX"OX;\/9HL56ED8HT$X832RT);U+CJ<\Q,> [P(FMSF34,G%F,=@?&I*>@B"
M0$+M P/'[0KW(&4@0AD_%TZZI@S [?F9_4.L'6NY< ?W1OX0C>]+>DM) RT?
MI7\PTT=8ZGE#R5+\9[B"Q/"@!'/41KJXDGITWJB%!:4H_C3O0L=]FF^R?('M
M ](%D*Z VYB'S8FB\O?<\ZJP9B)V[OW PQ,GQQ1[4P=G;$6\0_$.O=<JR9."
M70/1$G.:8])MS!K!D'U-D>ZE.*7_P=-]>+:K,(OP["^%+Q#DNP1Y),A?+7$O
M)OLG"=OT5('MXC0Y4IM1QTG>>->!O4OCF_P)GZ?]"[>=T(Y<C,>7C?UOC?&
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MP69#0NW#\0;/=ARST?"FFWX0F[]Q\1=02P,$%     @ L8BO3!G;28:R 0
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MX^MPMM.838;'?OY!;/G&Y4]02P,$%     @ L8BO3"6X2M'Z 0  RP4  !D
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MMK1OO$I* S:5S8/]/QH[66>#0V7<=F_W:IPOHV%D/XU..L_OX@]02P,$%
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M3?'J<&BL-S\Y6\]O>7:L&I8Q)>N_HOP+4$L#!!0    ( +&(KTSQ_@%BM@$
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M9M%@\ T&W6*6$ ;?8EXA#+G%K"!,TF$BXZ4SA$%#V!&0&P(*$Q"0@#B"I$=
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MFZEIR^:&;SI:U.W72]1]0LW_ 5!+ P04    " "QB*],?'R96N,"  "L"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R55MN.FS 0_17$>Q=L;B%*
M(FT25:W42JM6;9^]B9.@!4QM)]G^?6W#LF /4?8E8.?,F3-CSS"+*^,OXD2I
M]%ZKLA9+_R1E,P\"L3O1BH@'UM!:_7-@O")2+?DQ$ VG9&^,JC+ 89@&%2EJ
M?[4P>T]\M6!G618U?>*>.%<5X?_6M&37I8_\MXT?Q?$D]4:P6C3D2']2^:MY
MXFH5]"S[HJ*U*%CM<7I8^H]HOL58&QC$[X)>Q>#=TZ$\,_:B%U_W2S_4BFA)
M=U)3$/6XT TM2\VD=/SM2/W>IS8<OK^Q?S;!JV">B: ;5OXI]O*T]&>^MZ<'
M<B[E#W;]0KN $M_KHO]&+[14<*U$^=BQ4IA?;W<6DE4=BY)2D=?V6=3F>>WX
MW\Q@ ]P9X-Y ^;YE$'4&T;M!?-,@[@QBRR!H0S&YV1))5@O.KAYOC[<A^A:A
M>:RRO].;)MGF/Y4>H78O*QREB^"BB3K,NL7@ 0;UB$"Q]RXPY&*-'7,\=K!Q
M$8FE80N01+"("(PS,O;1R#Z#"6*0(#8$\8A@9B6JQ60&4[<8E$=6)! H36$I
M"2@E :3DEI06DPR\?,J1I7<+@&9Q#DM)02FI(R4*+26IXP3A++&4 * (39Q/
M!BK)'"6Y=<W6F>-D9EVS3>8<SN"01RIFH(J9>S1Q"!/D($%^_SU%(5S1X1TW
MM0.-$IZ'=M%!J"R?DC/18!"0DHG^@< &\HCP!Y("ES^*[DE*!"0%VSFY#1J+
M@5L) GI)/$4!MP"4?" E<.DBMW:!E+B%&2$[(S<Q8REP[2*W>'$\T=X17'AH
M]H&$P*6'\GL2DCO!8J=L;F+&7TRXAC%0PW$\00'7'4;W)P3#=8?Q'0GI0!,M
ML_MXNQB$[;88#$:6BO*C&0>%MV/G6NHO_V"W'SD?S<1I[:_1?-,.CN\T[1S[
MG?!C40OOF4DU4)FQY\"8I$IC^*".ZZ1&YWY1TH/4KYEZY^W\V"XD:[K9..@'
M]-5_4$L#!!0    ( +&(KTRMA*_I]@$  &P%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;'U4[6Z;,!1]%<0#U&"^L@B05JIJDS8IZK3NMP.7@&HP
MLYW0O?UL0Q %;W]B^W+.\3GVC=.1\3?1 $CGO:.]R-Q&RN&(D"@;Z(AX8 /T
MZDO->$>D6O(+$@,'4AE21Q'VO!AUI.W=/#6U$\]3=I6T[>'$'7'M.L+_/ )E
M8^;Z[KWPTEX:J0LH3P=R@1\@?PXGKE9H4:G:#GK1LM[A4&?N9_]8Q!IO *\M
MC&(U=W22,V-O>O&UREQ/&P(*I=0*1 TW*(!2+:1L_)XUW65+35S/[^K/)KO*
M<B8""D9_M95L,O?@.A74Y$KE"QN_P)PG<ITY_#>X 55P[43M43(JS*]37H5D
MW:RBK'3D?1K;WHSCK'^GV0EX)N"%X(?_)00S(=@0T.3,1'TBDN0I9Z/#I\L:
MB.X)_QBHPRQUT9R=^:;2"E6]Y3B,4G330C/F<<+@->8CHK @@@6"E('%!;:Z
MP(8?K/@^#NT"@54@, +AAQCQ)L:$20RF-YC(#S=!]A@<^78CH=5(:#&2;(Q,
MF&BU28 _;8SL,8E_L!N)K$8BBY'#QDBTVR3$VZO=8P+O'U<36XW$.R/!]F;B
MW:G[.-YT86$#)=LN0ZN^U^_0=\(O;2^<,Y/J+V0:O69,@A+T'E2H1CU]RX)"
M+?4T47,^/0#30K)A?MO0\L#F?P%02P,$%     @ L8BO3!'W!L(H @  *P<
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M.7.'T8LRS4RWQ7CPCAW%^^E20?/-5OT!4$L#!!0    ( +&(KTQYG>['4 (
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M^B/G"G2,P8/>JDJ_ ^."PE&9::KGHF^&_4+Q=FCT:'QMBG]02P,$%     @
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MJV*V*?""FL/<6Z,[._?.5*N,]1*3V6P97"Q1@]G4&-+!X!81&/8V!(%";,C
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M;W)K<VAE971S+W-H965T-# N>&ULC519;MLP%+R*P .8UI(X-20!L8NB!5K
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M4Y [*B=S/PRJN5/_R6Q[.7K=4D+7P75PI#$/(P9F&+)$[&P$)=&$"60$4QB
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M#Y(C7%;QY\B>B1U) :XR@*@,-8L?!;E.>%QD !$9:A:E!LU7*8+(<4X#KC.
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M,;7-DOY]?2&$W:7[@NWQ.6?.#+:3B?$WT0)(YYV27J1N*^6P1TB4+5 L[M@
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MSE)OMVK/[6"P@63#-/.">?"6?P%02P,$%     @ L8BO3($]6V 0 @  MP4
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MD\!N!$B;K:I6:J5HJ[;/#@P7K8VI;<+V[VL;0BEQ7[!G?.:<&>.9=!3R334
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M4&F[3<Q>3ETY&5KT\\#!R]3+_P!02P,$%     @ L8BO3)YJ=;[? 0  G@0
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M    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;'U4[8Z;,!!\%8L'./,1((T
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M?!B"PT&R=ASP:/K*9/\ 4$L#!!0    ( +&(KTQ&R &*2U,  /=0 0 4
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M9DN9:B.,B.B2%A6=266W"'SFF*(IIH9VH1+X2 55_)/^(U?NW$"-#]4+0@Z
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M ?9B@09/LH[D=8WF.N=88>0TK4)GI"/(]YYBI<LK43>^59$/-LU*@,/Q;>Y
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MVIY\^QSU7WQ;X/ W39CX;R04\R /Z.$B,5WP*^:AAM%6$7.&#5X1#[JM\)(
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M9YPUOX)JS/)FMG4=G7N>KL-=SC]=$_92*(9.$F%CLZF+Z];SP OVS.1T+R/
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M/%XE+I->0844;/.^??+Z#@QU7+&)NV^/PF5V?;.LLB)5FMDXL&LC@^');:3
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MQQ@E*@LQ54S-=1]&1V(TWM-":USTJVF[AQUN(:7,1":-DI>VV-0.%8*Z+%7
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M=AX[8;^_"OTCZI=N!_4%]E/3O05K!3N)\FP\,Y[D1?9H8L@)5HZ((*^0B)N
ME*Z\;!0/FP'2W%&#&%0O%&%BN,]11>7!23 !5KU<FK*Y$HHHG8X*[;+*8AQ;
M/4I_!YKY7;Z /92!,4*-FI42^D]BZ.<H<MLH)1YMW]E]>P+HBT4U;VWPN5Y4
M:IX1Y*XP XIR"2E@QVU)8NJ\GP6%X[-XYP0RLV1U3?>;R<3;V)!##@K!OFC;
MVJ+CA?KL(#TY/F4.!S\>'H8<JPN9UN'0'9+E%38BIC,-$6BF/5R H7=62O^0
MD7WZ':$C.4A/3T^UXP),8;12I\,L/[.D&\)3?[%C%,9![DW&>#M$GH@T=MR;
M3.%9O[UZPKCI]G,_/CX"E;?LHO<@G8QGGD O[3>$=BL)]2 M<B:7RN1PYA9'
M?4II86^7ACJQ:U_9>#?4(?$D4BQ;7G(;YT:CVX?(UVH%"[=3=Z3/>]7MHFJ[
M@VO+^!V"ZVDBITW\8,]W'6\'V'=M(\]JGB"2#)!F=3$OD]<DB,IO:&@S^GLP
M@ZSBB%OIYLRYI'@,-Q*C?LW/"*<$(5HC;=WRYS8U2[*^O(HCY%89H2E0%;YU
M[?1STB9SZCV>FR2M\M$[I6OC[I,=W'PU5!@S,5GO'A.VAF*2/#6?<T!<8(N<
M6@.8V'!1F31KI[L:37I-J0U4D0.+@&*5L#W'/4F9#T90P(YOZ'QJ<4X2QQ 2
M4V&*10& 1+)%.V;UGF4OBU];Z;="AJ:F6K;JPG@H&+'M>@"7NM^#^&/J4>P5
M3$424^"T#Z-($,<$YB5W-RY]H)'7C1QSG',=,D#(2_^(1$%FNP&^G6,5Y?M<
MXFBDA9*90/N3H/G#])A4&KYR:1Q R%=K12:(.]0?A=J8."4[?9J.@<9GVJ7T
M';"/GEFY%O22YD3IC/(4WQLD?3E?G<1X:7 80W;J\&,&<0MKZVFQS6UUW("S
M0)[WBI-[H6D?1%TYY[#)2R=LS(1S]M]:O1 ,7!364U:VA-@JWG&W<[+)=NK(
MBB2URPWYND1G"9+L>Y!=2)6<I >G)Z A'<"EU=N*W"B?:/*SC;TT7K&O>X8K
M7EV1%/$32Q$7)$6HG'6<?-A6I?I9<HHF@H.#Y ?NHL7Z\0)K.2'*.?I?'IX>
MG2:S&3X_(\5O=C+&9B-&U,JW+C/LF$1:]Q2DN^/$*>-H:H))S)*9@MPU&0B9
M).XO]C/,&KUU_333T8D$N/D&5U.Y #'[_3*;_[)_.0=^BH>%]GL?LUTH&[-:
MY$O?PNN'$?80#%.(6/QWF.$A<^,MD,1:;L3<R?3Q)X9-H8Q7MVL 1<#!Z=7(
M1A1!82HA%BEVR/Q(<[<RDRS-P&3+IK+A:.Q,7_-U=P>XQI1*YOX4'&8+W7L!
M#BP3.%^K4F3W$\5MS?AUL18ISYQV2PN'.\>P&["=^!2"OG$2LQ^DD#4!)XXT
M0BIN MXCU_;@B8,0@8@>L%"E 4[@+?%P=(K(.!J-A1@/1S/^X% ^^% TO^S?
MX-!&::#DJNGH>/I-,AF='G^#+TQ'D^-OOC,$#SSI%@N$CN%;,^-]A8(<96^?
M3$<'WR0GX]$)O7TR&TV"MT\FH_$WF+)\D[/%C^8]3+ZAOV94E:Z2QP+;.*K*
M]HWSTU6PM:8$J_%:B"#5%*NU.*DYF-QTONW@_W*3W7@UM+\'NL5 I(3C)R<'
MHY>CZ4@5-6FR93UL6L&'-MMIQ&8KN4KQ&^Z7G#A-)-R4]*P,B9;3?L.+PF<T
M?F<L22O<!1-:8,%T#-L*^ZKRNV"8!=C.)*3UDF,%W:O'DY/]R7A_-MZ?'AJ+
M$_XF7M>ZARB]7AP(GU?\\N/H$EZOJ3P)B.#8V8[?<BJLJ)FL0RZ:Y^;Y&0'5
MQ!1&/H$Y9.Y6^IUGR[G8BRG*<4W]LYE?FE?07L&1!-? 49@/+N26XDQ0-T<
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MT%P9>0[3_&F<A3/.@O0BJ[<. &$\"CR*!< T45YBI##32]MX'$7<_<ZO=Q(
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M?" _P+AP0.EV^4K7W&3J>3P"!6L=MW$&]W;J)+S$KP^)4DJWH+;W 1.XU/=
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M*+(.KRAK=TQK739_)?DP9GF8S[J_Y*=?4$L! A0#%     @ L8BO3!\CSP/
M    $P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%
M  @ L8BO3&;S"V""    L0   !               ( !Z0   &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "QB*],II!,*_     K @  $0
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M=#(N>&UL4$L! A0#%     @ L8BO3(%?UI+V 0  BP4  !@
M ( !.0\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +&(
MKTR6&_B*ZP(  /0*   8              "  641  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "QB*],UF LL^8"   S"P  &
M        @ &&%   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ L8BO3/+TV><.!   3!,  !@              ( !HA<  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +&(KTP;G5TMLP$  -(#   8
M              "  >8;  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "QB*],QKYO(;4!  #2 P  &               @ '/'0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ L8BO3!V:6+>S 0
MT@,  !@              ( !NA\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( +&(KTQ*HY^NLP$  -(#   9              "  :,A
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ L8BO3-([
M>;*T 0  T@,  !D              ( !C2,  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "QB*],")IZ\+0!  #2 P  &0
M    @ %X)0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M +&(KTR8C1Q:LP$  -(#   9              "  6,G  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ L8BO3 1L%MJT 0  T@,  !D
M             ( !32D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "QB*],J3JDY+0!  #2 P  &0              @ $X*P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +&(KTQ[O^W:LP$
M -(#   9              "  2,M  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ L8BO3 7\G$RT 0  T@,  !D              ( !
M#2\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "QB*],
M\+T!I+4!  #2 P  &0              @ 'X,   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( +&(KTP9VTF&L@$  -(#   9
M      "  >0R  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ L8BO3"6X2M'Z 0  RP4  !D              ( !S30  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "QB*],Z*G8>\0!   W!
M&0              @ '^-@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( +&(KTQ+N!X\M@$  -(#   9              "  ?DX  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ L8BO3&):1;K3
M 0  G 0  !D              ( !YCH  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "QB*],A_[(.,0!   W!   &0
M@ 'P/   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +&(
MKTS;EQ7PQP$  #<$   9              "  >L^  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ L8BO3,%3.$K$ 0  -P0  !D
M         ( !Z4   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "QB*],\?X!8K8!  #2 P  &0              @ 'D0@  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +&(KTP12DY", (  !('
M   9              "  =%$  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ L8BO3*.0-60F @  G@8  !D              ( !.$<
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "QB*],F]-P
MVM,"  #)"@  &0              @ &520  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( +&(KTQ' IL*A (  $X)   9
M  "  9],  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
ML8BO3'Q\F5KC @  K L  !D              ( !6D\  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "QB*],K82OZ?8!  !L!0  &0
M            @ %T4@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( +&(KTP1]P;"* (  "L'   9              "  :%4  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ L8BO3#"Q;T<M @
MY08  !D              ( ! %<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "QB*],>9WNQU "   I"   &0              @ %D
M60  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +&(KTS/
MZQ[M3@(  # '   9              "  >M;  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ L8BO3'H0!CDJ @  >08  !D
M     ( !<%X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M" "QB*],S/#UVZX"  #."@  &0              @ '18   >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +&(KTRQC$+KQ@$  %<$   9
M              "  ;9C  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ L8BO3-K,9LLX P  - T  !D              ( !LV4  'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "QB*],)KH'!>X!
M  #G!   &0              @ $B:0  >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+ 0(4 Q0    ( +&(KTSX4*&*&0(  (0%   9              "
M 4=K  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ L8BO
M3($]6V 0 @  MP4  !D              ( !EVT  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " "QB*],(Y6. Q8"  !4!@  &0
M        @ '>;P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( +&(KTS:"%'AXP$   $%   9              "  2MR  !X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ L8BO3)YJ=;[? 0  G@0
M !D              ( !170  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " "QB*],>[>C@!8"   $!@  &0              @ %;=@
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +&(KTQ<<O?L
M!P(  ' %   9              "  :AX  !X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ L8BO3#V;'&'L 0  5 4  !D
M ( !YGH  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "Q
MB*],.BS!)S$"  !F!P  &0              @ $)?0  >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +&(KTS@DV&8(0(  '$&   9
M          "  7%_  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#
M%     @ L8BO3$;( 8I+4P  ]U ! !0              ( !R8$  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ L8BO3!86J!9  @  )0L   T
M             ( !1M4  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "QB*],
M0)/<] X$   K(@  #P              @ &QUP  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ L8BO3 KH%A;H 0  P1\  !H              ( ![-L
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ L8BO3"=%
MD<;- 0  FA\  !,              ( !#-X  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     #T /0"=$   "N

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>70</ContextCount>
  <ElementCount>200</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Purdue Collaboration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/PurdueCollaboration</Role>
      <ShortName>Purdue Collaboration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Debt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/EquityBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/LossPerCommonShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Description of Business and Basis of Presentation  - Schedule of Error Corrections (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationScheduleOfErrorCorrectionsDetails</Role>
      <ShortName>Description of Business and Basis of Presentation  - Schedule of Error Corrections (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Purdue Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/PurdueCollaborationDetails</Role>
      <ShortName>Purdue Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/PurdueCollaboration</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails</Role>
      <ShortName>Debt - Principal Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Current Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Equity-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2422401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xcur-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Related-Party Transactions - Schedule of Revenue from Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails</Role>
      <ShortName>Related-Party Transactions - Schedule of Revenue from Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>xcur-20180331.xml</File>
    <File>xcur-20180331.xsd</File>
    <File>xcur-20180331_cal.xml</File>
    <File>xcur-20180331_def.xml</File>
    <File>xcur-20180331_lab.xml</File>
    <File>xcur-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001698530-18-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001698530-18-000021-xbrl.zip
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M(OH7SXD/JU1+VICLAU']%@N_RU]!MW\=#CJ;R&9;R#8Q 6X5DG+P-^!N/ ,
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M:;,, +O5VBIB.9$ )15C*9CS,U+6.KGIY,-PU/OOO'O@2$#@D< 0PXQ/5(8
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MTA+@L0%.O&09TX#7E-NV=GPD+Z.J9/^4Y^KX#(":$MY@I8X(6(\+,",X&!M
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M]F?T,-G<FRM6FAWL052<CK![01&UEX+]-?]4_+2['<+)U2/C2CA+E2$9GA6
M.Q(-[NU-1&,MMEA;OBIAUJQE>0MK>POCZ![\*S57<!'C)/C@O)2,&1$3Y=X&
M:R7VL5C#F)&<[<G6SL;\IV/Q?&,O)"!J29*CWDOOL?^_(!S@(\T(\6M/.7D
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M3@!;IYO3T_<@LPDFDF$I2$4BKBXCGE6:24N%8AZP06,V"0AYOCJO^\\F86T
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M.2H<U8#7 QH#T:"XRIG>F]X_[JY'0&JU ON@:KB<1P=?Q0%*.*>-#"H9;V*
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MTSSF<0@^&5A$O+=RWSQZ>-?)!VU@>9GVZLLT'.6=]GC2*#O,##.*!;"J49@
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MMX:OY[%(4HQ&,\?8NYU35#)SUI+^]V5-Q2COU/' 7(H=]$&%1N9%,<%,;Q;
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M0/ ;!']#WBX-4"K+MWLI%_GLZ<[XYJ\=RYCT.BUC]ZE;Z"('1'7X$I8WQ3"
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M9OP38/X_8&_(Z%F#X*;DQR.;!X2(0E?>J2=W>F<6(#]A$]58+9X,>OD*I^*
MH#([)$?EAHNZK>#[J2 *7N:-O[C!*(.<+HM,PZ5^K^F"7-]+6\W"[FVG@4D1
M&S_-&H5G<*]7.YG3*1QA"3^37!GU-P?'C)#E& BWH6!CB;ZX@P]D=J7X]7[&
M>I3[?GH"=\1YB4GL168V2,>@L^4VIH\='H?$$,XTZO)D!I=/>#@UD2&=! %?
MA].%FZ]PW>',LQ\ B];XZ"EI#[/9[;CST+N][=Q/AYWQ9 H_]T8/TTY_,GKH
MW_:O->TA5S:FH"TL'07JPS4"927TU:[6O(09BI-B2L<_6OO]P<=[EWW]-1V^
M)K43-:XVUO,GA<:Z*Y7^TI4I&BFO#BECA\,!O!P?"W==7WI8Y7VR'$K3 @LR
M5A0O2??5'P]ZUE*U@]C8F!JV;FMZ(-%)#YD]%U)=L:#6#$TSM*(8VGAZM*JB
M&5KABEPS]35R^B]]'*FVPJ*W(\J2WMGYH[X-/*:]HLBN*014/5JIG.#7='&%
M=*$]!(?1YC$*/"?$JB:,)BV<[_AS*1*G>;VD^N6/B6\**=:(ZNHKNS2%73&%
M:2LJ?AY3:R(J;:>*=W\1OIH!T]IBZOE>8<[8IM!/]4BEOH)(DT5CR$+;4,?(
M&RJ^$@TG'$]43O%RC*BK:]C;U_UZM1%6(]EW?13:[74TB6HKKFBTVI?F#O=?
MCFPMM\7VQ53:5G>J!U=H2[ ^EF M:&I47#;;-="4-B./2?[@_,M6KZYUP"S1
M1U[KJD7 ^-.TN,*'#T,O0<53P5<!;#UZX&*-J+R^<O8**7DRF&I*/BLE:^/T
MH'%ZVIRV<H,H%0#3.8<Z53!%O#<>%@6 IA@"U6,7E1/ZFBLTFROTCZ]QO1:N
M4,#(ML,]:-(=:WX5O>J_FO#$MV1< '_?/+;Q_</XL=/M3X</M\/[A^%T=C=X
M',TF8_AL/.G=5J)U3<'(7. \-GD9-W0;1OHZWL2?>O7RH=6>'!I\0NU#+;96
M"0. 4]UL-W><>D4]%6UC85JRK58KZ2H;FHN%L:*">I'EIOZ2=(N6T\ED&_Q9
M%)A/^'O+^.FGNQ:U^,8)&"PPUF:@!H6X9O",/;0XMJO$.B06M WC%QI]XG@+
M; ^&7Z41$]D-FR[WL?,CCW<2O]]V F9A=RLX[)PM37=!K?TR&Y+]QV GZ3$2
MV>]D>OH] Y:$LAOVUE+<7[&0KH;V<V ?J4.H.2?4;9?VPJ/5R@S@1FW9U5:N
M,'=<EV9YA*^,>5E Y#=$TSIDAS!\6 SH^!$'"HBND:UMH(FI)O;*\;"/KNAE
MENJ33EL3V''<%N 2'_:,WQBU#FU?#2E"M)5OC4?DF,\!8VHB G=6:]=9;$2#
M-@ 1HJ$9!-@N$[\#NTBZ?*I5]ZZ8W1<NQ[=WEF,/Q5'J7_-NPN(6QUYP<<LX
M,510H)9$O7APXWR3 <+:C; =J>PIC3WR<+@!+K $>@9*]X,_Q%/J"2X:0."B
M- S'_YV:'<>(O)?85#/.?;>4W*KL-AVI;H'405"^ 0='W;CFG#I:2S+<=SC1
M#E!2UJ[][,/@\4$,7D0!S<TZ#I.Y+QI#XZ()U2Y8AC7M)T[%&W*GV]K4G(E1
M'6*],E$Y'_XM!Y4)9QP<OV@%U!+2D2A!<[+28Z:$VX3F8:&$BZ@ *1Y<0K.V
M]L)7X$D\$O(0G)O4Z)56^Q9/S@)(JU%V6[@%  2J])@ )RD Q'-I'!0B.7R,
M,BV!*@V2*!,)>_E2C@*Q$/&IS-WO,-F*W/WVU'@Z3Z9CDN!S 4O:1S=O: 5B
M]L+'B:Z.:/!M2@6,!@PKG-\G(>3 8=FLUCXP2F3?S)"3*>=+6;>0:\VUUQS,
M^(0JVW43[O'9\<0FS2CTU0?":T>?R"Z8G?:PVYOT.NK?JK7I'$XOVZER4NL^
MF[4Z?$U"7I7S8<?;'5^@(V(E^Q\^RD;BWV@8U<\^#:-Z0'/D6 %RV5ZB[W#E
M:HIY#\54HX=H44F8Y\/4ZO6T+2RS4R-K Y%5-[HM,*KZ7QD_7=ZE>DG&4(FB
MI=JT@:Q<P+ZXXIDJX(&N+ZVF1-5<1W,=S75TR>R'D.8^'41.YUB0?WQM.MOA
MLO>H_!\M1:AMQ4%QO<@.0*@IE%D](JR<V-=455C7VFNAJKJ[ RI'@UKUUJIW
M^OF!5KVUP:^YCN8Z9^4ZA54*5@(/+EXL])&K>-<&:YIOI_)F V8QYX6A1>+Q
MR*4*DC@W&E-,1:D%^1 68C)\RP#(H)L!TZDM_V:!.(?U**]+'[/W/!_S? VV
M6KO^AC%C'H6T)"9;8VZ?*%]1-1BWOAELC4:GE^6 7MSY_]K+$UUQJV,J(<.)
M]?* (25^K'Q*_!!YZ#N2/C$PN"<)D2I3\I>#3XF_J@Q)4443)T(BL)/*DK?3
M(O$%:#69;^1(GCI9_H1:NVR)W@OS(O:K. @^L36!_HC"O.%@=M?KW<\>)[>C
M8?>N-WEXZ X&L\$ ?AE/QKU*%.9=8*:\J-1S0MB%E8]0OU6I1W=BI"ZE:4QQ
M7Y7)9*O*Q/;75 JRE+4(G-*'T>D*E!5Y1*-/(1 GL#4.C]DXA97@:7Q2E6R]
MS@^SI[BNK=?]X;,QZHQ:)?&\_,UG[I3J".[@.X&))4+$=>XB#G<#/+U,/AEQ
MA!4"<D50PKHF%@:^2G4'01$N?9NB^J;K$MF+/:*$03;FLE#P.<EJD7U1RCA>
M$D!<B)6 K?T@I-61B7):D!AOND+%7*]==5%XFT]W>"?&<P1,T;-8"RL5749?
MW;?@6%13K.'O5&,4Q45O:I5DY6$^L:[,RTY,E6-(N;A+3M[[29[[<^,*<T1M
MHT28++>(I3&''P7<7Y?,$YJ3I#'#GV,)*!?X[;N((\!95@X'%'KV?> B@%Y*
M[+>H2,J3,E\4K$DTYJ+2"MB18TN9+<MKTUL2U5>R0(MT/U)8OEM++.PC5 :J
M X4A]VJ@)M^P@>2"%=Q,?* @021!JDF)(!?[0[T$V8I40;@%.D6*QK(@ W4#
MZY/%89*JD 5NE(=L?:#PXJ0JABV$FBATV8,*QCY<VE\R,)@<8W-FK;RRLM3!
M*C[%%,R1W];IL[Z*0;J4I#C:ZAY0.H\PC^'8)YG N7-?JJ%"FG__:-,\]XTB
M<1*$29F2XB5Y:!4HKXW9UIO-A(>Q[U1K3,SMD_,YRW$\FLGC>%@^"ZS& _JV
MF*#3?>L1W[#9 NZ""VMJC69$IA4 ^620L3Z#JJ54B1S7DG6C(1H@"T8%R&@Y
M.0*@5%BZ3"I\U^9&5+4#DP->^\F19XDWB@T:0/6 /5J.Z1H\FH.U1/H!K@K?
MWSI\S"\E+\0*)FG? 0>4CX>PE+M12DZ*?2,_%2>BB4;QD11739\*+&\0&W."
MZ]Q$X>%[&>3(  ]N0]7CFG/L,T$EM'!\I=D*^9/93M9*)X4)-O-[9#\3S("]
MJ].JVSCMU2TIKN D\0%,X\4,'!92*> ";L G5++<R'[S)4O 1S] -A#?*4H^
M6(HNBQ)%Q=-8L(PZH^$!,:BU6L8ZFKL.7R(, +I.*.<D>G#9>/$.8O%*W-):
M-'&@_?@'Z/%4WY:69XV29STMS_+R3*I\PD "JGM.:G+3O+=<X?9USR9B5HAZ
M=R('D/O&,L3.,MQ]'/O5 0:_)8NV&$;"VH&&E\"<UD3_P)_F#/F+#6P-N%^(
MK!)L39G5%3]MF=CBQ@.Y&0J[7FTG)1$-YE!3#%^8(?ZKAW\,_6=&'Y,D]D7;
MC!?3<>G]8.CZ44#F![%M:O0A=I*^)4 L98HK0&4WJDZNOK6]->#\'(UGD,4@
M#Q5\:0MT'+$O>25Y!$$#!3^ ?9"$2:Y+2 QX9(5NU+7+MDVL]&UE#9(5 )>$
MW281=6':$((#IK>U:\4C;E0V&CH*J&WCQX7R# <.[,,QZ0WH%UDQV4'GT'9,
MX:]BTL'""5RKN8-E[KLI4DLS+<TR7+.OI9G(OXUY0<SD1*P#B!#HK5S!]6W7
M*PUJQR-WM26>LB8&L+*\DTA)*N2_H2N$7]9%I$08LK!=\FY+#][BS#O!E#!I
M5/F5?9AL-<N6&7!*T+^E_2;=8< G=S\KY"I?^I&+O=/4J^)N(?G-1"&8)O^F
MAGI"7HKMR]9%+Z8;Q0YJ6>&]\D%0N,X?*+KD?L076CC0@7EDL,@[\$QJ?23Y
M^NX]MXU_[3Z+PX_8O[-HJ3^JI.^T?:1$&7PIS)B.0@$Q.! 412[@%'&?)J!=
M;I*#4LZJ0*><\@,FWNZ450]HA$+)MZP(D&"6OK?6EAG'* "3$G78!,K!2_7V
M(@3*,89W0<8[;)Q<!<(_C^NBP:<B"/!N@<"\;=QOV:EY\,E^9CP#" 4T+0BU
M(,QPX8$6A+3^S'5]"X-PNXD*W3Q5L/5^S*K3] .%8)#O><_N/I-42" 4BL$>
MF6M* ,2&W9OKM8W_]%^1JP(O1 \41_\413-C0R#O\\OZ#.D=YHHZ%KK"GVD>
M/,>6+4LFWS$RETRAQ/!QWI)>!(TP#)QY))B=!(B$7OQRLCV3YI86.7KS!D\2
MH)9N5+JQE#FW!Z]47TH,F8F[D:[7O1@JO,V[X48.2?(5BW 4AOE=S(;B3'0]
M%:M0IU<0B"[C?)]X3FDYJ#FM&%,!/&71"<=U@E$"<NY&P&O?#B4XMQ%(@$U$
MUA2$#V")</?FM$7J7RF3QC(8#SJ/%*?*AM][*[$^>A"6_$"[.RULKT[8#K6P
ME0D\,KD@FUL@G#EIMLV!Q+@0#7M)O<Q\RV\[][*/-RCWY M:$_ N.A":)&O?
M$5$F_+1MJ$06AZ>3'I/'0#K)I51 ,G:3<@?EANDQ/^)NG ,K&ZICJN5*FI72
ME\IS;6?),,Y:5*GSI *';W\18TMDPV*C9&^)'U'2ILDY"Y-NQ(E_5Z2(<'7#
MXGL  ;&.G5K'IB!7$I \L!';9S*OBE9*-B$BLR@]02IY@EE'/"/.Y3BDU*]+
MF7N:"O52M%8&^LB'BD99!A1Q0A=Z5V$/RLNI%HVW*'!H\X805$C0R@9W]RA#
M/,9*>P>FT96GW1VQ8B)R=<RLIS7MSB9)G/A 'KZ;>$12\-0"J-$EB7#RWGU<
M$EM$[\K_D?<K52]T0V"6KG#8X^.\);X?A@!UUQ$A5D>Y[K&Y/_DA@EC.QB_^
MN%E;K^RM/7SU)X S=2S'%'<O9!2PCS"0+$>-E,@JOR0)<Q+Y7;$;16^[?#D[
M-[GE 12*6ZP5QL$A&5'99Y4E$2Z5/YYD=QU*=1/U UL*9,Y 4N<CV97^ )N(
MOQ$H4QPG_@!U46EG1'*20BX4)M<&I1+;,JK?$MLJ#H"DHF JVI0]KG /IM,?
MD-B!BJ3&GW7P'0BL[(XG'?-@AG>E16:"1SLX&L"&+,XM/FFN$7G ] @3UR9.
M&S%Y% B%W'\.\(#$NJ-@[4LJ47>/7Y*7G\T543XZ 1NQ(I.)CF+)W8X[M5$/
M)#3G9K !)F;_'O$POU */J(AM.#Y.[(4&Y> ^D8=8IE\\F<'9%F(%IL4Z3M2
M,\LXY$PH1<DD';A^0I_T< HBZ3B@8 ,6N#Z-A3)6N6UO!18RN"K\XB)+B3 =
M7A2GK:N5A.:X,R(A^.X1X894,OR>, +I0X>]]0G&2W?]*P4]8C>\VH/PZK>4
M^/=QWC3L, &/4"Z."3:TC3PN)$P5WYQ*_TVI3FFPRR"*Y,FP+Q[AE5)^'X8:
M_& C&!1LB[?BA95T01:I@!+'UO&NV MEX@.[-D1><[R(JI<2K@PI3P(&;"27
MW/QOX>N(@Q*BZ@ 0UY3H1NX>)7Y0# 2ANIMTV"0VU.(KP9$6/N<./-K>'\H+
M43AF1&=17JH6,?-\!'!'YKI)BF@LI_?I##OB0.2V5&*J;4@"9IX=DRXZ->60
MJ6TAL*UFW+Q)H/+*5?4:(=%.ZA<T*Y84HB().0E5>;?<06M04;K"892CF+RY
M@S PY"4PF9X7I*$*]0);)3FFXFEPQ=;R)EJK^Q%W(S#&%#$R:H,_EV5:B;I%
M3,@,,*H5.]2E(*6B&+4!+0 +<L#X&["*P;0ZCT'PN+.X0C)GH"] [!OA6 W4
MQM(QUKS<2]RP+E((J7*T3"O6KE/*N(UCDI0A(2B/V: :>RATG)"MLJD$\1XD
M?1TLC)&^#OPNY8>AUR9F-HI&:7M"CBG_QN=#+"G9%TZ(,V0UF21=L4WAL9BS
M#)>-/THT[$\^C<V3L9?X\\^B-"9W2EP!F7RZ*!</+]^9"!E5W$N&"DE#55V=
M)O1X5-6!4MP:4O",D"];%YV!9<;@]3UWLT=$IT9UX=-?HP!G)=UEX/@)] OC
MGS[P[_[G1DW3R?,I^N2X&M^WG3\[JKL/E&FG:[J?K"6S(Y?]LIA95A Q^Z?$
M+_4-U:93BKM[W=GDH?/8O;N]?1CVX9?[[J3?&4\[MX_#N_YM-::N7N#B<\W&
M):R3$7S(U8530\UC2_D'RZ*#JYUGU.UTJC;!:'SA(3Z]6H\@JM7A:](>MW+]
MN2HVXJ*24RP2/0U7WM4RJ7I#6312-API,V,SW\!+/7^EP.YU2L5TV;/IQHKF
M>S#[8"/D(@%;B0[(PZ[N.%HZ +3PN&82ZPV+:][?=!*KB<%P3JFV-C<!V.LW
MRJE8IGRK+8WU>].B:*PII%0]JJFO4*HM78R+LX";0A?:HCJ,-K^(3-XMUWTI
MZMX!7T'SU,%![VQ39QJO+M:(;.LK_*Z/1/N=XIPBUTZBVJ+;1:9'_E1@\+SL
M 3!%C9NOU1"8"P&FQ#&3K=ZHN&$P5<$);68W;-I451!+,YL/,IMQ<:.FJX(3
M%Y\^]7;*Y/%9D'MR)[W0L1TWPC*!)P9:"#WY\%U4YSP&_@J39:.0,CM_63S(
M4H"O+'A:FL%).9:WT[O9Y*YW=_LX[@YO1W>SQ^EH_#@=S$8/O6%O/+K"',NX
ME8$?A513X] T)G4-F [/&?73G#,0 6(6").7DY2@ O585.HA"M<\!GJDSZD8
MGQJ+P\<<;ZL%RU@F5K)2^4CJ1:(49&F^,)FQ#FAQH_#"P'3G-VJ%,^^C%\$3
M<5F[J!:A,56I9G4V%=O$YWM[ (/.%+UPINBXF$S1SF63)?NU3O4\[^YK8N<W
M7SEN&'SB[0XO&Z.[0&)KPUQLE4,M#9\C2>^C$8)B8'F\A5<52JY> GIA5K)&
MU@8BJ\Y*+S*'8BU:46 CM0@DNDDCE(5M'?K6'X4YOJH#ULHQA?,!KEZ>UT&K
MWQ^VQL4E3>Z%Y56X936):A(M/ >E-9KT6Y/>2)-H$21:$QOY'(K)?U/_GK!\
MS41SMY(]5E7@4X-NO]7O=8J"25/XC:8-31L_Q$'/7F%P:0I]%)O)4%!.PNZ,
M!WR6>9P>OO-Y^.B+QVZQ<=U7T<9NEFJ)-XM'O/RR2+ZXO0J_W7QU3>_DQE.S
M?K]S-QIV'SJSX?"^TY],@0//NKWAJ#>[NYN-KS4IXN'/R DWLO>@E0*V2IZE
MWJFNR7FFE3@'I)"=#+&#_5JV"*?A!@L?;O)U1T/ACZ0:9#( 1CMS#PXF%EQ?
M<L*XTQYV>Y->1_U;M:96P^EE@_V36J<JU.KP-3$E*Z?OI9.#SAZAJ63(Y=LR
M8,SX&?ZVY,8#\&9[GUJE<P*NL\E5+<.(.N:MD;4VR*ICW@4Z/'YEG)&DPCK%
M],0#:8-=DC%4/_YQUFJB@YC9F$C:5(?0=)2[:;[NZJ.BYF;EQ-O*[]=9&132
M"0%GH<)_, ]'1XE95/;*\1P<046%?*?K;1?-PZU$]YC>J+BTN@,P:@HQ5H_N
M*J=!:+KJ]XM3Y*^$KNKNLZ@<%9Y/CZ^:DE )5;URVGB_P&Y)5< $[3_0?$?S
MG1KPG4EA&;>5P(3:I!J>,1EP=S;B=O(BK.=8,\^^Q_Q'9I^<3SB=3*?]R>SA
M=C#H#Q\?'R:/XVFWW[WM#D>SWJ#3O]9\0FRR)!( 87-R_#GE%<HT4DP7W-DS
MB6:9TX1ZRNZ SS&[@V%VQ]9L67*X8 BRL S#Z7:"X18P=8*A3C"L18Y=Q1[7
M"89U4)*/3C!L> +A,9)$=S:Z"DK0B6$ZBU$C:_.156<Q%NA<^:=L3UM)_UQE
MDC-JX[RK5W[/IV%KV"F_+T^>"B\$R=)P[_/98'C%BJ;F>YKO%<3W>JW1L+C)
M>)KO-<6X/DM+)%*IF7UCPJG-9V;,,:HBJEA$7"7CXN?I\0OOL70:.V^V/VWU
MA^-6;Z+',5_$2U!K9:+YY-$=35OC:6$9_$VA#>V4.(PZ/V7GY=SD150EU?:J
M@;$2FGGUE.].NUM^7=&[=.^J(9!V*S3*K5 U]-+\:2=_Z@[;HXHZ!ZJ&0>^Q
M_S^>%WE26N+NS,;'*(P"]K/C.:MH]2OS0M.5"97\T0]^$:WYO.>?F,FW1U4>
MD>?XV'F<CH:W@]%T\#"<]AYGW?O;A]O[2>]VTI\-'Z87R7-\*U?O4HF/XAJ,
ME;@'PT5P&VMY$=@6T5_D\ACA^V?IEZC3&2\QS'%8S##'>F<0GC?]\GT6\5GR
M(XJ1=Z4E0_P/,X-X=NP]L]AJ#D;S"3EGVE%WO*.N&AD[E4S*B?450R@LVA=6
M8(>% K/S*@2ZZM+YP9X#10*Q$I[ZWK#\KF%7[;YO+&<J+/*I&= 51 3[@Z-3
M=W4TL!YB_#Q\IKB12Q4"77T94/,TH/ZPKS4@K0&]@S-UM0:D-:"C$6:H4P6U
M G0RUGP#\#-S$;) JT$5XD*''+[-4Y-*F/'X;B!>-0-L)I]+D>N.G[[YH>EJ
M;:LP/E>NAE4!="HLO:R.663=5J=;6+O.!O+:CV>!?2"%:W=.V,]F**?Y_K+X
MR?>>O[%@=<_FX>EM[CJ]67\\'=U-!K?#^\YX.GB<=:;][N"VUQW/'KO7VN9N
M%FXE<[6H=]TZ<#S+69NNL8IO !._\&^NCW0/%V'8<!/&*RLQ^^M8RJE=)E<)
M:5K]0M*T)J,/)CKUJY\HI36=RXX3J$D*3Y8Q:N_-%23P5$YG+<.]H-T'E9 )
M=<M'*7VP3!7H;=":3O7X)AVP*!RQOL86U=QT3<]B[^PA<L6RL%C:U%+P:J2@
MRSC_8D2>N?+AT/]FV#*!6W#W80U]PV56V78*;WI[=:6T6@ >3X3H/G0XCT@<
M6C@'Y5R:5[,%Y:=N<;7R'P6D9@!7)FQ_RH0'M(#-*+"3L<YVT[+S9,2YBX*
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M?!H++A650",,\,!(BQZQ4X03.DC,-8M 302B]&R"$Q#E?[/4J/O7)2-'"CX
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M-M+N?0JEX;J_RJC77.O:NV2OI[":MZNW(NZ5*WAT1I#5<7+#A@#LH8^NB50
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MA*+1%*R=B<[=*-^-KL/'>ZMJ^9VATLH)1(%D)A 05H<9P[6_HQI:KH:M=S3
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M!X+4 ^W/*4"#-+4-5&Z&$$"D@"#<4H8-0)8S%?  VS%J"#OUU38=0%09_Y(
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M<Y?>@4$_B/TZJ-:KGP[[SJLTD$"!*?56<$Z\D%+@H+SL7$V U3>3B',7O%8
M',)>?(+T/*R?, T\T !; B@R$,IU$M(U[4[47[7D"Q6>D_ ;=O8J2FQ01P7E
M /J8PY$JOS,@8>9/2. !SET83@&J_>C-BH&3\_>79C3_ZJ?Y]R'$<8;A;/+!
MA5\/C&>#6OPG*@C_^6__'U!+ P04    " "QB*],C6K)_N^3  "):@< %0
M 'AC=7(M,C Q.# S,S%?;&%B+GAM;-R]^X_;2)8F^OO^%;R]N+C50'HZWH_!
MSB[BV3#@+ONZJJ9W4;A(R!+3UK12S)&4+GO^^AND1$GY4C)(!DEW UVVT[+B
M.]^)^,Z)UXG_\;^^W:ZRK_EFNRS6__8G^"_@3UF^GA>+Y?KSO_WIMU_>J%_,
MV[=_^E__\[_]C__KS9O_K3^^RVPQO[_-U[O,;/+9+E]D?RQW7[*_+_+M/[*;
M37&;_;W8_&/Y=?;FS?X?9=5O5LOU/_ZU_,^GV3;/OFV7_[J=?\EO9^^*^6Q7
MM?UEM[O[U[_\Y8\__OB7;Y\VJW\I-I__@@# ?SG^JQ<_4?[I3?VQ-^6/WD#T
M!L-_^;9=_"D+%JZW5=L-&JD__NW)Y__ U:>AE/(OU=\>/[I=/O?!\+7P+__[
M;^]^J>Q\LUQO=[/U//_3__QO6;:G8U.L\H_Y35;^^MO'MR^BDW\I/_&7=?ZY
MY/M#OED6BU]VL\WNW>Q3O@HPJF_[LLEOGO^*U6;SX!M*AF3)$&0E0__]E2_>
M?;_+_^U/V^7MW2K0\Y<.^%L WCT%FPI=1<+/;4!>8O7Q%_:,]]<P=/-^$3_]
MRIXQ[SN:6R]2]-_'7]LS]GXA)^T9Q6ZVZKEG//G*%S&ORD^]"[\[?+#\]@OR
M6S5^$-6S+\Z_[?+U(E]4HOG@J[/EXM_^%'YW?;]]\WDVN[M6\WEQO]Z%N/6A
M6"WGRWRK/FUWF]E\=TT(!(@"R*QA BG,.!54.$P(Q8YY=%U]XW6^?O/;+W7[
MU8\:M^ M-81ARX6'E".OD!':8VRTD10Z\*<8%I[RN\FWQ?UFO@]. 5H9F_=H
M_^<)5%:CRGZO<?U__^,O)V,>4%C,G^L3%9J;V?93!>E@=X &^5_RU6Y;_^1-
M^9,W !XB[']_G:#'K!;S/EG=D[0J,XEB<^B%#SJ+VLRS8K/(-R'#J?_1;#-_
MQ1N'3_QE7H2P?;=[\\ Q9:;3OR%%[SUNSTTPY3E>G@PB?;]=KO/MUN;;^69Y
M5R9F:KW0L^UR^_[F0^B&(>^KTK5?P\C4P?I_7","K0(&(L8DT,!136$YN"BS
MG'F'KG?'</+J"&O1O$ ,"$&M$4Q0K)1B'D DK7 &>DQ4S,C;O1#X+@R_,Z19
M<9/5!F2S]2*K<)<_/4?^XH@<S!_-Q&YD5\2)X)'V<W>\Z(+L]Q)S5H$>6"'C
M6;V@G E=- U%36E@,5AWCU/@C_FJRF7#).S[KYO9>AO$/C1[$GX):!!]9A6A
M%",')3&>*ZB8L(0CC!N.[]?;0<0+'50#:D6A!YH@)S1@GA 4$JB$*<T!6E9A
MR\[!C9;9O,;6A5':&]'3&)/]F5,DZI!QXZU<G5G<K_+W-R\!T-\?_,WLTRJ_
MUDQ)S[T&G#A@A*72@'H0&BY$3-+3#@$!.$S1O/%!#"B"4!/&";72.(P!85'#
MLT7>4X,N8^O+X_4J^_3]T5__7L%_>?@.Z:1F2CF^?^+D,YEKDBAK*W8OR&U:
M;TU#@Q/;6 S9_^/4VI33X7QS5[;S\^PV5]^6VVL&N+12,0V4TE)JR""JQ[F"
MFL6(\;,-4*&4*P..P9IBYC72S@B(%1=6&^T3:^TYIJP$%=*@ "M20]M1UTPB
MD[,6IX#1A"51MN=(N2!<G3B<ABYU,Z'HL4_%SKGN0D_Z,MOFZO,FS\O-S<>M
MV^)VMEQ?2R8=ADQ13036G .LS&&\4.IH5-X7T:KF,K2EH/2,.FL5#;]Q5+*0
M#DNAR/#ZLP<6J4 ]TMQTCCL&PYVUZC5R$\UP&W)U<:K;-]_3T+4$=CV9_*9A
M[C4%_#:_WURK^\WLEWP=9.&=^5M^^RG?7%/L&1;2::T, D%U/;+U #0,FR8Z
M]])W:TV)E 9B#QCUP"IOJ.!*0@JE<"AU-G5$U$R\6C-T6:*&("=R([$&<Y4%
M.-GO>T -);XU2XO#8:)J;754MAX@2<;:(^TN#2L560!\T.,73'U&=;N2,JZV
M=D9?]-,U^EF=?S@#KE)5I*UE @+MC>1!F*F"HN[ZW**H66E$LY 89)"'0H6H
MX" 20 F.$0\_X%0ZFUA='ZTHM9BG]DEQMZV0Q.QVV1098S[;G*86NR$=N)Y*
MCMB_80UW2#ISUT;]CC,U) E!7(5Y&5.<62_JW4C*G-1M5>[P]11ZI1&FP#%#
M 07*0FHM=TY8$]K2PZI9RUEO/&GQNI6 KT[Z--(<]C$A#94HDKWI*4ZL 1>4
MI147317$+C?Y/)!V2-((#5](+',88TVLI0(>UWF(YB!&/1Y]-?30$^\D*?,_
MCJBB CO"C+22($-<8N70Q6RS*'?@:EC;.-6():J98B3D*$XM:B#1$Z9^A.(A
M#Q=$HB5ATQ"(MN"+7CI-+Q.K*IGQC'F,K96TS&8(LP#BXVJP%[*'F535CE8,
M 2> 5I13")$4Y1*;)E((+9W"@R8;9^#ZG$8U([33O*EW+KLD(A$T#CEI:C=+
MBF)V&AK4BR7-YD$MV.FH3H=4R3G/L,$*2*T0=$2>#2=C3.2FX*66D/+ *P*$
M$8P:1"46S):KJDR%WU(YGD)UGAJUH+632B5@M#>=&GWR](2G>*V*Y'?2:A5K
M2S.]:L50HPT]4ZRW]ZORVM O^>;K<IYO#[F;LXI1;T+\%YR&QJ!T]8E(JI&&
MC;?U7FS!$($!9E@A0*E 3 G+->?:6.,(%.F/*M2XLNT!6,0&5GO>&FSV#4)9
MG 2=L55C:K/OUYZVB-V_0>AKMP?8BL9F&X$O6?W2=F!GEB:P*=C=AJ+/?M-+
MIOANN<[?[O+;[;5%$$)NI>=**4X9M^ZXDN.L[F,R>VH,4^UI>1'0(A?FZDI3
MC+%!F@-=WJ: X^6+)<:L ME/SAA!<*>T,0VWO66.36@=,GL\TA6?0,8S/>D<
MLH4YS=+(MCPURB1?://_O0\_R#>K[Q_SK_GZ/O>!A?,=R;\O=U_._^DU4TA0
MKFQU9<L1!T"8G]=S.0R;)YY] 0)"$@"!Y%YZ"C&03!,;0H*7B"/.4L^DCWBS
MS1[POG+2YC"R]Z=!;XI-MEPOJN77;%YL=S&Y[&">:Y#Z3M%I/4GN579RY<&,
MK+3CX;75TI*'EZVFZ,F(;'R*'FV7O _GV689?T_,OC1!&-IQ$YA/#&YR,>)
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MYE_RQ?TJ3,P^;(J[?+/[_F%5%L]?+]Q_WB\KD=Z79A4F)"!8*1R2$DJQ=]A
MQ2S7G#&FX\JD-FZ4<QBF&(9J"APUU"D1 *"@(@ ;9T%R<3R@N\HJ?%6F<D38
MK@YV?WPWD\I1J([3R6XLIZE2TI"U"\+8._'34,7^S7I<TB0-;TWU\,5&]?=?
MPQ?M:\%RP@R23MC04)@.2JM%/32-L%%2V*0]AS"#R"%'A:0<8Z%!0."%A@1H
MPM&8*GB5E3!;E6#JA>IF*C@TRST*8#."DZA@ ]8N"&"?G$]#^WJUJ$C70WM2
MO++=0R482 4T(+3G&9<>.,F)KH<A8$KUHGAG[5&@G47 ,8LX-4;K,&.DUA #
M+ 0<IUXZ;S0@6Y6"ZH7LCIJ7B.<$FC=*!:D&O+51O1:L3USUVEC45/5:L]54
M]8XM'8K7",$$LU@@RQ42$(4$TM6#CE=/YS97N,??C86#0:\%=%Y2J:%4B@IN
M&;**.$A@8C7[9;X,6,I7\;*\1A:G6M%D-5.HE#S%J='9='.4$E2/F+B@+VTY
MFX:6M$9?]--SXC3B73[;YE^*U>+M[=VF^+K?/S^TR!F1 %*-<= @00R%F!R'
M "11-Y@NM4.)(5!+Q9#AE!DGG( <(2]YR $!PHFUXP@M6YYABU./3C0V4Y*A
M&(Q3E1-YY[!&DI@+%%V0FSZ(G8;T]&))T7^WBSS;=+]9+W?WFSPD2W[YK?Q=
MW2 1TE'FN3(:8,FUHIZ=@G+D2S\O-X/*=6AHI;+$4X.L5MBY,"OQ$C@*DPO2
M$5DU8[@Y8(L\U-2!Q&9Z-!!_<7+TD+H:UDAR]#)#E\XQ=:=U&F+4AR&/3S#U
MQ4VCFQ*FN+V[+X=OZ$J_%#>[/V:;O"X#BB3W!B("&.$08^L%KH<0<@@VO@!Q
MH0UBO;0,4NNAHTH:8:GB5I:9G\ 6IYY1'9%5(VE[P!9QRKT+?9<5:$CFXN3G
M(6DUK#9OOW1A+^+H_T LMCO1WY;-9N?S7S;]&77NBZP)G*;OPXJBWRX4>^)M
MO=UM[N=E7WJ[_K I/H<^5,>!T"!"5%$CP_^\A%+:X\*RHQ;$'7&[T%!Y*@5Z
M)!!AA(:YN238<(>I8)!QKE,_Q'6.K;QN%G+S>0 7>ZRM"Y/-TL3!2(Q5ZH?\
MU<!&J\_^,DL73Z;U0.XTTL5^3'ER]JPW?CIO-;X[EN<EQ%J)D3& >"*-!8R:
MX\A"-FH=OD%SP")" <0,0$\Q58(BI2&@6DHL%$U=$^B5HT_OVM90[X/HCKN,
M:3CN<9-QQ-KEKY/69H<QGO%IJ%N?!C7=7VS+56>E^^NFV&ZO=9B44,,P\M!#
M"V 0V^.Q)HIDU"7$5YIRT%FG$!.$<"H!D;Q<D@RM.L0YQD,='JO&7G[:X/]<
M@NM)U!IRVE'0^J>S1S&[ROYZD=!A9:S"TD;"XCB>N'Q%&M-4NMIPU%2VU'Q^
M?WN_FI5%T?*[33[?OQP=?K_*R]\$'.JVV.R6_U7]_$6,U\I;KY473."01'I!
M+*?U8"2(D>MU_GFVKV?>5.=ZP^8=%)!SHH61%%DE,:4.:R25P$(3VV@(R_T0
M?F)&Q.;@=ONOV>QD5+8XLRI.&8=S6S,-G9:K6JGMF0G9N0U7V=&*2H'/[;C*
M'FGTU4.1'E:=^W+"!1T?W,_34/SAS2Y&'E\]);\_Y[MK*Z"2PDK'/;;4"*NI
M/YYN-<A<[XK=;-4Q]:T:PH12((D)ND41A,)[3JU&7F/$H(RZV7["U#GQ7>>1
MA^^ZL=DQZ>V;R%Y3WI\O4#ELPAN0M$EW8]B=AO3U8TK35#>>GZ82=2Z;YU)9
M*N=\OJE4M&R=:H4UQ$  0@"!G"%9GW3E7#,;,U%OVB9T  I,>'DHCD*.I&1*
M:ZJ !HY#[A//V,]A5B-N=H8U3KIZ8[F9BHU!<)R@/<PDSS'ND\D:Y0C:UI"\
M"S+7-_W34+S>K2K2=MKXQ[B7N^K<8FC0%.O=<OTY7\^7^?94@^!8I0433\OS
MC%AJIRSRW#A*PYQ16484<$UO)L4UZCVE$!%G)'=44B< #'-3!I&U6H9?DYY8
MJ7%6P_,!T@=%/$:J6!1%Y,6MTA0.F<;X363;,Z]AIV*PU[%\7KP/":$X4\@K
M0:45@(IR,'MO.?<P*K6);!H[@Q%AVGC'*%!&0JZM-,QJ%ZQW.OWQO9?'=>PI
MD7XY[U% T]"=2D%'+(,4PV57$8UWR@^DHBV,:R.C;3EL/C?\M'M&M*5@@!$#
MN0 8 F&%(XIPP@7B82R+IL\-O_#MACJ'5/@R G"8#E'-B' LF.8D4E"HE'.2
M3[LI)#//$W-QOM&)R6D,K*Y&/)E-],!)NX%R&I;&0.(<!UYH@R7CSI7E*<+4
M12,4?HDZW?!2&U@JA F@7A))I8":(B2]K]ZQ8X*DKA!1PHI="VE)5AM92<-3
M1UT9+<2_P$UC:8EG<XK:TL**B^+2EI7FY9&_YNO[_.UZN5O.5NKN;K6<[[>S
M\LVR6)C]#MCR:^YN;O+Y[M?-;+U=EG^_+P^&(5.".ZB]=Y@2B8T/JD<!X 18
M$W?$*C&4Q%IU0'^5'?!G9P9D>PNRDPG9WH;L9$2[0H>IW==,%B?DN3CU3.ZT
M1"6TN]!]09 '\N,T='LH8Y^4Z!Z0X\;U:7>S776OOMP4W'TO+U05ZVI^6%9$
MPY)P;Y52H2$B@05 ND.;D#,159>L6TN)-7R/*3N!:E5QL2.9S21W.![C%#6:
MPC2592^Q<T$ ^V%U&OK6DRV/"\?VR%!,%;&SI@X5RS!E$AG&F+":4 @4]L>V
MPE]%W;-LU\+ :M2R&&)+]IK)4'KBNLG/2-4-GZ7E@NYTHW$:>M/1AF=JCW5E
MI/D<>!>^/%^XV6:]7'\^5JG1D!)'H , 28VI9)Z=Q Q'O572LHG$"O/P^/7-
M<KZ,7&YKRUS3:65RTF*GBWM 68UHI+O:SQ-S<6+7B<EI"$Q7(YY,Q'K@I*G$
MQ$_WJGQ*0NR),<IQS;P70BN!:C  $!8C08D@)):HU@LS+29NJ9S43.TFX)\X
M-4SDFB2*V8[<"XJ:V%O34-S41A:#CH#4BGW(4354FFMK- 3:>H(,YD<X&KNH
MU;)D(*:JVJUFN.E<E4JY$WAI(.T>93K=EN!>]3O29S^J@L>:V5G#6_':^/#,
M,K2VR0-7.M_]D>?KP_;+7^^7BUGXZ=OU'H[.;XJJJ*>Z"7+W:W&WG#/ ZC)-
MWF+@-/ >"V&(HXB+ S1$/=%1)VV& )3Z6,[1ANS3WHCL8$56FU$6-#NHQZ?*
MDOT=I]*6K#(F"]9$'NT9Q)4-SP%-S8N1AX9Z<N!(RQ]]L'_I6-*0SIU&F!C6
MY,<'GH;GNW&EEL5_W&_W)Z5]L?DY_T/-Y\5]=5[ZPZ98A]_.]^7H][M?G@GM
M%<, $6$PU9C4(0PYJJ,6C/MM.?4Z\@EL%GR4!;C9"6_V$'"KI9F>'=%,Y<?S
M09R<]TI_FBHI,4Q>D.8T'IF&!B>R[7%1DX0,-E75\MFQ]S=J4=R5^?]!P &U
M$EKAJ5,*4NH$Y?[8E,!1)TE;-9!8(ZNW]HJ;K$;5<JVC'7?-]"XY;7&R%L]8
M$NUZCI4+$M6)Q&DH43<3BAX[571=O8.4_;(+LY799K'][6XQV^7!LP3(NFW$
ML1&HO%N/I:94  CJMIGP*"I+ZZ7%]+O\=2IP1)GM868ESC= 1A?"ZX/GADG8
MX!1')E^OLSO2-+D1<Y>2K5Z9GX:T]6S3TXIQO3.6_"+/NU.Q<N4E=)A9!*PF
ME@&ACL X55$G*@> DU@VN]\->=>VL/P0OFQZ!&M2;HP]KC6$!Z=UQ>==@]KV
M SIU&JH_I,%]7?=IRW7C.C:/6GY_\V@Q8+F>+^]6 ?D>Z2F'OU:.26XL5])K
M8)APR!Q7!:#!46]@)H21?-'S,"T-4]1U_D=99+I.!+>'Z)^]R=0O)GZK*Z5O
MFNG^1-P2I_=/M3RXYLEBZ %Y]>32/@:<K3$,7!6G-<L7U'T UTU#U8<P]''E
MG*&X;7MUX4'-ZNI _S6EBA%/!40FS$(L4EP?UUHT8U'GT7IH;L K#8L^KC2T
M8;1I;CTHF;&Y\^.K#C\]<UODS^/>>WC*6,0=B YT3T/_^C3HE;L1G;EJ7NSH
M)M]L\L4A;3;WX0]E!7UNB+ 4:J,M,PIBA8_B:;3VUU_SS:>B>;6C5HW$#+9S
M/,V/Y1QP99MZXCK?0XNM@=2.PX9'G]*3%WF8J6;M.-TWK["6J/S1<[Q<.F;4
MC<AI:%!7(Y[4/NJ!D\@5T^TU8-ARS*4TE 1-PQX3&;Z>>PPXMR;JEE7C+QUF
M]3*RT&IS2J*6#_MEH]4BX,"/MM6MOKX*UYR;:8SX>-C/KXC%VMUT5+^_RS>S
M<C+V=CTO;O-WU3-N@%+)M \I"C9&"5;59J3$6$01)5%3H#;?GWBL'R%EJ^CG
M'EO1U6SPIV8J3@=.).WA9#^5@ :>P#Q#R06%Z$+@-,2BDP5%?]TI3D)^SG=G
M;4!)@&%,AF]W#BJF,"AE"C"M&7<8QHA'W#<GEHT IH5@1)+33"K2\1(G$B4E
M#^0A4[O=9OGI?E<67\MV1?9A-OS4X@$[%_2B'8O34(J6V(L^^E'LQ>"R@5]G
MWYZI  TQY5J%KR=AFJ*=,@!J"A%##DL%2=.7!RXU08#FT!JID6 4"2<)EM("
MC2'6@M.$VRN'@1%@3:&0^06.+@R1/IB=QH#IQ9(GES?[8J?#8#I5/.:.>\]D
MF/=K3(3BU@M2CB;":&C?147>RPT1SP "V%/(0P+A)0_9@PD&<F:=P*G?@CL-
MK-CY>C?Z6HM1&N9Z4:/1RI]?HBE.D.+9G:PBM3#E=4EJRT_S.^-U2^]OR@)T
M^7I;G=CYF%<;(*;8[K:_? EYH)YM\\6'V??JOLP)E7 , ,N )-X092'4@!->
M/MT&L:(J:K6A*Q8$',/26P, I !9X;&@4C,<?@RQ3:UL^RI^;RIPV3G^V*O?
MB3W2<.MC0LZ(W",Y*61Q\\ 1V0%\5J&_RBK\;SY5#JLM&/-1B6Z47]I^&<B9
MT]#FP:Q]<K=[2)8;%Q0^;&M_R#=5X\<DEPGHE"!$ABDB=YICCT-;0 84 "%(
MFU;%?>G[@=!&>H&YLI*614R9@0(9PK"2U*><O!V/<01,^T$^VLSM)78N#-;.
MA$YC%'8WXW&5W'YX:3IN_IXO/W\)PU9]S3>SS_G/]^5]EO<W5=/O[W?5L=<
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M3UM6C\3V(JSQ;OK1I+6%A:W%M2V;O<NK#T-B#X1CQRGE$C+B+#*",@DJ(-A
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MD250.V=TZK>,3V@B(N'XGKL<_GXHITTFYIUUA8NA;F)=(:)LW8_2)=I5O9M
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MJPL'C=."<LKUI5@%2K;[!G\N=KE=;N>K8GN_R<^3=,:9%I98*PC$W'MIRZ'
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M+G;9]WR7;8X86UZ&'-ZAS6+:C^'+R/6(XQQC;U3V4I0+P:NV;!_-RB<WSOM
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MI"=3SGD=ENY1[M]UF()@/F(N6"ECF9^R1$;;U$D;^S&65A2EU:"^KU(88IP
M%!'=EHXJH:T[B*)=+5)*XJ56PR6Q!9A$$*OZY/=%*?R.YVA7_K^G.=K9IJ@Y
M&L98Y_<_%XMEG:";W[0/5MF;YKFJK4?T_N[KU_WO[O_XU>K3>G/;O/%WW+/
MTB].E66E0$PPJ$N@90L-&H.#W@D= E#F[853F,5BN;V^66_O-OO]A79#UR\B
MC[@#7Q(=I,NZA4*3ZZVP2.D>_LDS?JT%C38_Z,K[OW-BQHAOV??G_HR.#]JU
MTY#Y84U^\C;]X'QWWESQ]/E&[^N$5HMCGO+5KKJ]W[TNH2086>P$@4##NFKH
MF*J$6,"@:IUDK>8N<5RO?M[K>H+JG'14=]Q.&87EP-V4/<:3$L9:FN\W41J<
MXU7?=&7PW$Y*\EZ8AJ)FL.OQ/DHFYKIJ8[/)73]F7BW@S!D'Z[MO+:!^*0T=
MIZ2NFM22,2N9";JQ+.C#F17N^%C[XPH9[X'J#>5/U7:[#Z.VU>;WY77H+G(8
MB=V$+1M_8=JUKWW9XQA6ETX).",]43Q-0UWBH*\3C)-N&O'']=WF_OOU!-+U
MQ?.O]O=-+,Q=?1G]0<#6F^8QE_G-X?<?-O/5M@XCUJN9):)^TD65@#IH/%,<
MB*-R.=5)5H;"DEF)7KC+O_AI_N@>V/:AOP<W*KZ\/SA.OYU7LBEV6:SX-=ZC
M@5^T^(N] 44;W7E7<K#A^*,3*R;6<XOU]5VS'&O^^O?4@P^0Y^G)-W$]^<@+
MUN35OHT#=/!LB>A\QAD.W5'C^L_!K5V/,QW"(GE3?=Q=QO7F#"[&%%,EPQHI
MA0&7B,KVPG=E,"A#PO_\:#)[ZN<.Q:=UTP-V7+<EQ[3Z+,Q5U]@S>^HLJYS>
MG)]9&@W7G]-83PUH[WJLF1/F$UZO5Y\_5)O;&M\O<Z]A34[W7?7U<._ FT]O
M/;[KY=?YS;OJ=KY<^1YZ\\DMM]?SF_^HYIN9*A573E@@2XTL)]9Q4T)F@2 E
MYS#HXM/L8#)[A#J6"U/V_/1W$_9),1^FZS7TGWUGW18U^*OB'OY5<6] G=@[
MFE#_P<&(^N=[,XK:CF&EO2_K9Y1]L Z=AK /9^YZI(F33=9?K6H<'_ZZGI5"
M2J"8TUI9Q0@S3((6BK4,99+R[@#RR[?()M\!-">7[#P,9Y?I^AA*#;SPR"<K
MS$=NTXAQ>%=]=P(<86*\Z,;R&91366UWFR;EV!8TRMLZ!S"#D!M:.L(X)]P'
MZ[XY>F@2 :=,R*&R7@T%"6?X(;+[&?MQ?K/?1KW;;7?SU<)#C$AU1/,9D,48
M@LI^"OFGS7H[\*'9<\Q<2B/T)70:.I;&E.<6_VGXB=.E/Z_FM^O-;OE?U<+X
MT+-IER)DG<(EIUC5KW=JS7G;KH<0<Z]I_T8[S:[>UYG>5-OM/Q1W]_B:&N8:
M8!^QBB(Y1K&R$=LCKWH$=U6<P"O,)5X'D+%GZ.JL97VHGJ*@];+GK*KU9ZJ[
MM.TK)/95</MLZJ_5;F:=+%W)&2Z-DDA0J!AL6^.V-%&"%M?4:#)6S\5EN\?1
M%(Z$*EHDMUUU+".?J7:%K@H/:6C!>I:7LS+5C\FIB%-/*YY(4@I68I)L,U!_
M#6HBG&&6E4"6G+1-8&QDR%HOZ,.9UW;WJY):7.+38Y<)"D][)>6FSV)MO.Q4
MQZQ39Z:FH0MQT,]DB0+MCU$ O7]B;58*C1E $"$*)<0.PA*W+5'_![/?J\W'
M=4P>O6L+(:/^%$SWRI?#>X-?Z[@C]'1G%&?AVI"#K'[YG):U^XSE>+)QP-)1
M/4*YG)Z(!%MP1DOBV(B1E/N'&V=:(R,P!)J5UE(EA76L;8Q@SN-5):"1[,)R
M\I9I;VT)(2]<7C*QUD]A[!_7-W=USGU26G-/54>YB>!V>HH38\09T8GFI/LQ
MO_FN.7_]YE-3P/QE?>/9VM;W=>R^G1PQ=*BD5FL&.2)6,JA*B@ERVFJ"D>Y\
M="U%8_DFUA%?O1]]BO!OBSW&T<[B=F+NS#Q+R_PTIEUBFYX<GTO/6/"D_%"7
MDL^ 8<RW4LH28F:<5MJQMA&,K0L[?1OTZ<RE-_<3[K<&S\NS*@E/@2J5GJ)8
M.;K$3E[-:1KO(BYAA$U,10+!OR07,1R$7VKU=KY<O%H=CJ+\4MU^K#8S9Y#E
MRBKHPP)8.E=:@MLV'75!=7S]6LJL&B>W&]7H?EZN?BX. &-OG(KBLYN<#$=E
MF+H\9;$EL?AM#VZT>Y^>(>J,_*0A>!IJE,B6%Z]@ZL]0< SS>KFJF@M+9MQP
M#'&) ,;$82XTL+!M"" BH^*8[I\?+I:I,>TO[XD-: )("PQJ\O 5'=ATH2IO
M=',DI$N$$\[>-'2ECP$O13JQ7'15D,=7G+]:/5V(O5O?W+CUYJ_SS6*&J4%>
MOP0'EDI&%49&']=B7((0>4G==F;M>>;%@+J*_OD41HV[.  /U*?D7=)-O,;L
MC3!ER] 16=0OD-$STIBK;Z:AF]FL6P\SP@-CMB]S/[;?W!?QSQ@LE9..*T4!
MQ-(W2DW;CA1&A+_L$-Y&R&R-?L5!'5]J:,\R_.3G[;8!&WAM0P2+'6.XK-0%
MAG -EJOB38<3'WGBM\=DG O?HHF;A@KUP/\X>.O)1-#MD0_4:P:P,0Q9PHUB
M2#.(%%5M0Y18'"$EX8V,HR41ET8&<M=U$9B5L-!%X#,QD=SM-LN/=[OF"IW=
MNKZ.I1KZ&,%3ELZN#*,IG8BV]##@N1LG^W 1KRX^?MJ70+S=UX^<CJ,/ZWH7
M?;W:>5INZMMS5WZ%56UW<O%_[[:[:J'VDQ3. *&0::RT+.N].P*90"U8??]B
M2R^%&@3H."IW5<P/0/OJW3"]&:N9D^O"_KI[51R-*@Y6/9'BAX85K65716M;
MH2YXNX'4.D7_!"G^H -BJEYC6!(N>IX1^B3B9O7]+6#[%QWWH?GS;XLC ;'R
M8%P)&%1:8*'H,4CGA$3>OYZJ^<S9S19(796UWF/KL3K/P'Z )QF/^(CU_<\?
MY_7+WGI]6]]?N7\52&XV_N_M=V\^?BM._][;_3T<A:Q35%?%P9JZ/G5OS[9.
MA;X=X>FW<.8OZ7^>;IR0MF<R\.4[ZO-PV5.3FQ?JGL<A+3164F$,XD!  8D]
M5O@P@H(N0$S?^O"*G$2%^_#=2X0'HCHB4C\\L=%>5;N'>[5_Y/9JO['4*NU1
M:*<AKR]S&JZN"?IGTN*:PKYNVIJ,R>Y%BW54W5S0]6']0B52(_A-$'$::[RK
MWX[=+G?5^_WC.WL#WE77Z\^KYBO[!T0]1@BD4,10PSB4O'D ?0];61%T._GH
M8',+=[,X.L1KUR?P0PLGQ^[3;FH_.LZ<Y9M'T^KLS*-JSN*^FO.J>"F6KV]@
M/%A9',P\^)?BQ-"ABT#S]MC9.M*)#)9I>*KIT/&DFG4JP-*E?7ZM_MK\T796
MGR,BSG#&L.-"<$3AT0D;0$6R5$_W)G,7K[WP"-]5L:IVF1(] 7PG2.[DH3K=
M8J(MYO X]W]CX&/#W<B+S<F$LS\- 4YM5$CN)9:S%/F6^[:I @XH@ P&I-00
M"@#!L6W+@R+[-"V.*87I,BP!#/?/JN0A-WDF96+:]Y"ZR(1)./635KY8FP(2
M([&,Q5?8:H5+B4KNN!-04,=*?MQCI!":0]&)72TZZEQP"^'5(BV8[FF'!DE0
M:>T$BT:[$CF1212/_V+1:!@3/8I&D>$E$=1/.<Q)20Q TAUW>R J@V='>!.#
M3X^QZV?"JAV[TC>12='#@,O5CF%<=)X6=Q^WU7_>5:N=_;U.>APO'Z$<(L9<
MJ2WG6'.$(9(EM-(!PQS&G8^&QGX_8[QVA%3L,8UW\<X+Y)R;)'WYG,A4Z6W&
MXPF3AI?8:?.A^F.GO(%_F4DD+ -060A]DU25FJBV/8)$6(HMNI7,2\DG4RAP
M^1C/7ISJY"&NM^S4L(H&U\C"<^0G0'G".9VF]$38<4%[8IFY)#[-2^#F\!*]
M7/E0<-<4HWY:;VZ;+8BCZ!G I0%$.B0()0Y91OSOE#72$J3)I=MENC>D.*8*
MEA:4V!*G.=?6"$Z8A-!I@&V^Z=3"*SR^8@^P.$'8Q:?G(G=Q^$KSSR9&\@-L
M0Y+]2,=JZVMUX@ =M*DS'\]H5'HNQ]6J#/:L<XVZ;MJUJ):S?5OOJL_+NHG5
M[M?Y;373EC+!A'688,I("82$A]G$(5:=TO O?MPQ;*D6JKY)F5@$9?UM3K5V
M$ CA@F[[C"F(V<^4>U!%C:J;'L43=E[;!^$J3,H#:3H3$6VKZ[__O/[]?WLC
MZV (U[^H50:?Q$ O$?",K/3F:EP5Z0]_G6C,A&J$]N*TJ1_:7%1__$OU;>8H
MMXY*69K2-R0TAPRU8[X>_F$B\?CK4A.#(5 (<$2\)0(:"QD0"B%<^MAM&)4X
MH"H:6(7'%:H3P:1U%8J<?$4I17>JDFG%(P[.BD4L7U-1BVC\3^2B'Q-=].)P
M*?W]X^=VM3#S737CI2-(*D2 Q HJB1!KHW0A4=GI7N.S#1C*#-%(UEDE@AB2
M3C&(L/ K H++,O?MQNUM_'M@^S>M/;2BQM9=.>+INRP>@S 7IA]1I"70D)>H
M>$%&>C,WOI+T-V&=<"2%QA]N>5-MM&_A\WKS;88HEUIIQ4NBL$6&"76<"P+*
MP.CCX;<!K'<U2T.(*XG56'$?0V$BA"+*E"![R?[>H3:8BA94:. 1R%;7L",?
M45%!1T>.DD4<#\P_&V_$$36^1O1"_R36Z,-"%V5HDR8?_+^8 <Z@)4Q;["CR
M<D.L).T@1Y32KI+PX*.(.6:5]3I6:B*LE@8*0!%'FCND2.YSE\<D7PVFNP:$
M\7)Y\F>C)#*_?):-!+/]U-X7IGD4)>//[SC8ZYY#(7Q&OVT+:YJ8@BFG2T0L
MM=25COLPPIIV"%LE3>C4?OAUB"35ADI*G"$""5E*+@A'D#&)*,B]<7L<U8>C
M6.$KADC2NL_[?'Q%"D!7JA)JP0,.+HA"'%_348=(_,_(1!\F0O3B?AWB_$^V
M,\6=I+"DFB@ME*, 8]4.?A]_=+H;_-SW)=3 RYR11 )2)TH@UEHI *WTZW.4
M^_[OXT0X734WR,)5(YBZ[KJ1D[5(Y>A.6$+M>,3#!?6(96TZ^A%MP3,*TH^-
M< W9*]:^+2*Y]5Y40VCJ5Z2Y<:3=UQ,E[_;"TOD6!&,6(Z*XXHA(9GAI(-*2
M&@,L #KW/L?C:7'PJ[V4)(C 4"W)Q5T_->E$6W(].>&BDZ+$<#<U38FRX455
MB6>DBZY(W]"B:>QF_GE60D*5THAH4@)+;%GR8P[.20F[:LG#KQ(L2N",LJ[.
M[97^.\*5V&#A*"VQRIVK/((I:C3=%2.0FLLJD8^5,&7H2$@"+7A@\0OS/XZ5
M\>=\).YUW_$07!/1'-EM#H8\/3,%A52@Q*406)#F64CJVE$-G.T</'1HRNL3
MM:6U&@E*!(5"EPPQ#IB3C#,;5(W8HUIB?X#Y_?X \QYEI_<BLK#;=4MC,&*C
M=CBB.4U797&&G_,E%RF('5^+4AKSM!@C'4==C\F\^5IMYCO__=?UNT/;=UXC
M[1_UC3G5+\O5\O;NMO[)_&8[\PLKA Q#"!I6'X56R  *(*=^@@EF.B5=@QNU
M=0UEB3@F2A.!L;1&,5 ZQPW@6O',2O9^MYDO/W_Q Z)^IK"I2ZCV.,-.TZ0C
M^;R,C<IOF* =(19[C/5E9/6YFSW,J^( M#@@'?;P35?^GA&\;%TPC:,YZ<U:
M9QZZJ>10KU?US_T/6@1(",!066]>0PJ<<JHD]635# ,'8= YPI!V#;**&,ZM
MTMX1**R(0U @6SH?^- R=[+Y'E 618S@N:\HYJ4XK2Z>L#\Q:7S"8I0ZQO?%
MU 6RAV6=-;(O>_UE\M=J-X, .B_!?OWEK&68E<10/V%%R3P(C'VHN/;8^@IC
MW1(U7$HF4 F-(<0*18%V%"*D 2 *A.7+CZ Z3]8/]3_)HH*=:.RK>ZD93*MT
MOYZY\FQ@:?-0HL0LA."IRU>0+9T%*YRASO<_7'^I%G<WU9M/O\QW=YOE;NF7
MTY]>KU>?/U2;6U-]W'UH'@,ZG@17TD%.L"& 6&>0@49QS#"O[Z(06O"@:R%"
M&T>84ZBT]$H-B:9:U'<N*LT8\91HE#ME]W:S7%TOOWHQN\=;7T)8(_[9?^^V
MJ#$'7B&1O .ZZ=VHW(=)8 NUIOH<\<5O#>1BO-LH CD]HY;9NF<: IK/O,=7
M6N3E,5QFWU4W\UVU>#O?[+Y]V,Q7V_EU\\#$(QC<<4*X7\)9R_TTQT 939P5
M$AKH".I4EQW=>*F4;P\SYRPA6&DNJ>]CCB760&.8N[[B=+Z_JWZO5G=540^A
MX@"_:/#'RFRJ#@B5V1&XCY?9!TP7IW G)++=&.TDLHD[9VHBF]J\%T4V"X]=
M1?;5ZGI]6[W?>03U)O;KFO[Z(I _EMN99D (3#!C#%+.F3)2$TI*1R B?JZ'
MZ.FY=K#!&NOZ,)]"_NN<>Z\!G110&,M=F?V5@ 9:<<16M."*WVIX':\02D)H
M-WT<BLLP*8RF,8OBG>'HC+BE8'8:.I;$DG7Z<9=$G<SZ=KY<S:3700DM@T93
MY ##S#@_G;! 3D+G@N*]\RT9RWQTJ[206A(_A3E'1"&+8>DHI :-IU![@&DT
MJBNMO50J Z/)=.H2F4,JU1Y+N%8%\CMIM0JUI9M>13'45;'>5=O*_]TO<K4P
M?AEVL_YZ>[+/7-U^K#8SWZY5F"%8,JI9?1\D@'Z"(0R0!V([W4X2TAXH#7):
M.\6T)0XS;[,3S%K+K ; Y2YU:2$6\]6B6-R#C-O82$)P-P4;FMLP'7M ZPF^
M=INC^&T/<6 YZT#:&5%+2?DTI"VI1>M\ S1,YOY4K:K-_,8W+!>WRU5S+=QN
M^7OUL&UE%!&:< *5,KH4NB2FGH=^]4,!@4$!6K<6C772&&]L??13(22Y%-[@
MTI6$E!+DOD7A +*9DO,',./$+A'-W>1N>(;#!.^4W(<(1Y:\3L2=$;VTQ$]#
M]A+;M,XY5 -?G;YIN*WV[]FIQR^!'B#,L/:A)$ ::"@)UK0^.> G);3.0N*H
M#GH[NEN3D"* O;03B1%A4-5EW(19)K#1&LF@5S5BMB!.'@,^?0 Z3OI2T=Q-
M^T9@.$S\C@!??'.Y%<&!7U7N1-P9\4O,_#34+[51C]\ISL%95_VK]W]?K;SB
M[F_GJ3<I9E(*A87!0G&IO.9260),*))^/<VQ4B%B%_/] 3=7'Y5/W"-M=_D"
M<W%1='83M=Q,QF^5]B QBXH]P]09R>K#ZS3TJ9<%ZW2C+/05OT,F[_UUM9IO
MENMFYX$)A"7URUO$J2B559SHMBU$>5AQ750+V=5GCR5J.S*2LXZ%&MGI"I68
M;DQE>N[P&3+.%5+T(F\:.M+3AB?O'O9GI'MQV;Z)/Z^V7ZOKY:=EM3CL"SC.
M*'4EAT8XS8"AAMEC>Q"RL"JRV%8&TI2KX@1:Y&YB#RH[RLP@+,9)32"!F:J[
M7N#G;!E77TXGHD#][7A2F)6&F5 E<NM-=3W?[@[)*R(!%%8#PAV5H+ZTQL=3
MA\:LQD'YH\@F!M.@%E><[H02%R8Z&3F+59P6TDCI[N>9Z: UD51.2VABC7A!
M97IQTE5B]*9:+'=N?KV\6>Z^-5$5U-AQ(Z&%4G(-J%*4M U!1H-.F$=\/K.T
M[!$5+:2HE5,,:=VD)3-?8;(22%4617E*R!DUZ<'>-)2DCP'K9".ICX(<XB&D
M2VJ=T?4;J-0JZ)7K*%9 \$[WCO5J8&@5B5H>Q5$7HR096.NI):,LAYXCI;.>
M!'(X144)->&LID3QT7GI4UW?^=;J#');R@*)PDPQ(!A@KCGB MMVB 6='H2-
M_WKN!<\>4,R!YW"B.JYRLG(4N, YH6>LI<UC.LZM:J*IFX9H],#_>"W3DXFN
M<O%ZN:K>?'HFYA&42^/_SU(,D9"6.8>.JR;?<(AJ1#>263Q>5RL_()K'D:.6
M,_'D=5.207@+$Y0 RK*HR4N4G!&5WBQ.0UOZF[%./+KZ*\U^-!WB(<8U1U0(
MZ##"#I?"T38>(ISSH"M+>S>66WGJ&TK7GXI'T?U5<9A?<<NB_A3'ZU(V=@/U
MJ2^Q@ZG6*6&!ZA7%]715+,Z<#FK6@Z=+JO:'#\]F_UQMKN]NJNV'ZOK+:GVS
M_OSM3YOU7W=?]/SK<C>_.01N5B@B,*6LM$H 0"7FKFW8D6YIX83-95:V%F1Q
MC[+8PRP..+MI6DJ"SZO:2-R&Z=IE6B\O[[+QNSB\R])4RDZ-YP?@!N7[D2NI
M[:\=! ?HX!ZZ,_*,@\A Y[@N(H=!ZVQ#+S#X7:\^[]J+OOR_;.+L^G8O1XGE
M1*N2N)(CT=8^$$1UV!([IH'<0>Z#BN2KYN'?N'5V%'L=8]G<Q 7&KQ&<Y0E9
MG^'E7)C:A\:)A*:]3'@<CO;G(U9;VNT%S@D@U!J%!#,,&UWRMC$JNCU9UK.)
M4?0E;N4<R6&<QF2@+X7*C+,T?I:; *4))'.:6A-JQ 6UB>*DN][,5]NW\V_U
MJ93V5#!EV"%"?6P+L8^;F!/D&#1Q$QC)!'\^N\YX1,4!4JBNA'/555.RTA2J
M)R<,C;3/^)20LR(2S=Y4!"3>@"?BT9.+N%.N=<+NU:ZZW<Z<=190Y2CW[2"_
M_!*E:EMC4MKXDZ[=V\@L(8^.9!:_-7GJ!EJOLZT!)':3E2'X"].6*.H&.-%Z
MY.:,S/1E<QI:T]N*LZ=;8UGIE*%_V-3^Q>CEM1>[^K>F^E1M-NU#TC-=*@8H
M4\9JJZ3E!J-C\R6WW?/T*1L=0I>^[I%MBT6#K5I<%7YD;*OKN^8BH*\-TH"L
M<E+2.^3NQ^*[EXY=%2W0XH#TJFBQ'OYH+,H#TOEC41^7U$_8!=UR^P'TO)3A
MS\'P!/+\6<Q:9QZ9J1R/OE?7 P*)B*4(<*0,*KWK TB7+8+ZZKDTOB>\W<SN
M1]ZN-[OE?^WO6EI_*KX>'S:J+Z1;KOPGJ^TNISN*Z(J^'BEO+R1W2B=P$_NE
M".Y3N::\?9#-.P7T10(']82D*!\53_74W50/RSI[JK[LA6PBM2]1S1@16&O#
MF5;$00P4I;)M E@:E) )^O!@&T:+<\=%LNUSM#Q<V-T(IFL::8(XZ,_L9$3:
MW_T!C'U8\7:^7,P@YAH)YB"B"!$#B-3'+1+KX\&P]RX"/IQYJ+=8_.)^V=%A
MQ_'3+:V8C9JP<.?(RMMSK&1ZDN*>@3/S/XJH:<S_..A/WI>(MC_F#<3CS>Z/
M'@:3"CHLR_H]9R0AL8AA)1!CD$'J;"ECGSU\J3WAEYG(0@7KC*>5A$, "%'"
M*:B-,]E/43YX<N_^O8/XMPVCB>VF)T-S&B8S+]$YJ3<+7Z#MC#:E)'T:DI74
MHC./$:9A*US@W-WN;E/]LEPM;^]N:QCSF\.Z8NO6FT?O?#]^&Q%K0*"CN'[,
MGF$"3#-32ZNXDTY%OOS:!Y&34C$I ,00$<FY $Q181W&)<6<YRX#.9W5>S.*
M@QW%WI!VG;Z-E<VLW14JK%/IJ7CI/=])Q:?UICB:4>SMF)!"]^"_DX8/T;]3
M4_E!;'[1#PS'>%=/X>;+S;_-;^ZJU\OYQ_K(W++:_N*;KZ\>>+-Z5]]!L/&(
MU'R[W/YYM?ZXK3:_U[A>K;[>[?P?>_[]OVK2G/M+JH&PTEFJ';;0N5+X-;L/
M\ @MH3&E1$&7U@\.+K/_J.TI&H.NBA.3BM:F8KTJCE85C5GU3:CWAA6-9<5#
MT^)NR!^^X[NYGTGW>9@G&JF[LWBEU-URQD&--@*FX:O&,W\]D9D8Z<'4M^,O
M_WGI/>GF^LNWU_4#?LW)&PLMH]AAZ&-C5_JEE=3 -ZY8?0P'\J#%3*(F!_0V
M1W11I^]241SH 89C-U[7.Q.;5Y7/4M5%:]-P/3$%36342[J8DK-@M3LH\7[M
M\ 3&X?@/I) 1*V0))$,280D!W6.@&!D1=!]QVI8'T[[3&1IU,# QXX$:.#C9
ML5(8PG->+>Q"61=)3$K]Q)0QK6TO"60&!H-ULHE&MXTLH\/9)H<$%Z9T4%JM
MH55 <%ZW*+%3!,B@:\;ZM#.<!IYV1/'G;;W<?+_\O%I^6E[/5[MGUIS;XJ?&
ME +]7:1:QO >J(V9*8\/"O? ZAO'&@I'.@YYAJ<N\M>#W8F)71]+7I*VWNR,
MD*!]?7_.2AIE%%/ ""DA=024O%V)2US&Q85# OQ.$[6O8\]\CC,*!L_8YAD
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M76<B)[7'SMF'@SGM9TI[SIO!C($E8U@)(2V'VJ"C0B,%@F[U'AR\XY(P0Q$
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M]OS5Z X*5!^<-(P@(+15])@4!"7ETW*]9TW!PEFG-%*<:<(Q\&[%F1(88H1
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ME\^TDL[S#764E+K[)GXPP%S,U>9V Y<'M=>_UT<AQRJ$J,XP2.-#VCX^TLX
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M8(N@7G%600 ([1FZFX1BUCGI-;4N=HCQ6?Z*\),'FP5Z)\YAI8R#D' ?;^Y
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M8S#04&AGXFV/%2V@7$')KN+@7"D>W8T_CW]-8>'#9#"-U=5/&)3=9DGPYRV
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M I?)BBJ>T/MR)7S^J?>;ENNUK)=V(PDF#&(6(Q[/2KV"4@//.',: AS^4N8
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M5AZXVI59+Q(ZLS9[$T5JB"FSB'DL#&62:4\A], ;++$'HLSA6?^W05M?C:V
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M$T@MD,Q((IB@A@L-@OK4T%DLM8*R#-0ZZ'I5#K5&N-[8YL3KC9O"X#O1,X'
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M">V]ZK%-"39SO>!C&D+&=/1AD,^_[_*NQ<L%^R=4Z'K!\:Y)K .HK'#&AH#
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MO<^FPVPZ#Z()4[F_F0;1IK.Y&OW'8C9/1^O30GB6_JSB@_%=+L@-T4:A>.Q
M(9=XPUUC2IW-G)WWTW\=W(+(&ET0JY+1=I%'$E?27/HRRU_>+M?SS'U+\^%X
M=K2\]_F#)3CF503.> 0XU$82J;=;CDK0,GD&';P0TRB$ZQ1$R_!<%LBO")V'
MQTJ4@]8I)FU\KU9"":G;[F)PBGOV=&O+X*Q,#LV=2T0-O[PH_3D[L"6^7'%?
M!LN$F<=8Z72)@X]I8.9L/$\_I?G7\3!=,6#GW>XE+XX>;=3[Z22P%P(E-;7,
M<@&5B,6YUAS73I;)*^[@>QY-(;]C8NN$CQ$"BN6OCN^N%QD@B2DYU%O!.?%"
M2H&#P[4]+@>LS.96!Y\0Z80O<2GSN^ _E$#>R_X)T\ ##; E@"(#H01P>X!E
MG2BC+3OX]D@7_(1+>=\4[M['].%A]IB^.W[C]D6[A!(;W&]!.8#>4P&I\MNM
M/LS*E=,"/RZ0RC#Y.HYUC"9(822\\,$]#D0@L=U;8!"6*2L!+SS7<=-1+\!3
MEMG7<JJ#8ZD5R8+2)((B:@%6VYP.!7$9&P8O/-;I#83*<KM3ESQFMW=F,'OP
MD^S/%M_>VKERLIG,_U_>M?2VC6OA_?P:OA^; ?@<='-37,Q@EH23JAD#'GNN
MW 33?W])VY+;))4E4Z(4=]$6:4Q:_,ZGP\/#\QB6RO%J6.!2I=.3X(8CK!A4
M'EM&&:=1[$C[&3,XX@:6'O=CO7M>1WSUUS^B<#YL[^)KLDKW,.KAR_KYD$O4
M X/ADP4I(>5":FNLD<@2!TB##!,>9NF&Y9DEXY#DM0TR+>K+MFR!@10Z);&C
MF#"FE;3\M!:!H+ZQ..TIA=UIVPZ#>19':?)9;1_6F^J[)_]]-YZ"F^+K@O2&
M"RZP--YXJ8!+B5]'9*5!]L9J:Q4D\ *D=7ME02BUUEO*XR&7QO.M$1"[=OV"
MY-RJ+E#=SDNA*PN)#!-143>$?GG[<,D7\6I L$H0 :WWBE*..!4.R79U43G<
MEKI<% %'D4@QT^";-^3NLU]O5Q&Z[:/9[;]T&9==PX*V+$('-6:INZ[#E#'3
MK#2>WW.XM\!0P$5Q;T2YE&+@H3O9&U@T1[_V--A!Q]YSQ+?0"TXPT#"U;'4,
M(> C!@)1JJG.RFY>8+VN17%S*B&5(JI?K>O#W=<9U;O/?Z[J>K7MU)6=XP(2
M!$(HM,>> JP)%) U: +"<[*)%AA_MRA"CBF8^=+>6F1.\2L]#NC])TF-3( R
M&" 5@1!,62!A@P*+6\AM1> MBIZ326D^KOZQO5]O-E6*FZK6S]^51.Q%TS?&
M!\]4W!ZX!)(@PA 6IO5[* D+M< J76IX"FY<I%\^^O,QSSY5/J)XZK#\<57W
MZR@[;*(@O$%Q<W".,BSQ 0?:H&$=[W6#]>[*7L_"Q1'%,!\I/];5/ZOU)WL2
MJ_LW>0M2TYYCQ^;]ONHT+*^;,' J  ,8*,(QY9Y"Y4&#CC.B3 &-GX*D$XAC
M1@UZ6H7Y:U4_#MRW7XP-DBKDH ?&:V E5-CQQA>F,+1EJF;_%!3,0W[&4TUZ
M0U)BWU&E7Z$+WYPA0,4M8HY;'1$%"@/N&F05,R+'-]G_N/U3,&\,_.?CWRG'
M>O]Q]?5"T=:+8X,'.IX!H3*(&H($HDXV?E<%+<BYNE[@&7H6LN5!/BO-7A2C
M'LJT%\,#Y$@)!@RVT%/$#=8"G6U?H#/(]BX2Q\J0+0_U^8VX_U;/U;8SP_'B
MV" YXQX*! &1P&MA+=3-F@67.3'O[R+;JZ#U=AWDB['>KE5O/YXF:.4)4\X#
M2A#&4=5[U 3:1=1)CM?O761\E3?@KD>_8&1L3]_\*-'9@>)HOEJ-TEUZ-#5,
MM#9:WR=P F9P<($=QLK&U$XC@YF9^&'[7.W'RA?HF"S$I6OK#0/0Z6@*,T"=
M;U#Q\<Q_6]%?)?,%QD.]%!?CD:@I>/#POZ=U75W3&+3_)$&*:/P"ZTPT591$
M'GE!VC<2^S)=2TI[6*9DR\L.6E.)8GG*<12E&&C*0T=:2Q3?? 6(=N;L8)<N
MIX/; I5A029.)H.9F=B&38ZQ37=,%KB@%%%J/(E6C-(&*]DZXZFS.<Q<8*!L
MR6UZ/-2+;=/U[J&J/NW3K?;0PFH7QP9"5;H'MP 821T#4K4[@78NKS[!\I@V
M)2E>][,<%?KEJ;Y15%[ ,MH@Z00(J.<197YVD&HALN*NAV_"<YV5IR#@9#(H
MQ<3T]-%J3?\DR_5YM4G6[;'4T$NG5 <7ATP3$!3>"@\).=1GBW\P;I# 3N=4
M4!^>!3 Y&R?9>"?$>U[FJ?@^U?77^.I<*@+9:WQ WA"#!1"0.<^%-$8V>8::
M1].[9(!_J4K1!1F7!_=M44W%4U4*>9266B\!P]0TR&J95Y1\<*!!F0I",Q)M
M&-CE2CTT14T;/-RQM?8^KNC;1MO-K]]HLMW!PS&F#T1%&T0[CB3FDD.#@%$-
M<M#:G-UW@2$*DU!T!CD4.YGLM@_QH<]>I.VGUI@]])_JXXOI.T>T3!0EV!$O
M*00&)K]4:Q-#(G/N\!9X,"Y+FY<GE8F$4K3 W[$<ZL6&(Z>/!6\]3'&V#K!H
MD$ O&$U^3Z,X=XK;G&BL!=)K @G_N"3M4' OT^3?AZ<Z"5\ ?!)]^I_S=Z8V
M(H=,^@_'F(A35=S3JG?U(0MEM3G]_'N]VN[C6M\NWS'2S,%1F;)<- +,0QME
M)H!L@?0ZAV!+O-R8C&#SR*-<X:/[+Y?7=3>(P:/-'3C77",>CVU:$R 49JH)
M6=*6@)QLD 5>@TRO)$M+Y,SB951'/<4)Q=]^_YP%RZ,>\\7;A^J7D__6B* 1
MLQ)1*+U"41H:84O.W0=%KT#':=9X"DKM8X^__&C0Q$BLG%+6*8M2;SKFFE4A
MJFZL'&6V;%^U\<Z"\VI+R.PV4;B[X\NE'NOJL)P?QY)?'I1J$E&N-816:2&$
MTU'3-4_N:%9]B042X7K![29"M)0%TJR\AY((UCDO<>J?XYPTD%()V_[2%(BR
M 3N3W\YD<R(3OV)UOIKHW5,:=)]]XX=C@E7& @LXYDXJY! 52+5-)(C(T1L+
M//>,O8&,A6LY[;&OXG<EK[R-+-_L#O&-IX?O5"D=XP*G&$EA'<**>T8L$ZY%
M3RM_8U751Y#Y*X4S'KJEF/1;M8TP;%(QV$]_K[?K!,&AO?)%+ET8&8Q .FIG
MDOH?4<D\5;SMO^6PR3%I%ZB1QF?3N/C.MJL-V<V"BANS,4Q:@0V&47L+T78A
M(=*4#0"=W-(9GS.YB!9G2:_.#6]\.A ";%2FFEAI%.*I>W7;\TBZK#O3!48L
M3<B4JS$M>/^Y^_YAF[I!O>X]N\<&H@VT3!K!C1>2.Z@$;=;L#<C9I1;H:QW;
M;AX;WW(9VA'K:M_#8G[QR4  0%Y YI4U&&@-#3^?)1G-V:$6G,TUGIA?95GG
MP%MLNSIE?K\-0M?.U3DP $8,8HB[%)9'K+84MZXIDU>;9($F\G0L&A7FV?>U
M:_:SP*7@@%.1,BNXP("E[AVG-0*4E=2W0,MY.BJ-A7#!O)4KNI\QZWFTZ!PG
MG(L(4]2QK9K5AI6I-UB,+:-;/1E8EN*%6]7;2.&4@-#T7UD_),?4>O/TI3-Y
M[L+(H(00AB(KH?<:>R>TI&?4<$ZEF<'Q^\]5?;][9S;SN/B6XM.?U?KQK_AX
M*D*^>JS^\_3W?57??3ZLX)M>Q/UI=MV$ 5(N(S3:*&J-=5ABT3;+UL[EY,T-
M#NE_C^PK GN/ )C3+])?]ZM]]>LO_P=02P$"% ,4    " "QB*],T.BE;VR[
M   _-0@ $0              @ $     >&-U<BTR,#$X,#,S,2YX;6Q02P$"
M% ,4    " "QB*],_'#L/Q .   1C0  $0              @ &;NP  >&-U
M<BTR,#$X,#,S,2YX<V102P$"% ,4    " "QB*],*'5B>!T5  #8X@  %0
M            @ ':R0  >&-U<BTR,#$X,#,S,5]C86PN>&UL4$L! A0#%
M  @ L8BO3)*:5";K,@  =GD" !4              ( !*M\  'AC=7(M,C Q
M.# S,S%?9&5F+GAM;%!+ 0(4 Q0    ( +&(KTR-:LG^[Y,  (EJ!P 5
M          "  4@2 0!X8W5R+3(P,3@P,S,Q7VQA8BYX;6Q02P$"% ,4
M" "QB*],45*%)%I9   )?00 %0              @ %JI@$ >&-U<BTR,#$X
B,#,S,5]P<F4N>&UL4$L%!@     &  8 B@$  /?_ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
